




1/184



**FIG. 1A**

PDB: Growth in solved protein structures




FIG. 1B





FIG. 1C

**Number of Entries in *Mendelian Inheritance in Man*****FIG. 1D**






FIG. 1E




FIG. 2




FIG. 3




FIG. 4




FIG. 5





FIG. 6

11/184



**FIG. 7**




FIG. 8



13/184




FIG. 9




FIG. 10




FIG. 11




FIG. 12




FIG. 13




FIG. 14

Top 6,000 implicit relationships for Prozac  
(Fluoxetine) by score




FIG. 15

19/184




FIG. 16A




FIG. 16B




FIG. 17



21/184




FIG. 18A




FIG. 18B




FIG. 19




FIG. 20A




FIG. 20B




FIG. 21A




FIG. 21B




FIG. 21C




FIG. 21D






FIG. 22




FIG. 23




FIG. 24

FIG. 25A
FIG. 25B
FIG. 25C
FIG. 25D
FIG. 25E
FIG. 25F
FIG. 25G
FIG. 25H
FIG. 25I
FIG. 25J
FIG. 25K
FIG. 25L
FIG. 25M

FIG. 25

Query object	red	Implicit Relationship	Type	Quality	B_Int_S	C_Int_S	p_Int_S	t_imp_V	ect	Expect	Obs/Exp	Score
Alendronate	245	Osteoarthritis	D	221.60	0.83	0.45	0.63	0.52		53.28	4.16	921.57
Alendronate	224	Uremia	CP	201.23	0.81	0.28	0.35	0.47		49.58	4.06	816.65
Alendronate	219	end-stage renal disease	CP	195.90	0.81	0.26	0.36	0.46		49.72	3.94	771.91
Alendronate	239	Breast carcinoma	CP	215.06	0.83	0.46	0.32	0.50		54.98	3.91	841.22
Alendronate	214	Hyperlipidemia	CP	190.28	0.75	0.35	0.27	0.44		49.28	3.86	734.64
Alendronate	261	Chronic renal failure	CP	235.87	0.85	0.30	0.52	0.55		62.11	3.80	895.70
Alendronate	245	Renal insufficiency	CP	222.06	0.84	0.26	0.41	0.52		58.75	3.78	839.29
Alendronate	244	Renal disease	CP	217.90	0.79	0.24	0.36	0.51		57.74	3.77	822.33
Alendronate	182	Synovitis	D	162.50	0.74	0.40	0.25	0.38		43.22	3.76	610.98
Alendronate	227	Coronary artery disease	CP	204.39	0.76	0.26	0.35	0.48		54.44	3.75	767.32
Alendronate	187	rheumatic diseases	D	167.21	0.71	0.34	0.24	0.39		44.91	3.72	622.61
Alendronate	215	Renal dysfunction	CP	190.98	0.79	0.27	0.29	0.45		51.68	3.70	705.73
Alendronate	205	Hypercholesterolemia	CP	183.28	0.72	0.40	0.28	0.43		49.66	3.69	676.36
Alendronate	176	PRIMARY BILIARY CIRRHOSIS	D	158.67	0.75	0.21	0.30	0.37		43.07	3.68	584.56
Alendronate	149	Demineralization	CP	135.12	0.75	0.43	0.30	0.32		36.99	3.65	493.52
Alendronate	209	Inflammatory bowel disease	CP	187.78	0.75	0.27	0.32	0.44		51.55	3.64	684.04
Alendronate	170	Prostatic carcinoma	CP	153.62	0.72	0.42	0.23	0.36		42.27	3.63	558.34
Alendronate	190	Peptic ulcer	CP	170.73	0.70	0.42	0.24	0.40		47.12	3.62	618.60

FIG. 25A

Query object	red	Implicit Relationship	Type	Quality	B_Int_SC	C_Int_SC	p_Int_SC	t_imp_V	ect	Expect	Obs/Exp	Score
Alendronate	203	SARCOIDOSIS	D	183.27	0.78	0.23	0.32	0.43		50.72	3.61	662.19
Alendronate	184	PAI-1	D	164.96	0.61	0.23	0.24	0.38		45.69	3.61	595.61
Alendronate	202	GASTRIC CANCER	D	183.36	0.60	0.40	0.25	0.43		52.25	3.51	643.42
Alendronate	213	IDDM	D	191.46	0.74	0.24	0.32	0.45		54.61	3.51	671.25
Alendronate	167	THYROTOXICOSIS	D	149.57	0.75	0.26	0.24	0.35		42.73	3.50	523.55
Alendronate	170	BENIGN PROSTATIC	D	151.78	0.70	0.37	0.21	0.35		43.40	3.50	530.81
Alendronate	236	ANGIOTENSIN II	D	213.87	0.59	0.23	0.36	0.50		61.49	3.48	743.80
ATORVASTATIN	325	ATORVASTATIN	SM	274.04	0.97	0.97	0.97	0.71		30.90	8.87	2430.26
ATORVASTATIN	220	FISH OIL	SM	201.04	0.87	0.51	0.57	0.52		39.39	5.10	1026.12
ATORVASTATIN	224	Angina pectoris	CP	202.74	0.87	0.56	0.48	0.53		42.62	4.76	964.38
ATORVASTATIN	221	Hyperinsulinemia	CP	199.10	0.83	0.55	0.50	0.52		42.96	4.63	922.67
ATORVASTATIN	212	Arteriosclerosis	CP	192.14	0.85	0.50	0.45	0.50		42.74	4.50	863.81
ATORVASTATIN	197	diabetic nephropathy	G	177.77	0.80	0.42	0.34	0.46		40.19	4.42	786.21
ATORVASTATIN	230	Malondialdehyde	SM	207.49	0.84	0.46	0.51	0.54		47.58	4.36	904.86
ATORVASTATIN	217	essential hypertension	G	196.87	0.84	0.40	0.51	0.51		45.47	4.33	852.45
ATORVASTATIN	236	Prostacyclin	SM	213.79	0.82	0.37	0.40	0.56		49.48	4.32	923.69
ATORVASTATIN	233	alcohol consumption	O	210.13	0.73	0.40	0.53	0.55		48.68	4.32	906.97
ATORVASTATIN	203	Lipid Peroxides	SM	185.40	0.78	0.47	0.50	0.48		43.14	4.30	796.77
ATORVASTATIN	176	chylomicrons	SM	159.27	0.84	0.67	0.52	0.41		37.14	4.29	683.07
ATORVASTATIN	179	Albuminuria	CP	161.60	0.81	0.41	0.31	0.42		37.68	4.29	693.03
ATORVASTATIN	225	end-stage renal disease	CP	201.76	0.82	0.36	0.35	0.52		47.05	4.29	865.17
ATORVASTATIN	191	Clofibrate	SM	174.16	0.86	0.47	0.50	0.45		40.69	4.28	745.44
ATORVASTATIN	185	DOCOSAHEXAENOIC ACID	SM	166.95	0.67	0.44	0.40	0.43		39.05	4.27	713.70
ATORVASTATIN	198	NITROGLYCERIN	SM	177.92	0.83	0.45	0.24	0.46		41.68	4.27	759.48
ATORVASTATIN	194	High blood pressure	CP	174.56	0.62	0.50	0.43	0.45		41.03	4.25	742.74
ATORVASTATIN	225	Linoleic Acid	SM	203.12	0.85	0.40	0.54	0.53		48.15	4.22	856.75
ATORVASTATIN	201	BETA-CAROTENE	SM	179.53	0.81	0.39	0.48	0.47		42.78	4.20	753.48
ATORVASTATIN	225	Nephrotic syndrome	CP	203.90	0.89	0.26	0.50	0.53		48.84	4.17	851.23

FIG. 25B

Query object	red	Implicit Relationship	Type	Quality	B_Int_SC	Int_SC	p_Int	t_Int	Imp_V	ect	Expect	Obs/Exp	Score
CELECOXIB	267	CELECOXIB	SM	228.96	0.95	0.95	0.95	0.95	0.69		27.63	8.29	1897.14
CELECOXIB	178	ANTI-INFLAMMATORY AGENT	SM	160.80	0.81	0.49	0.54	0.49	0.49		33.78	4.76	765.40
CELECOXIB	210	Salicylate	SM	189.23	0.83	0.36	0.64	0.64	0.57		42.43	4.46	843.84
CELECOXIB	199	leukotrienes	SM	181.54	0.88	0.38	0.54	0.54	0.55		41.32	4.39	797.72
CELECOXIB	187	Leukotriene B4	SM	170.75	0.80	0.36	0.52	0.52	0.52		39.06	4.37	746.36
CELECOXIB	186	Peptic ulcer	CP	170.61	0.81	0.38	0.55	0.55	0.52		39.17	4.36	743.06
CELECOXIB	177	Ranitidine	SM	160.76	0.75	0.25	0.42	0.42	0.49		37.12	4.33	696.31
CELECOXIB	166	Omeprazole	SM	151.11	0.78	0.23	0.40	0.40	0.46		35.05	4.31	651.39
CELECOXIB	210	Cimetidine	SM	193.34	0.80	0.25	0.54	0.54	0.59		45.06	4.29	829.67
CELECOXIB	167	PENTOXIFYLLINE	SM	151.37	0.64	0.32	0.36	0.36	0.46		35.47	4.27	646.01
CELECOXIB	185	PGE1	SM	167.68	0.78	0.34	0.43	0.43	0.51		39.69	4.23	708.48
CELECOXIB	201	Ulcerative colitis	CP	181.70	0.80	0.37	0.51	0.51	0.55		43.10	4.22	766.05
CELECOXIB	162	FISH OIL	SM	146.73	0.70	0.29	0.43	0.43	0.44		34.91	4.20	616.71
CELECOXIB	187	prostaglandin E1	CP	169.84	0.78	0.27	0.43	0.43	0.51		40.91	4.15	705.18
CELECOXIB	182	Lipoxygenase	SM	166.41	0.85	0.41	0.48	0.48	0.50		40.44	4.12	684.81
CELECOXIB	156	PGD2	SM	142.12	0.80	0.47	0.37	0.37	0.43		34.68	4.10	582.51
CELECOXIB	189	Oral Contraceptives	SM	169.91	0.68	0.23	0.40	0.40	0.51		41.48	4.10	695.99
CELECOXIB	192	C-reactive protein	G	175.35	0.77	0.26	0.51	0.51	0.53		42.93	4.08	716.14
CELECOXIB	189	ET-1	SM	172.90	0.78	0.33	0.40	0.40	0.52		42.48	4.07	703.76
CELECOXIB	177	Endothelin	SM	161.40	0.76	0.34	0.35	0.35	0.49		39.70	4.07	656.13
CELECOXIB	170	BETA-CAROTENE	SM	152.73	0.61	0.30	0.30	0.30	0.46		37.67	4.06	619.34
Finasteride	233	Infertility	CP	211.55	0.80	0.34	0.45	0.45	0.47		52.67	4.02	849.68
Finasteride	165	Hyperprolactinemia	CP	150.42	0.68	0.43	0.32	0.32	0.33		38.36	3.92	589.88
Finasteride	241	BODY MASS INDEX	D	219.31	0.83	0.32	0.48	0.48	0.48		57.32	3.83	839.15
Finasteride	168	ENDOMETRIOSIS	D	153.10	0.59	0.40	0.28	0.28	0.34		40.67	3.76	576.32
Finasteride	157	Endometrial carcinoma	CP	141.59	0.54	0.52	0.24	0.24	0.31		38.63	3.67	519.03
Finasteride	202	Ovarian cancer	CP	182.81	0.72	0.35	0.32	0.32	0.40		50.48	3.62	662.05
Finasteride	169	CORTICOTROPIN-RELEASING	D	152.08	0.48	0.34	0.23	0.23	0.34		42.04	3.62	550.14

FIG. 25C

Query object	red	Implicit Relationship	Type	Quality	B_Int_SC	Int_S	p_Int	t_imp_V	ect	Expect	Obs/Exp	Score
Finasteride	161	Amenorrhea	CP	147.44	0.53	0.39	0.32	0.33		40.89	3.61	531.59
Finasteride	216	Breast carcinoma	CP	194.31	0.72	0.46	0.34	0.43		54.29	3.58	695.52
Finasteride	234	prostaglandin E2	CP	211.91	0.70	0.20	0.31	0.47		59.26	3.58	757.78
Finasteride	138	Precocious puberty	CP	125.93	0.67	0.45	0.26	0.28		35.38	3.56	448.17
Finasteride	197	Insulin resistance	CP	178.64	0.64	0.20	0.41	0.39		50.30	3.55	634.39
Finasteride	210	Osteoporosis	CP	191.24	0.73	0.33	0.40	0.42		54.29	3.52	673.63
Finasteride	195	Bone Resorption	D	177.56	0.75	0.30	0.33	0.39		50.49	3.52	624.40
Finasteride	176	Pancreatic cancer	CP	157.63	0.67	0.35	0.25	0.35		45.11	3.49	550.72
Finasteride	165	CERVICAL CANCER	D	148.42	0.54	0.46	0.23	0.33		42.86	3.46	514.01
Finasteride	230	ANGIOTENSIN II	D	209.19	0.71	0.21	0.35	0.46		61.04	3.43	716.96
Finasteride	154	HMG-CoA REDUCTASE	D	136.56	0.47	0.31	0.18	0.30		40.33	3.39	462.43
Finasteride	166	PAI-1	D	150.43	0.65	0.19	0.23	0.33		44.65	3.37	506.76
Finasteride	160	Choriocarcinoma	D	142.53	0.46	0.33	0.21	0.31		42.47	3.36	478.30
Finasteride	210	Type 2 diabetes	D	191.15	0.75	0.17	0.34	0.42		57.29	3.34	637.81
Finasteride	261	LIPOPROTEIN	D	237.54	0.84	0.35	0.50	0.52		71.52	3.32	788.96
Finasteride	118	Anovulation	D	107.60	0.46	0.51	0.23	0.24		32.69	3.29	354.20
Finasteride	177	BETA-ADRENERGIC RECEPTOR	D	159.55	0.47	0.20	0.23	0.35		48.71	3.28	522.63
Finasteride	244	Cysts	D	222.04	0.77	0.30	0.39	0.49		68.75	3.23	717.11
Fluoxetine	597	Cerebral ischemia	CP	539.08	0.55	0.59	0.20	0.36		148.40	3.63	1958.35
Fluoxetine	508	Ventricular fibrillation	CP	460.59	0.54	0.60	0.14	0.31		133.48	3.45	1589.29
Fluoxetine	487	Ventricular tachycardia	CP	440.43	0.52	0.60	0.14	0.29		129.29	3.41	1500.31
Fluoxetine	479	Hyperventilation	CP	434.21	0.50	0.57	0.16	0.29		127.80	3.40	1475.25
Fluoxetine	548	Myocardial Ischemia	D	497.89	0.54	0.55	0.21	0.33		147.12	3.38	1684.96
Fluoxetine	616	Coronary artery disease	CP	561.26	0.55	0.54	0.26	0.37		167.18	3.36	1884.29
Fluoxetine	550	prostaglandin E1	CP	499.03	0.53	0.53	0.15	0.33		148.67	3.36	1675.11
Fluoxetine	626	Acidosis	CP	566.73	0.50	0.49	0.19	0.38		169.56	3.34	1894.27
Fluoxetine	525	Angina	CP	475.28	0.53	0.57	0.22	0.32		142.74	3.33	1582.57
Fluoxetine	691	Ulcer	CP	627.52	0.62	0.44	0.22	0.42		190.67	3.29	2065.30

FIG. 25D



Query object	red	Implicit Relationship	Type	Quality	B_Int_SC	Int_Sp_Int	t_imp_V	ect	Expect	Obs/Exp	Score
Fluoxetine	537	Ischemic heart disease	CP	487.22	0.52	0.54	0.16	0.32	148.89	3.27	1594.40
Fluoxetine	695	Encephalopathy	CP	630.45	0.65	0.43	0.24	0.42	193.46	3.26	2054.50
Fluoxetine	455	High blood pressure	CP	408.49	0.45	0.64	0.13	0.27	126.01	3.24	1324.19
Fluoxetine	436	Status epilepticus	CP	393.78	0.47	0.69	0.14	0.26	121.50	3.24	1276.19
Fluoxetine	566	NGF	D	515.97	0.53	0.56	0.20	0.34	169.34	3.05	1572.17
Fluoxetine	475	Cerebral Infarction	D	427.73	0.46	0.51	0.14	0.28	141.12	3.03	1296.45
Fluoxetine	459	Tetanus	D	412.04	0.44	0.32	0.13	0.27	136.00	3.03	1248.32
Fluoxetine	409	Ventricular Dysfunction	D	370.09	0.44	0.58	0.12	0.25	123.34	3.00	1110.44
Fluoxetine	572	Contracture	D	513.33	0.51	0.48	0.15	0.34	171.93	2.99	1532.65
Fluoxetine	455	Anaphylaxis	D	406.38	0.41	0.50	0.11	0.27	136.54	2.98	1209.45
Fluoxetine	449	Asphyxia	D	403.89	0.44	0.47	0.13	0.27	137.30	2.94	1188.10
Fluoxetine	547	IDDM	D	493.52	0.46	0.52	0.16	0.33	167.79	2.94	1451.57
Fluoxetine	427	AMYOTROPHIC LATERAL	D	382.68	0.43	0.50	0.13	0.25	131.86	2.90	1110.55
Fluoxetine	497	RESPIRATORY DISTRESS	D	449.25	0.50	0.40	0.13	0.30	155.55	2.89	1297.50
Fluoxetine	599	CYSTIC FIBROSIS	D	541.48	0.45	0.38	0.15	0.36	190.06	2.85	1542.69
Fluoxetine	531	Aneurysm	D	479.92	0.45	0.50	0.15	0.32	169.65	2.83	1357.59
Fluoxetine	390	THYROTOXICOSIS	D	348.42	0.39	0.49	0.10	0.23	124.10	2.81	978.22
GEMCITABINE	552	GEMCITABINE	SM	476.63	0.98	0.98	0.98	0.74	48.89	9.75	4646.57
GEMCITABINE	297	BCNU	SM	272.13	0.85	0.66	0.33	0.42	58.17	4.68	1273.01
GEMCITABINE	325	myelodysplastic syndrome	D	296.57	0.82	0.52	0.28	0.46	63.53	4.67	1384.51
GEMCITABINE	376	Osteosarcoma	CP	342.55	0.85	0.49	0.35	0.53	75.50	4.54	1554.10
GEMCITABINE	374	ACUTE LYMPHOBLASTIC	D	341.24	0.83	0.52	0.35	0.53	75.28	4.53	1546.86
GEMCITABINE	295	GANCICLOVIR	SM	270.38	0.76	0.42	0.30	0.42	60.06	4.50	1217.30
GEMCITABINE	337	GRANULOCYTE-MACROPHAGE	D	309.33	0.88	0.45	0.36	0.48	72.52	4.27	1319.38
GEMCITABINE	320	carcinoembryonic antigen	G	292.37	0.76	0.53	0.38	0.45	69.53	4.20	1229.33
GEMCITABINE	273	Chlorambucil	SM	248.97	0.75	0.53	0.22	0.38	59.91	4.16	1034.74
GEMCITABINE	270	FAS LIGAND	D	246.12	0.76	0.55	0.21	0.38	60.00	4.10	1009.57
GEMCITABINE	274	Colon adenocarcinoma	CP	249.68	0.79	0.54	0.26	0.39	61.89	4.03	1007.20

FIG. 25E

Query object	red	Implicit Relationship	Type	Quality	B_Int_SC_Int_Slp_Int_t Imp_V ect	Expect	Obs/Exp	Score
GEMCITABINE	256	Endometrial carcinoma	CP	230.33	0.68 0.52 0.25 0.36	57.56	4.00	921.78
GEMCITABINE	267	Medulloblastoma	G	241.67	0.76 0.52 0.23 0.37	60.40	4.00	967.05
GEMCITABINE	244	Gastric adenocarcinoma	CP	219.98	0.72 0.58 0.23 0.34	55.10	3.99	878.26
GEMCITABINE	277	T-Cell Leukemia	D	249.65	0.65 0.44 0.17 0.39	63.28	3.95	984.92
GEMCITABINE	241	Telomerase	SM	217.59	0.66 0.54 0.26 0.34	55.38	3.93	854.97
GEMCITABINE	330	AFP	G	300.47	0.77 0.43 0.31 0.46	76.52	3.93	1179.83
GEMCITABINE	287	Pancytopenia	CP	261.03	0.75 0.41 0.23 0.40	66.60	3.92	1023.01
GEMCITABINE	261	PROSTATE-SPECIFIC ANTIGEN	G	239.11	0.67 0.58 0.26 0.37	61.05	3.92	936.49
GEMCITABINE	293	MACROPHAGE COLONY-	SM	266.06	0.73 0.41 0.25 0.41	67.94	3.92	1041.90
INDINAVIR	260	Ranitidine	SM	231.35	0.44 0.20 0.15 0.37	59.81	3.87	894.90
INDINAVIR	293	Chronic hepatitis	CP	263.60	0.59 0.48 0.33 0.42	68.26	3.86	1017.93
INDINAVIR	284	beta 2-Microglobulin	SM	254.96	0.59 0.37 0.24 0.41	66.14	3.86	982.93
INDINAVIR	273	Liver failure	CP	244.25	0.66 0.35 0.18 0.39	63.41	3.85	940.82
INDINAVIR	268	Normal renal function	CP	238.73	0.45 0.41 0.16 0.38	62.08	3.85	918.07
INDINAVIR	260	Skin rash	CP	230.63	0.64 0.40 0.14 0.37	60.26	3.83	882.60
INDINAVIR	287	end-stage renal disease	CP	256.49	0.52 0.38 0.20 0.41	67.39	3.81	976.23
INDINAVIR	296	Azathioprine	SM	265.53	0.43 0.44 0.19 0.42	70.13	3.79	1005.43
INDINAVIR	275	Liver dysfunction	CP	245.30	0.62 0.37 0.17 0.39	64.81	3.79	928.51
INDINAVIR	312	METHYLPREDNISOLONE	SM	280.70	0.53 0.35 0.20 0.45	74.48	3.77	1057.93
INDINAVIR	268	Arthralgia	CP	238.74	0.44 0.35 0.16 0.38	63.48	3.76	897.77
INDINAVIR	292	Nephrotic syndrome	CP	261.22	0.60 0.43 0.20 0.42	70.14	3.72	972.90
INDINAVIR	309	Cimetidine	SM	277.94	0.70 0.23 0.19 0.44	74.77	3.72	1033.17
INDINAVIR	264	Myalgia	CP	235.75	0.43 0.39 0.16 0.38	63.73	3.70	872.02
INDINAVIR	274	Chronic Infection	CP	248.04	0.59 0.40 0.23 0.40	67.21	3.69	915.44
INDINAVIR	297	Lymphadenopathy	CP	266.07	0.53 0.41 0.25 0.43	72.25	3.68	979.78
INDINAVIR	257	Allopurinol	SM	229.32	0.46 0.29 0.16 0.37	62.49	3.67	841.55
INDINAVIR	275	AMPHOTERICIN B	SM	247.33	0.63 0.43 0.22 0.40	67.66	3.66	904.07
INDINAVIR	277	IBUPROFEN	SM	244.89	0.46 0.26 0.16 0.39	67.02	3.65	894.80

FIG. 25F

Query object	red	Implicit Relationship	Type	Quality	B_Int_SC	Int_SC	Int_Slp	Int_Slp	t_Imp_V	ect	Expect	Obs/Exp	Score
LOSARTAN	541	Angina pectoris	CP	498.49	0.82	0.77	0.36	0.39			121.88	4.09	2038.81
LOSARTAN	621	brain injury	D	571.79	0.76	0.58	0.30	0.45			141.78	4.03	2305.93
LOSARTAN	487	Endotoxemia	D	447.01	0.70	0.65	0.23	0.35			114.85	3.89	1739.79
LOSARTAN	565	Septic Shock	D	519.19	0.74	0.54	0.28	0.41			134.39	3.86	2005.76
LOSARTAN	512	Subarachnoid hemorrhage	CP	471.43	0.72	0.48	0.29	0.37			122.30	3.85	1817.16
LOSARTAN	661	Hypothermia	CP	607.05	0.81	0.59	0.35	0.48			159.08	3.82	2316.53
LOSARTAN	501	Arteriosclerosis	CP	458.84	0.80	0.65	0.25	0.36			122.26	3.75	1721.97
LOSARTAN	574	RESPIRATORY DISTRESS	D	528.87	0.79	0.43	0.28	0.41			140.94	3.75	1984.56
LOSARTAN	618	Liver cirrhosis	CP	564.29	0.83	0.44	0.30	0.44			151.14	3.73	2106.72
LOSARTAN	454	Hyperoxia	CP	413.82	0.69	0.68	0.19	0.32			111.88	3.70	1530.63
LOSARTAN	691	Alzheimer's disease	D	638.53	0.76	0.43	0.33	0.50			173.54	3.68	2349.44
LOSARTAN	432	Hemorrhagic Shock	CP	394.97	0.72	0.69	0.19	0.31			108.08	3.65	1443.34
LOSARTAN	502	Chronic obstructive pulmonary	CP	459.37	0.79	0.50	0.27	0.36			125.90	3.65	1676.13
LOSARTAN	545	Cardiac arrhythmias	D	501.22	0.81	0.61	0.32	0.39			138.97	3.61	1807.73
LOSARTAN	544	Bone Resorption	D	500.16	0.63	0.50	0.22	0.39			141.06	3.55	1773.42
LOSARTAN	510	Spasm	D	467.36	0.73	0.60	0.27	0.37			134.09	3.49	1628.93
LOSARTAN	714	Rupture	D	659.14	0.84	0.47	0.39	0.52			191.88	3.44	2264.31
LOSARTAN	577	Parkinson's Disease	D	527.10	0.70	0.37	0.25	0.41			153.98	3.42	1804.39
LOSARTAN	740	Sepsis	D	685.18	0.83	0.41	0.43	0.54			202.06	3.39	2323.45
LOSARTAN	553	PROSTATE CANCER	D	508.70	0.61	0.44	0.22	0.40			153.11	3.32	1690.07
LOSARTAN	471	Cerebral Infarction	D	428.73	0.74	0.53	0.23	0.34			129.11	3.32	1423.64
LOSARTAN	548	Aneurysm	D	506.25	0.79	0.51	0.33	0.40			152.51	3.32	1680.49
LOSARTAN	439	Cholera	D	398.12	0.59	0.46	0.16	0.31			120.60	3.30	1314.33
LOSARTAN	529	Osteoarthritis	D	482.62	0.63	0.45	0.24	0.38			146.99	3.28	1584.68
OLANZAPINE	477	OLANZAPINE	SM	409.37	0.98	0.98	0.98	0.77			37.56	10.90	4461.43
OLANZAPINE	245	Anxiety disorder	D	222.74	0.56	0.70	0.31	0.42			42.09	5.29	1178.64
OLANZAPINE	261	monoamine oxidase inhibitors	SM	237.11	0.71	0.53	0.27	0.45			45.66	5.19	1231.36
OLANZAPINE	282	Homovanillic Acid	SM	257.57	0.84	0.62	0.40	0.48			49.92	5.16	1329.00

FIG. 25G

Query object	red	Implicit Relationship	Type	Quality	B_Int_SC	Int_SC	p_Int	t_imp_V	ect	Expect	Obs/Exp	Score
OLANZAPINE	237	METHYLPHENIDATE	SM	213.41	0.79	0.59	0.24	0.40		41.42	5.15	1099.41
OLANZAPINE	219	PANIC DISORDER	D	200.44	0.54	0.57	0.26	0.38		40.79	4.91	984.94
OLANZAPINE	244	Disinhibition	CP	220.04	0.80	0.57	0.23	0.41		44.87	4.90	1079.19
OLANZAPINE	251	Sleep disturbance	CP	228.77	0.80	0.51	0.24	0.43		46.81	4.89	1118.00
OLANZAPINE	232	autoreceptors	SM	211.33	0.78	0.67	0.28	0.40		43.42	4.87	1028.44
OLANZAPINE	244	METHAMPHETAMINE	SM	219.86	0.78	0.60	0.29	0.41		45.82	4.80	1055.02
OLANZAPINE	296	Migraine	CP	267.59	0.72	0.41	0.30	0.50		57.34	4.67	1248.70
OLANZAPINE	327	Naloxone	SM	298.67	0.86	0.41	0.39	0.56		64.37	4.64	1385.82
OLANZAPINE	268	YOHIMBINE	SM	243.58	0.77	0.48	0.30	0.46		52.65	4.63	1126.77
OLANZAPINE	266	Myoclonus	CP	238.79	0.67	0.39	0.24	0.45		51.64	4.62	1104.16
OLANZAPINE	238	Cyproheptadine	SM	216.79	0.66	0.48	0.24	0.41		47.13	4.60	997.28
OLANZAPINE	300	Monoamine oxidase	G	275.56	0.85	0.39	0.35	0.52		60.43	4.56	1256.50
OLANZAPINE	244	Physostigmine	SM	222.28	0.65	0.49	0.26	0.42		48.77	4.56	1012.96
OLANZAPINE	217	LITHIUM CARBONATE	SM	194.15	0.65	0.55	0.20	0.37		43.00	4.52	876.72
OLANZAPINE	239	Amnesia	D	214.85	0.53	0.40	0.21	0.40		47.78	4.50	966.10
OLANZAPINE	326	gamma-Aminobutyric Acid	SM	298.24	0.85	0.52	0.36	0.56		66.70	4.47	1333.41
OLANZAPINE	256	Midazolam	SM	232.03	0.55	0.36	0.22	0.44		51.95	4.47	1036.42
OLANZAPINE	290	Melatonin	SM	264.10	0.83	0.37	0.31	0.50		59.73	4.42	1167.83
Omeprazole	1419	Omeprazole	SM	1235.92	0.98	0.98	0.98	0.77		262.60	4.71	5816.86
Omeprazole	834	Tachykinin	D	763.93	0.66	2.65	0.27	0.48		229.93	3.32	2538.10
Omeprazole	843	calcium channel	O	768.36	0.73	1.47	0.23	0.48		232.27	3.31	2541.80
Omeprazole	807	bradykinin	G	737.98	0.54	2.03	0.24	0.46		223.27	3.31	2439.25
Omeprazole	921	noradrenaline	SM	844.80	0.66	4.17	0.31	0.53		262.04	3.22	2723.61
Omeprazole	852	Hyperglycemia	CP	778.04	0.67	1.62	0.23	0.49		244.26	3.19	2478.31
Omeprazole	871	Cisplatin	SM	793.64	0.73	2.77	0.25	0.50		250.71	3.17	2512.33
Omeprazole	845	DMSO	SM	769.36	0.64	0.84	0.21	0.48		244.10	3.15	2424.92
Omeprazole	883	gh	G	809.03	0.59	4.07	0.27	0.51		260.93	3.10	2508.47
Omeprazole	940	Hydrogen Peroxide	SM	859.56	0.69	2.36	0.26	0.54		282.73	3.04	2613.22

FIG. 25H

Query object	red	Implicit Relationship	Type	Quality	B_Int_SC	Int_SC	Int_Sp	t_imp_V	Expect	Obs/Exp	Score
Omeprazole	891	TNF	G	814.88	0.64	3.74	0.25	0.51	268.66	3.03	2471.62
Omeprazole	891	Concanavalin A	SM	811.21	0.64	1.61	0.24	0.51	269.60	3.01	2440.90
Omeprazole	886	Thrombosis	CP	809.45	0.70	2.70	0.25	0.51	271.14	2.99	2416.46
Omeprazole	1017	Lactate	SM	933.64	0.78	4.77	0.30	0.58	316.37	2.95	2755.26
Omeprazole	934	Glycerol	SM	850.67	0.60	2.04	0.24	0.53	290.43	2.93	2491.57
Omeprazole	969	Glutamate	SM	888.48	0.61	3.83	0.29	0.55	303.69	2.93	2599.40
Omeprazole	1030	Heparin	SM	947.54	0.77	3.63	0.33	0.59	323.97	2.92	2771.34
Omeprazole	1000	Seizures	CP	913.12	0.72	2.76	0.30	0.57	325.69	2.80	2560.08
Omeprazole	1013	Leukemia	CP	930.32	0.75	3.77	0.30	0.58	355.65	2.62	2433.58
PIOGLITAZONE	151	Insulinoma	CP	134.71	0.69	0.41	0.47	0.40	31.70	4.25	572.58
PIOGLITAZONE	141	Glomerulosclerosis	CP	126.54	0.81	0.33	0.40	0.38	30.72	4.12	521.27
PIOGLITAZONE	152	cardiac hypertrophy	CP	138.36	0.74	0.37	0.36	0.42	33.83	4.09	565.92
PIOGLITAZONE	180	IDDM	D	162.86	0.84	0.42	0.65	0.49	40.46	4.03	655.57
PIOGLITAZONE	162	Hypercholesterolemia	CP	147.79	0.77	0.53	0.58	0.44	36.98	4.00	590.67
PIOGLITAZONE	115	Metabolic Syndrome	CP	105.01	0.80	0.67	0.55	0.32	26.38	3.98	418.09
PIOGLITAZONE	137	Endotoxemia	D	123.94	0.60	0.31	0.35	0.37	32.03	3.87	479.58
PIOGLITAZONE	136	Fatty liver	CP	123.83	0.80	0.33	0.45	0.37	32.21	3.84	476.03
PIOGLITAZONE	134	Steatosis	CP	120.46	0.79	0.38	0.42	0.36	31.35	3.84	462.84
PIOGLITAZONE	166	GLUTATHIONE PEROXIDASE	D	149.37	0.72	0.22	0.45	0.45	38.95	3.83	572.78
PIOGLITAZONE	172	aldosterone	CP	155.31	0.67	0.23	0.56	0.47	40.82	3.80	590.89
PIOGLITAZONE	148	Pancreatic cancer	CP	130.85	0.70	0.28	0.34	0.39	34.49	3.79	496.36
PIOGLITAZONE	154	BETA-ADRENERGIC RECEPTOR	D	139.98	0.66	0.28	0.46	0.42	36.94	3.79	530.49
PIOGLITAZONE	170	Acidosis	CP	154.18	0.82	0.20	0.51	0.46	40.80	3.78	582.64
PIOGLITAZONE	175	Colon cancer	CP	157.14	0.82	0.28	0.39	0.47	41.76	3.76	591.25
PIOGLITAZONE	154	Exhaustion	CP	137.89	0.70	0.26	0.49	0.41	36.67	3.76	518.45
PIOGLITAZONE	149	Myocardial Ischemia	D	134.16	0.67	0.29	0.41	0.40	36.50	3.68	493.06
PIOGLITAZONE	183	Starvation	D	165.03	0.69	0.31	0.59	0.50	45.13	3.66	603.48
PIOGLITAZONE	149	Septic Shock	D	133.02	0.58	0.24	0.32	0.40	36.59	3.64	483.62

FIG. 25I

Query object	red	Implicit Relationship	Type	Quality	B_Int_SC	Int_SC	Sp_Int	t_imp_V	ect	Expect	Obs/Exp	Score
PIOGLITAZONE	132	Reperfusion Injury	D	118.49	0.59	0.26	0.27	0.36		32.87	3.60	427.09
PIOGLITAZONE	151	Bone Resorption	D	136.14	0.80	0.22	0.29	0.41		38.14	3.57	485.92
PIOGLITAZONE	126	CORTICOTROPIN-RELEASING	D	113.84	0.59	0.21	0.31	0.34		32.41	3.51	399.92
PIOGLITAZONE	152	COLORECTAL CANCER	D	135.81	0.64	0.27	0.34	0.41		38.74	3.51	476.10
PIOGLITAZONE	159	PROSTATE CANCER	D	143.09	0.79	0.28	0.34	0.43		40.96	3.49	499.88
PIOGLITAZONE	174	Alzheimer's disease	D	157.53	0.83	0.13	0.45	0.47		45.72	3.45	542.70
ROFECOXIB	156	Peptic ulcer	CP	142.19	0.81	0.40	0.53	0.61		32.39	4.39	624.24
ROFECOXIB	157	prostaglandin E1	CP	143.56	0.79	0.25	0.47	0.61		33.78	4.25	610.08
ROFECOXIB	150	Anaphylaxis	D	134.78	0.77	0.30	0.42	0.58		31.77	4.24	571.78
ROFECOXIB	150	Gastritis	CP	136.48	0.80	0.33	0.46	0.58		32.86	4.15	566.89
ROFECOXIB	154	Spasm	D	138.55	0.74	0.33	0.41	0.59		33.54	4.13	572.37
ROFECOXIB	144	Chronic obstructive pulmonary	CP	130.58	0.62	0.28	0.38	0.56		31.88	4.10	534.83
ROFECOXIB	138	rheumatic diseases	D	125.49	0.79	0.31	0.55	0.54		31.04	4.04	507.37
ROFECOXIB	156	Inflammatory bowel disease	CP	141.33	0.84	0.24	0.46	0.60		35.09	4.03	569.27
ROFECOXIB	156	Colitis	D	141.29	0.85	0.25	0.45	0.60		35.26	4.01	566.13
ROFECOXIB	147	Myocardial Ischemia	D	133.62	0.66	0.37	0.40	0.57		33.53	3.99	532.49
ROFECOXIB	161	Chronic Inflammation	CP	145.94	0.86	0.30	0.49	0.62		36.65	3.98	581.10
ROFECOXIB	148	Cerebral ischemia	CP	133.74	0.72	0.37	0.39	0.57		33.74	3.96	530.10
ROFECOXIB	142	Migraine	CP	129.08	0.64	0.39	0.52	0.55		32.74	3.94	508.95
ROFECOXIB	155	Ulcerative colitis	CP	140.09	0.78	0.23	0.44	0.60		35.55	3.94	552.06
ROFECOXIB	132	Reperfusion Injury	D	119.68	0.62	0.40	0.35	0.51		30.38	3.94	471.48
ROFECOXIB	135	Angina pectoris	CP	122.29	0.55	0.34	0.33	0.52		31.07	3.94	481.30
ROFECOXIB	146	Pulmonary Edema	D	132.96	0.62	0.27	0.38	0.57		33.99	3.91	520.07
ROFECOXIB	141	Angina	CP	127.73	0.53	0.40	0.36	0.55		32.80	3.89	497.38
ROFECOXIB	169	Renal insufficiency	CP	153.52	0.85	0.23	0.52	0.66		39.48	3.89	596.89
ROFECOXIB	148	Pulmonary hypertension	CP	134.87	0.77	0.26	0.42	0.58		34.84	3.87	522.02
ROFECOXIB	118	Pleurisy	CP	104.80	0.68	0.27	0.35	0.45		27.16	3.86	404.44
ROFECOXIB	142	Bronchial asthma	CP	127.93	0.55	0.28	0.41	0.55		33.30	3.84	491.51

FIG. 25J

Query object	red	Implicit Relationship	Type	Quality	B_Int_S	C_Int_S	p_Int	t_Imp_V	ect	Expect	Obs/Exp	Score
ROFECOXIB	154	Peritonitis	CP	140.31	0.78	0.21	0.45	0.60		36.60	3.83	537.88
ROFECOXIB	158	Liver cirrhosis	CP	141.79	0.77	0.18	0.38	0.61		36.99	3.83	543.52
ROFECOXIB	127	High blood pressure	CP	115.04	0.56	0.35	0.28	0.49		30.03	3.83	440.80
ROFECOXIB	124	peripheral vascular disease	CP	111.89	0.52	0.35	0.29	0.48		29.21	3.83	428.63
ROFECOXIB	148	RESPIRATORY DISTRESS	D	133.74	0.70	0.20	0.42	0.57		34.93	3.83	512.13
ROFECOXIB	173	ANGIOTENSIN II	D	157.25	0.88	0.26	0.45	0.67		41.16	3.82	600.80
ROFECOXIB	125	Endotoxemia	D	112.66	0.66	0.31	0.37	0.48		29.65	3.80	428.10
ROFECOXIB	142	BETA-ADRENERGIC RECEPTOR	D	128.35	0.65	0.12	0.33	0.55		33.90	3.79	485.94
ROFECOXIB	148	GLUTATHIONE PEROXIDASE	D	133.94	0.76	0.18	0.40	0.57		35.65	3.76	503.21
ROFECOXIB	131	PAI-1	D	118.11	0.67	0.18	0.33	0.50		31.51	3.75	442.71
Sertraline	300	Delirium	D	272.18	0.80	0.62	0.31	0.40		56.65	4.80	1307.66
Sertraline	352	amygdala	CP	320.50	0.84	0.66	0.36	0.47		71.27	4.50	1441.32
Sertraline	244	Sleep Deprivation	D	220.15	0.76	0.60	0.25	0.32		50.53	4.36	959.09
Sertraline	249	sleep disorders	CP	224.29	0.65	0.51	0.22	0.33		52.07	4.31	966.25
Sertraline	394	Exploratory	CP	356.79	0.83	0.41	0.35	0.52		86.81	4.11	1466.39
Sertraline	254	Hyperalgesia	D	227.89	0.55	0.41	0.17	0.33		56.17	4.06	924.52
Sertraline	225	Catalepsy	D	205.30	0.66	0.62	0.18	0.30		51.05	4.02	825.69
Sertraline	239	Tiredness	CP	215.13	0.64	0.54	0.17	0.31		54.48	3.95	849.44
Sertraline	231	Cognitive dysfunction	CP	205.59	0.45	0.57	0.18	0.30		52.47	3.92	805.56
Sertraline	421	Epilepsy	CP	383.32	0.82	0.50	0.42	0.56		100.21	3.83	1466.23
Sertraline	362	Vasoconstriction	CP	325.10	0.61	0.38	0.31	0.47		85.28	3.81	1239.41
Sertraline	251	Disorientation	CP	223.66	0.56	0.43	0.16	0.33		60.01	3.73	833.60
Sertraline	243	Asthenia	CP	217.24	0.73	0.47	0.16	0.32		58.54	3.71	806.11
Sertraline	286	Angina	CP	257.03	0.48	0.47	0.27	0.38		69.49	3.70	950.76
Sertraline	256	Hyperventilation	CP	231.77	0.47	0.35	0.21	0.34		62.66	3.70	857.29
Sertraline	250	Palpitations	CP	223.05	0.56	0.53	0.19	0.33		60.31	3.70	824.89
Sertraline	294	Spasm	D	264.25	0.52	0.41	0.23	0.39		71.52	3.69	976.28
Sertraline	276	Myocardial Ischemia	D	246.93	0.47	0.42	0.26	0.36		71.49	3.45	852.88

FIG. 25K



Query object	red	Implicit Relationship	Type	Quality	B_Int	S_C_Int	S_p_Int	t_Imp_V	ect	Expect	Obs/Exp	Score
Sertraline	351	ANGIOTENSIN II	D	317.20	0.57	0.33	0.29	0.46		92.50	3.43	1087.69
Sertraline	169	NARCOLEPSY	D	152.19	0.57	0.43	0.13	0.22		46.00	3.31	503.48
Sertraline	196	Senile dementia	D	174.49	0.43	0.52	0.14	0.25		52.83	3.30	576.36
Sertraline	175	chronic fatigue syndrome	D	157.43	0.55	0.55	0.16	0.23		48.33	3.26	512.84
Simvastatin	413	High blood pressure	CP	373.10	0.65	0.70	0.29	0.41		91.17	4.09	1526.79
Simvastatin	526	Liver cirrhosis	CP	474.48	0.69	0.51	0.27	0.52		117.49	4.04	1916.10
Simvastatin	391	Preeclampsia	CP	356.90	0.60	0.50	0.21	0.39		89.73	3.98	1419.53
Simvastatin	390	Fatty liver	CP	352.77	0.76	0.57	0.26	0.39		90.35	3.90	1377.49
Simvastatin	390	Glucose intolerance	CP	350.73	0.70	0.69	0.29	0.38		90.24	3.89	1363.20
Simvastatin	444	Chronic liver disease	CP	397.42	0.60	0.48	0.21	0.43		103.69	3.83	1523.20
Simvastatin	469	GLUTATHIONE PEROXIDASE	D	424.75	0.74	0.59	0.31	0.46		112.43	3.78	1604.73
Simvastatin	413	Hepatic dysfunction	CP	369.47	0.76	0.46	0.17	0.40		98.47	3.75	1386.30
Simvastatin	406	Chronic obstructive pulmonary	CP	365.03	0.60	0.39	0.20	0.40		98.19	3.72	1357.03
Simvastatin	446	Cholestasis	CP	404.84	0.75	0.52	0.26	0.44		109.02	3.71	1503.40
Simvastatin	367	Endotoxemia	D	330.98	0.53	0.52	0.18	0.36		89.75	3.69	1220.65
Simvastatin	426	Septic Shock	D	384.86	0.55	0.46	0.21	0.42		104.69	3.68	1414.84
Simvastatin	522	prostaglandin E2	CP	474.54	0.68	0.48	0.26	0.52		129.30	3.67	1741.59
Simvastatin	497	Cardiomyopathy	CP	451.41	0.78	0.50	0.29	0.49		123.65	3.65	1647.95
Simvastatin	361	Diabetic Retinopathy	D	326.28	0.58	0.51	0.19	0.36		89.45	3.65	1190.09
Simvastatin	442	RESPIRATORY DISTRESS	D	397.49	0.59	0.35	0.21	0.43		109.69	3.62	1440.40
Simvastatin	420	BETA-ADRENERGIC RECEPTOR	D	377.98	0.58	0.42	0.20	0.41		105.82	3.57	1350.07
Simvastatin	330	Pre-Eclampsia	D	297.51	0.53	0.49	0.15	0.32		83.82	3.55	1055.97
Simvastatin	387	DILATED CARDIOMYOPATHY	D	349.61	0.58	0.55	0.20	0.38		99.39	3.52	1229.80
Simvastatin	276	Hyperhomocysteinemia	D	251.55	0.61	0.63	0.17	0.27		72.26	3.48	875.72
Simvastatin	503	CYSTIC FIBROSIS	D	456.17	0.70	0.35	0.25	0.50		131.33	3.47	1584.49
Simvastatin	455	PROSTATE CANCER	D	412.68	0.65	0.48	0.20	0.45		119.00	3.47	1431.16
Simvastatin	404	Pulmonary Edema	D	366.69	0.49	0.45	0.20	0.40		106.16	3.45	1266.56
Simvastatin	412	Cardiac arrhythmias	D	373.31	0.60	0.40	0.20	0.41		108.19	3.45	1288.12

FIG. 25L



Query object	red	Implicit Relationship	Type	Quality	B_Int_S	C_Int_S	p_Int	t_Imp_V	ect	Expect	Obs/Exp	Score
Simvastatin	427	GASTRIC CANCER	D	382.82	0.57	0.41	0.19	0.42		111.94	3.42	1309.25
Simvastatin	390	Hepatitis C	D	351.74	0.58	0.46	0.18	0.38		103.37	3.40	1196.89
Simvastatin	508	Systemic lupus erythematosus	D	463.51	0.69	0.35	0.28	0.51		136.26	3.40	1576.73
Simvastatin	416	Colitis	D	374.01	0.45	0.31	0.18	0.41		110.97	3.37	1260.60
Simvastatin	436	Aneurysm	D	397.65	0.66	0.52	0.24	0.43		118.54	3.35	1333.94
Simvastatin	421	Osteoarthritis	D	380.97	0.59	0.35	0.19	0.42		114.32	3.33	1269.60
TIROFIBAN	136	TIROFIBAN	SM	114.41	0.97	0.97	0.97	0.78		11.57	9.89	1131.04
TIROFIBAN	91	Fibrinopeptide A	SM	83.30	0.89	0.43	0.51	0.57		14.02	5.94	494.82
TIROFIBAN	101	STREPTOKINASE	SM	91.50	0.91	0.54	0.59	0.63		15.59	5.87	536.93
TIROFIBAN	97	Antithrombin	CP	88.08	0.91	0.37	0.53	0.60		15.06	5.85	515.21
TIROFIBAN	87	VENOUS THROMBOEMBOLISM	D	78.26	0.76	0.39	0.50	0.54		14.30	5.47	428.22
TIROFIBAN	97	peripheral vascular disease	CP	87.58	0.79	0.28	0.48	0.60		16.13	5.43	475.53
TIROFIBAN	94	Coronary Disease	D	84.28	0.78	0.47	0.43	0.58		15.60	5.40	455.39
TIROFIBAN	90	Coronary atherosclerosis	CP	80.89	0.61	0.35	0.39	0.55		15.00	5.39	436.34
TIROFIBAN	95	Arterial occlusion	CP	85.30	0.78	0.36	0.44	0.58		15.86	5.38	458.80
TIROFIBAN	92	Deep vein thrombosis	CP	82.74	0.65	0.39	0.53	0.57		15.49	5.34	441.98
TIROFIBAN	102	Angina pectoris	CP	92.03	0.66	0.47	0.50	0.63		17.33	5.31	488.85
TIROFIBAN	101	Atrial fibrillation	CP	92.25	0.67	0.28	0.55	0.63		17.39	5.30	489.34
TIROFIBAN	111	WARFARIN	SM	100.43	0.84	0.43	0.62	0.69		18.99	5.29	531.27
TIROFIBAN	76	Peripheral arterial disease	CP	67.39	0.72	0.34	0.36	0.46		13.03	5.17	348.48
TIROFIBAN	83	Cardiogenic Shock	D	75.81	0.88	0.48	0.46	0.52		14.78	5.13	388.81
TIROFIBAN	91	PLASMINOGEN ACTIVATOR	Gh	82.06	0.64	0.21	0.44	0.56		16.06	5.11	419.35
TIROFIBAN	85	Transient ischemic attacks	CP	77.08	0.85	0.49	0.49	0.53		15.14	5.09	392.51
TIROFIBAN	77	Coronary Stenosis	D	68.61	0.71	0.57	0.35	0.47		13.49	5.09	349.06
TIROFIBAN	80	Intermittent claudication	CP	71.37	0.54	0.27	0.33	0.49		14.10	5.06	361.21
TIROFIBAN	86	ABDOMINAL AORTIC	D	76.79	0.61	0.30	0.38	0.53		15.20	5.05	387.95
TIROFIBAN	105	UROKINASE	G	94.50	0.82	0.25	0.60	0.65		18.71	5.05	477.32
TIROFIBAN	95	Reperfusion Injury	D	85.27	0.77	0.31	0.40	0.58		16.88	5.05	430.66

FIG. 25M




FIG. 26

FIG. 27-1A
FIG. 27-1B
FIG. 27-1C
FIG. 27-1D
FIG. 27-1E
FIG. 27-1F

FIG. 27-1

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Cytokine	15	8.80	8.49	1.04	-0.40
Kinase	15	7.66	8.97	0.85	-0.59
Carcinoma	15	8.33	10.01	0.83	-0.61
Actin	14	11.61	6.42	1.81	0.37
Transcription Factors	14	11.60	6.79	1.71	0.27
repetitive sequence	14	10.67	6.91	1.54	0.10
BREAST CANCER	14	8.90	6.45	1.38	-0.06

FIG. 27-1A

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Adenocarcinoma	14	9.38	6.86	1.37	-0.07
Serine	14	11.53	8.96	1.29	-0.15
EGF	14	6.81	5.90	1.15	-0.29
Apoptosis	14	6.49	8.58	0.76	-0.68
Calcium	14	7.45	10.16	0.73	-0.71
Ribosomal RNA	13	10.65	4.44	2.40	0.96
Ribonuclease	13	11.80	6.22	1.90	0.46
Alternative splicing	13	10.59	5.88	1.80	0.36
Chromatin	13	10.05	5.83	1.72	0.28
Fibronectin	13	9.23	5.36	1.72	0.28
Threonine	13	10.81	6.93	1.56	0.12
Tyrosine kinase	13	7.12	5.48	1.30	-0.14
Alkaline Phosphatase	13	9.03	7.00	1.29	-0.15
Phosphatase	13	8.17	6.85	1.19	-0.25
Immunoglobulin G	13	8.98	8.18	1.10	-0.34
Glycoprotein	13	7.98	8.27	0.97	-0.47
Glucose	13	8.40	9.65	0.87	-0.57
Sodium	13	8.53	10.88	0.78	-0.66
Myosin	12	10.39	4.58	2.27	0.83
Methionine	12	10.72	5.92	1.81	0.37
HEREDITARY NONPOLYPOSIS COLORECTAL CANCER	12	6.48	3.79	1.71	0.27
Tumorigenesis	12	7.06	4.24	1.67	0.23

FIG. 27-1B

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Cysteine	12	9.48	7.72	1.23	-0.21
Melanoma	12	6.15	5.99	1.03	-0.41
INS	12	8.16	8.10	1.01	-0.43
secreted	12	7.37	7.54	0.98	-0.46
Immunoglobulin	12	7.81	8.17	0.96	-0.48
Dexamethasone	12	6.40	6.71	0.95	-0.49
Translocation	12	7.71	8.37	0.92	-0.52
Estrogen Receptors	11	8.98	2.68	3.35	1.91
ERBB2	11	6.64	2.12	3.13	1.69
Antisense Oligonucleotides	11	9.78	3.20	3.06	1.62
Untranslated Regions	11	7.91	2.62	3.01	1.57
Surface Antigens	11	9.44	3.61	2.62	1.18
Keratin	11	9.47	3.64	2.60	1.16
NP220	11	10.33	4.06	2.54	1.10
MULTIPLE MYELOMA	11	6.78	3.75	1.81	0.37
TYPE 1B CHARCOT-MARIE-TOOTH DISEASE	11	9.48	5.29	1.79	0.35
Interleukin-2	11	8.09	4.74	1.71	0.27
Laminin	11	6.93	4.24	1.63	0.19
Phorbol	11	9.30	5.71	1.63	0.19
Lectin	11	8.09	5.12	1.58	0.14
PROSTATE CANCER	11	6.47	4.13	1.57	0.13
EGFR	11	5.06	3.30	1.53	0.09

FIG. 27-1C

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Cycloheximide	11	9.05	5.91	1.53	0.09
IL2	11	8.13	5.59	1.45	0.01
ESR1	11	7.90	5.52	1.43	-0.01
Progesterone	11	7.98	5.70	1.40	-0.04
Immunoglobulin M	11	8.56	6.18	1.38	-0.06
Collagenase	11	6.40	4.71	1.36	-0.08
Metastasis	11	7.74	5.92	1.31	-0.13
Sarcoma	11	7.30	5.62	1.30	-0.14
Integrin	11	5.74	4.62	1.24	-0.20

FIG. 27-1D

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
LUNG CANCER	11	6.62	5.34	1.24	-0.20
Trypsin	11	7.50	6.53	1.15	-0.29
Ischemia	11	7.12	6.28	1.13	-0.31
Hypertrophy	11	7.63	7.15	1.07	-0.37
Adenoma	11	5.58	5.29	1.05	-0.39
Estrogen	11	5.88	5.89	1.00	-0.44
Chloride	11	7.74	7.76	1.00	-0.44
Membrane Proteins	11	7.54	7.84	0.96	-0.48
Hyperplasia	11	6.55	6.90	0.95	-0.49
Lymphoma	11	6.50	6.96	0.93	-0.51
Adenosine Triphosphate	11	7.32	8.27	0.89	-0.55
Acetate	11	6.99	8.14	0.86	-0.58
ras Proteins	11	3.81	5.06	0.75	-0.69
Collagen	11	6.16	8.18	0.75	-0.69
Oxygen	11	6.74	9.14	0.74	-0.70
Necrosis	11	6.64	9.10	0.73	-0.71
Fatty Acids	11	4.74	7.59	0.62	-0.82
KALLIKREIN 3	10	7.29	2.55	2.86	1.16
Steroid Receptors	10	7.56	2.82	2.68	0.98
PGR	10	6.99	2.75	2.54	0.84
Nuclear Proteins	10	9.60	3.78	2.54	0.84
Caspase	10	8.42	3.38	2.49	0.79

FIG. 27-1E

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
DNA Probes	10	8.63	3.71	2.32	0.62
Staurosporine	10	8.72	3.82	2.29	0.59
CEACAM5	10	7.37	3.23	2.28	0.58
COLONY-STIMULATING FACTOR 3	10	7.60	3.46	2.19	0.49
Tissue Extracts	10	7.90	3.61	2.19	0.49
Oligonucleotide Probes	10	8.11	3.72	2.18	0.48
NR4A1	10	7.40	3.44	2.15	0.45
DNA-Binding Proteins	10	8.21	3.84	2.14	0.44
MPO	10	8.26	4.02	2.06	0.36
KRT1	10	6.95	3.46	2.01	0.31
SNTA1	10	9.48	4.77	1.99	0.29
VIM	10	8.06	4.08	1.98	0.28
Glioblastoma	10	6.54	3.32	1.97	0.27
Histone	10	8.23	4.19	1.96	0.26
Deoxyribonuclease	10	9.08	4.64	1.96	0.26
Starvation	10	8.56	4.78	1.79	0.09
GAMMA CCAAT/ENHANCER-BINDING PROTEIN	10	9.21	5.20	1.77	0.07
Acetyltransferase	10	8.17	4.68	1.74	0.04
Dimethyl Sulfoxide	10	8.56	5.20	1.65	-0.05
Interleukin	10	8.23	5.00	1.65	-0.05
Chloramphenicol	10	9.06	5.58	1.62	-0.08

FIG. 27-1F



FIG. 27-2A
FIG. 27-2B
FIG. 27-2C

FIG. 27-2

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Disease Progression	10	7.09	4.45	1.60	-0.10
CUTANEOUS MALIGNANT MELANOMA	10	5.95	3.81	1.56	-0.14
Retinoid	10	6.32	4.14	1.53	-0.17
Lipopolysaccharide	10	9.06	6.01	1.51	-0.19
Transferase	10	8.31	5.52	1.50	-0.20
Mitogen	10	7.09	5.02	1.41	-0.29
GASTRIC CANCER	10	4.98	3.72	1.34	-0.36
Concanavalin A	10	7.05	5.27	1.34	-0.36

FIG. 27-2A

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Cyclophosphamide	10	6.88	5.17	1.33	-0.37
Disulfide	10	7.32	5.53	1.32	-0.38
GLIOMA OF BRAIN	10	5.15	4.03	1.28	-0.42
Conjugate	10	7.32	5.80	1.26	-0.44
Arginine	10	8.67	6.91	1.25	-0.45
Iron	10	7.98	6.79	1.18	-0.52
Glutathione	10	8.16	7.27	1.12	-0.58
Adenosine	10	6.64	6.41	1.04	-0.66
Glioma	10	4.95	4.81	1.03	-0.67
Recurrence	10	6.01	7.10	0.85	-0.85
TNF	10	4.90	6.49	0.76	-0.94
Urobilinogen	10	6.71	8.94	0.75	-0.95
Sulfate	10	5.99	8.38	0.71	-0.99
Inflammation	10	5.93	8.65	0.69	-1.01
Phosphate	10	5.99	8.97	0.67	-1.03
Ventricle	10	5.30	7.96	0.67	-1.03
Tyrosine	10	4.38	7.60	0.58	-1.12
HEPATOCELLULAR CARCINOMA	10	2.99	6.58	0.45	-1.25
Stress	10	4.57	10.33	0.44	-1.26
EGR1	9	8.73	2.43	3.60	1.90
BETA TUBULIN	9	7.83	2.49	3.15	1.45
KITLG	9	8.67	2.77	3.13	1.43

FIG. 27-2B

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
BENIGN PROSTATIC HYPERPLASIA	9	8.56	2.74	3.13	1.43
Transglutaminase	9	7.61	2.50	3.04	1.34
Progesterone Receptors	9	7.37	2.44	3.02	1.32
MDB	9	6.98	2.51	2.78	1.08
SPP1	9	6.72	2.43	2.76	1.06
ACTC	9	7.88	2.86	2.76	1.06
T-Cell Leukemia	9	7.48	2.80	2.67	0.97
Propidium	9	8.39	3.16	2.65	0.95
Ribosomal Proteins	9	7.58	2.89	2.62	0.92
Embryonal Carcinoma	9	7.11	2.74	2.59	0.89
Gastritis	9	8.22	3.17	2.59	0.89
Fucose	9	7.39	2.87	2.58	0.88
Apoprotein	9	8.02	3.24	2.47	0.77
IL3	9	8.12	3.30	2.46	0.76
IL2RA	9	8.59	3.55	2.42	0.72
Metaplasia	9	8.24	3.45	2.39	0.69
Lyase	9	6.72	2.83	2.37	0.67
GAPD	9	8.37	3.55	2.36	0.66
ACTB	9	8.24	3.50	2.36	0.66
AP4B1	9	8.19	3.59	2.28	0.58
Chronic Hepatitis	9	7.58	3.43	2.21	0.51
Bromodeoxyuridine	9	8.57	3.96	2.17	0.47

FIG. 27-2C

FIG. 27-3A
FIG. 27-3B
FIG. 27-3C

FIG. 27-3

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Vaccinia	9	7.21	3.34	2.16	0.46
Fibrosarcoma	9	7.54	3.61	2.09	0.39
Mannose	9	8.52	4.13	2.06	0.36
Rhabdomyosarcoma	9	5.81	2.88	2.01	0.31
Colony-Stimulating Factors	9	7.57	3.77	2.01	0.31
Phorbol Esters	9	6.96	3.47	2.01	0.31
Biotin	9	8.23	4.14	1.99	0.29
IGF1	9	6.62	3.37	1.97	0.27

FIG. 27-3A

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Lymphocytic Leukemia	9	7.59	3.91	1.94	0.24
Proteoglycan	9	8.23	4.29	1.92	0.22
CD44	9	5.40	2.83	1.91	0.21
AUTOIMMUNE DISEASES	9	7.56	4.04	1.87	0.17
Galactose	9	8.26	4.43	1.86	0.16
Phytohemagglutinin	9	7.85	4.21	1.86	0.16
Ornithine Decarboxylase	9	6.63	3.60	1.84	0.14
Myristate	9	7.92	4.36	1.82	0.12
INTERCELLULAR ADHESION MOLECULE 1	9	7.23	4.08	1.77	0.07
SEVERE COMBINED IMMUNODEFICIENCY 1	9	5.75	3.31	1.74	0.04
BETA SUBUNIT NERVE GROWTH FACTOR	9	7.37	4.27	1.73	0.03
Myeloid Leukemia	9	6.56	3.81	1.72	0.02
CD8A	9	7.39	4.33	1.71	0.01
Endotoxin	9	7.97	4.69	1.70	0.00
Ferritin	9	6.71	4.05	1.65	-0.05
beta-Galactosidase	9	8.54	5.21	1.64	-0.06
Forskolin	9	7.45	4.57	1.63	-0.07
CYSTIC FIBROSIS	9	7.36	4.53	1.62	-0.08
Esterase	9	7.81	4.82	1.62	-0.08
Silver	9	8.56	5.32	1.61	-0.09
Nitric-Oxide Synthase	9	7.62	4.74	1.61	-0.09
Sialic Acids	9	6.74	4.20	1.60	-0.10

FIG. 27-3B

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
SYSTEMIC LUPUS ERYTHEMATOSUS	9	7.38	4.63	1.59	-0.11
Valine	9	8.16	5.14	1.59	-0.11
Iodide	9	7.47	4.71	1.59	-0.11
PCNA	9	5.39	3.39	1.59	-0.11
VEGF	9	4.92	3.14	1.57	-0.13
Antimetabolite	9	7.71	4.93	1.56	-0.14
Hydrocortisone	9	7.20	4.62	1.56	-0.14
IL4	9	6.82	4.39	1.55	-0.15
Tamoxifen	9	5.52	3.64	1.51	-0.19
Proline	9	8.40	5.62	1.49	-0.21
Lactate	9	8.34	5.60	1.49	-0.21
Luciferase	9	7.48	5.05	1.48	-0.22
LMNA	9	8.36	5.68	1.47	-0.23
Isoenzyme	9	6.98	4.79	1.46	-0.24
Tryptophan	9	8.26	5.69	1.45	-0.25
phorbol ester	9	6.90	4.76	1.45	-0.25
Guanosine	9	6.91	4.79	1.44	-0.26
TF	9	6.81	4.77	1.43	-0.27
Paraffin	9	6.78	4.79	1.41	-0.29
Anemia	9	7.73	5.51	1.40	-0.30
PTH	9	6.15	4.49	1.37	-0.33
Cyclosporin	9	8.40	6.20	1.36	-0.34

FIG. 27-3C

FIG. 27-4A
FIG. 27-4B
FIG. 27-4C

FIG. 27-4

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Estradiol	9	6.96	5.27	1.32	-0.38
Angiogenesis	9	5.57	4.36	1.28	-0.42
Glycerol	9	8.33	6.55	1.27	-0.43
Androgen	9	6.16	4.88	1.26	-0.44
Nucleoside	9	5.98	4.86	1.23	-0.47
CALCA	9	5.34	4.37	1.22	-0.48
Cystadenoma	9	6.06	5.06	1.20	-0.50
Toxin	9	7.10	5.96	1.19	-0.51

FIG. 27-4A

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Glycine	9	7.98	6.71	1.19	-0.51
Dopamine	9	6.82	5.74	1.19	-0.51
Phosphatidylinositol	9	6.15	5.20	1.18	-0.52
Thrombosis	9	5.95	5.12	1.16	-0.54
Proton	9	6.84	6.13	1.12	-0.58
Testosterone	9	6.24	5.73	1.09	-0.61
Heparin	9	6.63	6.11	1.09	-0.61
Serum Albumin	9	7.22	6.73	1.07	-0.63
Lysine	9	7.38	6.91	1.07	-0.63
Cytochrome	9	6.91	6.60	1.05	-0.65
Cyclic AMP	9	6.15	5.91	1.04	-0.66
Glucocorticoid	9	5.51	5.39	1.02	-0.68
Alanine	9	7.33	7.18	1.02	-0.68
Nitric Oxide	9	5.65	5.90	0.96	-0.74
Lactate Dehydrogenase	9	5.63	6.02	0.93	-0.77
BETA-1 TRANSFORMING GROWTH FACTOR	9	4.40	4.75	0.93	-0.77
Fibrosis	9	5.91	6.38	0.93	-0.77
Interferon	9	5.40	5.89	0.92	-0.78
Genomic Instability	9	4.49	4.92	0.91	-0.79
Leukemia	9	6.92	7.60	0.91	-0.79
ALB	9	6.38	7.08	0.90	-0.80
Methylation	9	4.96	5.86	0.85	-0.85

FIG. 27-4B



Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Ethanol	9	5.89	7.31	0.81	-0.89
Phospholipid	9	5.63	7.26	0.78	-0.92
IL6	9	3.80	5.64	0.67	-1.03
Prostaglandin	9	4.39	6.62	0.66	-1.04
NB	9	3.24	5.60	0.58	-1.12
p53	8	7.47	1.83	4.07	2.37
ALPHA	8	7.72	2.24	3.45	1.75
LIF	8	7.52	2.19	3.43	1.73
SLC2A1	8	6.61	2.04	3.23	1.53
KRT10	8	5.98	1.87	3.19	1.49
MAPK3	8	7.57	2.58	2.94	1.24
Cyclin-Dependent Kinases	8	6.32	2.16	2.92	1.22
Fish Oils	8	7.10	2.49	2.85	1.15
CD28	8	6.71	2.36	2.85	1.15
F9	8	6.98	2.48	2.82	1.12
Phalloidine	8	6.17	2.20	2.81	1.11
FGF1	8	6.24	2.25	2.77	1.07
Quercetin	8	7.61	2.78	2.74	1.04
COLONY-STIMULATING FACTOR 1	8	6.92	2.53	2.74	1.04
Interleukin-3	8	7.12	2.61	2.73	1.03
SUPEROXIDE DISMUTASE 2	8	6.89	2.54	2.71	1.01
B-Cell Lymphoma	8	6.74	2.51	2.69	0.99

FIG. 27-4C

FIG. 27-5A
FIG. 27-5B
FIG. 27-5C

FIG. 27-5

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
CDKN2D	8	6.86	2.56	2.68	0.98
Oligodendroglioma	8	7.79	2.95	2.64	0.94
T-Cell Lymphoma	8	7.60	2.89	2.63	0.93
Fluorescein-5-isothiocyanate	8	6.68	2.58	2.59	0.89
HXB	8	5.99	2.34	2.56	0.86
Kallikrein	8	7.27	2.86	2.54	0.84
TYPE I NEUROFIBROMATOSIS	8	6.95	2.74	2.54	0.84
DNTT	8	6.56	2.61	2.51	0.81

FIG. 27-5A

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Medroxyprogesterone	8	6.04	2.41	2.51	0.81
CDK2	8	5.99	2.40	2.49	0.79
C RECEPTOR-TYPE PROTEIN-TYROSINE PHOSPHATASE	8	7.14	2.86	2.49	0.79
Nevus	8	5.70	2.29	2.49	0.79
Tunicamycin	8	7.31	2.95	2.47	0.77
Diabetic Retinopathy	8	6.20	2.52	2.46	0.76
SELL	8	6.96	2.85	2.44	0.74
Spermidine	8	7.93	3.30	2.40	0.70
Papilloma	8	7.24	3.01	2.40	0.70
Glycopeptide	8	7.30	3.07	2.38	0.68
NGFR	8	6.52	2.76	2.37	0.67
ANTITHROMBIN III DEFICIENCY	8	7.34	3.12	2.36	0.66
Interleukin-4	8	6.98	2.96	2.36	0.66
CD34	8	5.98	2.61	2.30	0.60
Spermine	8	7.93	3.46	2.29	0.59
TFRC	8	7.23	3.16	2.29	0.59
Phosphopeptide	8	6.03	2.64	2.28	0.58
IFNG	8	7.24	3.20	2.27	0.57
Metallothionein	8	7.34	3.26	2.25	0.55
AR	8	6.43	2.95	2.18	0.48
GLUCOCORTICOID RECEPTOR	8	7.24	3.33	2.17	0.47
NEUROD1	8	7.47	3.44	2.17	0.47

FIG. 27-5B

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
SARCOIDOSIS	8	7.18	3.34	2.15	0.45
Glycoconjugate	8	6.46	3.02	2.14	0.44
GFAP	8	6.53	3.07	2.13	0.43
Hypercholesterolemia	8	6.85	3.24	2.11	0.41
Triiodothyronine	8	7.59	3.61	2.10	0.40
TG	8	6.35	3.10	2.05	0.35
Bacteriocin	8	7.30	3.57	2.05	0.35
alcohol consumption	8	5.92	2.91	2.04	0.34
Irritant	8	5.96	2.95	2.02	0.32
Ulcerative Colitis	8	7.41	3.67	2.02	0.32
TIMP1	8	5.10	2.53	2.02	0.32
ACUTE LYMPHOBLASTIC LEUKEMIA	8	7.21	3.59	2.01	0.31
Retinal Pigments	8	7.07	3.60	1.96	0.26
Blood Groups	8	6.93	3.53	1.96	0.26
NON-HODGKIN LYMPHOMA	8	6.16	3.15	1.95	0.25
CTSD	8	5.69	2.93	1.94	0.24
stress-induced	8	7.47	3.88	1.92	0.22
Ionomycin	8	6.56	3.42	1.92	0.22
Genetic Markers	8	6.97	3.65	1.91	0.21
bA430M15.1	8	7.39	3.92	1.89	0.19
Glycol	8	7.00	3.71	1.89	0.19
Neuraminidase	8	7.20	3.83	1.88	0.18

FIG. 27-5C

FIG. 27-6A
FIG. 27-6B
FIG. 27-6C

FIG. 27-6

65/184

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Hyaluronic Acid	8	5.95	3.17	1.88	0.18
Chorionic Gonadotropins	8	6.48	3.45	1.88	0.18
Genistein	8	6.58	3.51	1.87	0.17
Ovalbumin	8	6.90	3.76	1.84	0.14
Lactic Acid	8	6.73	3.69	1.82	0.12
COLONY-STIMULATING FACTOR 2	8	6.40	3.52	1.82	0.12
Glycosaminoglycan	8	7.46	4.17	1.79	0.09
CCND1	8	4.55	2.56	1.78	0.08

FIG. 27-6A

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Interleukin-12	8	5.40	3.05	1.77	0.07
Guanine Nucleotides	8	6.33	3.58	1.77	0.07
Vitamin D	8	6.71	3.81	1.76	0.06
SELE	8	5.06	2.87	1.76	0.06
Teratoma	8	5.30	3.01	1.76	0.06
Creatine	8	7.22	4.10	1.76	0.06
Diphosphate	8	5.84	3.33	1.75	0.05
Thyroxine	8	7.35	4.20	1.75	0.05
EPO	8	6.80	3.88	1.75	0.05
Psoriasis	8	6.77	3.88	1.75	0.05
Polyamine	8	6.24	3.57	1.75	0.05
MAPT	8	6.79	3.91	1.74	0.04
MAPK1	8	6.58	3.80	1.73	0.03
Ion Channels	8	6.13	3.55	1.73	0.03
Vinblastine	8	6.03	3.50	1.72	0.02
Nifedipine	8	7.26	4.25	1.71	0.01
beta-catenin	8	3.82	2.26	1.69	-0.01
Neomycin	8	7.16	4.28	1.67	-0.03
Recombinant Proteins	8	6.36	3.84	1.66	-0.04
Thiomalate	8	7.37	4.49	1.64	-0.06
HIV Infection	8	7.12	4.36	1.64	-0.06
Endonuclease	8	7.29	4.51	1.62	-0.08

FIG. 27-6B

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Isoleucine	8	7.26	4.53	1.60	-0.10
Tubulin	8	5.74	3.59	1.60	-0.10
Pertussis Toxins	8	6.16	3.86	1.59	-0.11
Acetone	8	7.05	4.43	1.59	-0.11
MN1	8	4.97	3.14	1.58	-0.12
Imidazole	8	6.49	4.14	1.57	-0.13
Interleukin-1	8	7.47	4.82	1.55	-0.15
LYZ	8	7.21	4.66	1.55	-0.15
Purine	8	6.89	4.47	1.54	-0.16
Adenosine Monophosphate	8	5.89	3.82	1.54	-0.16
CAT	8	7.82	5.14	1.52	-0.18
Sepharose	8	7.33	4.86	1.51	-0.19
Hyperglycemia	8	6.23	4.22	1.48	-0.22
Agglutinin	8	6.15	4.18	1.47	-0.23
Interleukin-6	8	6.57	4.48	1.47	-0.23
Oligosaccharide	8	6.92	4.72	1.47	-0.23
Phospholipase C	8	6.56	4.52	1.45	-0.25
GNRH1	8	5.58	3.86	1.45	-0.25
Isoproterenol	8	6.27	4.35	1.44	-0.26
BDK	8	5.71	3.96	1.44	-0.26
Fibrinogen	8	7.07	4.92	1.44	-0.26
Fluorescein	8	7.33	5.11	1.44	-0.26

FIG. 27-6C

FIG. 27-7A
FIG. 27-7B
FIG. 27-7C

FIG. 27-7

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Neuropeptide	8	6.39	4.48	1.43	-0.27
Inositol	8	6.32	4.44	1.42	-0.28
Peroxidase	8	7.57	5.34	1.42	-0.28
Calmodulin	8	6.33	4.57	1.38	-0.32
F2	8	6.15	4.45	1.38	-0.32
BLADDER CANCER	8	4.24	3.10	1.37	-0.33
Casein	8	6.41	4.70	1.36	-0.34
Transaminase	8	6.71	4.94	1.36	-0.34

FIG. 27-7A



Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Matrix Metalloproteinases	8	3.95	2.94	1.34	-0.36
Bromide	8	7.47	5.58	1.34	-0.36
Mucin	8	4.89	3.70	1.32	-0.38
HGF	8	3.97	3.00	1.32	-0.38
Aneuploidy	8	4.40	3.33	1.32	-0.38
Glutamine	8	7.65	5.81	1.32	-0.38
Thymidine	8	7.00	5.37	1.30	-0.40
Phosphatidylcholine	8	6.35	4.89	1.30	-0.40
ALPHA-1 INTERFERON	8	5.24	4.08	1.28	-0.42
Phenylalanine	8	6.57	5.12	1.28	-0.42
Gold	8	7.23	5.67	1.28	-0.42
Citrate	8	6.71	5.34	1.26	-0.44
Herpes Simplex	8	6.32	5.04	1.25	-0.45
Leucine	8	7.55	6.03	1.25	-0.45
FGF	8	5.92	4.76	1.24	-0.46
Bone Resorption	8	4.20	3.40	1.24	-0.46
Arachidonic Acid	8	6.57	5.33	1.23	-0.47
Creatinine	8	7.37	6.12	1.20	-0.50
tyrosine phosphorylation	8	5.58	4.67	1.20	-0.50
RA	8	6.64	5.58	1.19	-0.51
Anion	8	7.81	6.58	1.19	-0.51
Adenine	8	6.12	5.16	1.19	-0.51

FIG. 27-7B

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
blood alcohol	8	5.20	4.42	1.18	-0.52
Catecholamine	8	6.37	5.51	1.16	-0.54
Serotonin	8	6.73	5.86	1.15	-0.55
Hepatitis	8	6.23	5.42	1.15	-0.55
Fever	8	7.25	6.33	1.15	-0.55
Plasminogen Activators	8	4.80	4.21	1.14	-0.56
FGF2	8	4.41	3.94	1.12	-0.58
Histidine	8	6.58	5.90	1.11	-0.59
Atrophy	8	7.75	6.99	1.11	-0.59
Doxorubicin	8	5.58	5.10	1.09	-0.61
Acetylcholine	8	6.37	5.92	1.08	-0.62
Methotrexate	8	5.03	4.71	1.07	-0.63
PRL	8	5.51	5.27	1.04	-0.66
Hydrogen	8	6.74	6.46	1.04	-0.66
APOLIPOPROTEIN	8	6.58	6.41	1.03	-0.67
Arthritis	8	5.18	5.16	1.00	-0.70
Myocardial Infarction	8	4.98	5.05	0.99	-0.71
Zinc	8	6.81	7.67	0.89	-0.81
Diabetes Mellitus	8	5.16	6.19	0.83	-0.87
Potassium	8	6.13	7.40	0.83	-0.87
Indomethacin	8	4.40	5.60	0.79	-0.91
Edema	8	4.48	6.53	0.69	-1.01

FIG. 27-7C

FIG. 27-8A
FIG. 27-8B
FIG. 27-8C

FIG. 27-8

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Hypertension	8	3.41	6.92	0.49	-1.21
ERBB4	7	6.06	1.31	4.63	2.93
ERBB3	7	6.38	1.40	4.55	2.85
TOP2A	7	6.00	1.32	4.54	2.84
SPARC	7	6.65	1.75	3.79	2.09
Ecdysone	7	5.86	1.57	3.74	2.04
CADHERIN 2	7	6.23	1.69	3.69	1.99
KRT14	7	6.16	1.70	3.62	1.92

FIG. 27-8A

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Caveolin	7	6.41	1.79	3.59	1.89
IGF2	7	6.38	1.86	3.44	1.74
GAMMA	7	6.50	1.92	3.39	1.69
Ependymoma	7	6.03	1.87	3.22	1.52
ALPHA-1 GAP JUNCTION PROTEIN	7	6.36	2.02	3.15	1.45
Fibronectin Receptors	7	5.61	1.79	3.14	1.44
Retinoblastoma Protein	7	6.57	2.10	3.13	1.43
CSF1	7	6.55	2.09	3.13	1.43
KRT8	7	6.20	1.98	3.12	1.42
ARHA	7	6.15	1.98	3.11	1.41
IL7	7	6.56	2.11	3.10	1.40
PTK2B	7	6.94	2.25	3.08	1.38
F2R	7	6.10	2.00	3.05	1.35
Neuroectodermal Tumors	7	6.30	2.10	3.01	1.31
Leiomyoma	7	6.82	2.28	3.00	1.30
CCNA2	7	6.39	2.13	3.00	1.30
FGFR2	7	6.16	2.08	2.96	1.26
ESR2	7	5.47	1.85	2.96	1.26
Laminin Receptors	7	4.98	1.69	2.94	1.24
IL13	7	6.54	2.23	2.94	1.24
Digoxigenin	7	5.95	2.02	2.94	1.24
VCL	7	6.24	2.13	2.92	1.22

FIG. 27-8B

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
TYRO3	7	5.81	2.03	2.86	1.16
TNFRSF8	7	5.78	2.03	2.84	1.14
Annexin	7	6.02	2.13	2.82	1.12
Medullary Carcinoma	7	5.59	1.99	2.81	1.11
CHGA	7	6.58	2.34	2.81	1.11
CDKL1	7	6.91	2.48	2.79	1.09
SHC TRANSFORMING PROTEIN	7	5.87	2.12	2.78	1.08
OVCE	7	5.13	1.85	2.77	1.07
Papillary Carcinoma	7	5.57	2.02	2.76	1.06
CCNE1	7	5.50	1.99	2.76	1.06
Hepatoblastoma	7	6.36	2.32	2.74	1.04
BCL2L1	7	6.47	2.36	2.74	1.04
Monokine	7	6.19	2.27	2.73	1.03
CCNB1	7	6.34	2.33	2.72	1.02
Ricin	7	6.13	2.28	2.69	0.99
Sphingosine	7	6.96	2.63	2.64	0.94
Calpain	7	6.76	2.57	2.63	0.93
XPR1	7	6.47	2.49	2.60	0.90
JAK2	7	4.91	1.89	2.60	0.90
SYNAPTOTAGMIN 1	7	6.78	2.62	2.59	0.89
Lovastatin	7	6.20	2.41	2.57	0.87
VDR	7	5.36	2.11	2.55	0.85

FIG. 27-8C

FIG. 27-9A
FIG. 27-9B
FIG. 27-9C

FIG. 27-9

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Interleukin-10	7	6.38	2.51	2.54	0.84
BDNF	7	5.87	2.31	2.54	0.84
Cytochalasin D	7	6.72	2.65	2.54	0.84
Cytochalasin	7	5.72	2.26	2.53	0.83
LEUKOCYTE ANTIGEN CD23	7	5.52	2.18	2.53	0.83
Heterochromatin	7	6.12	2.42	2.53	0.83
Peanut Agglutinin	7	5.65	2.25	2.51	0.81
RNA Probes	7	5.11	2.05	2.49	0.79

FIG. 27-9A

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
CDC2	7	6.46	2.60	2.49	0.79
Glycosyltransferase	7	5.74	2.31	2.49	0.79
Liposarcoma	7	4.72	1.90	2.49	0.79
PLATELET-ENDOTHELIAL CELL ADHESION MOLECULE 1	7	5.23	2.12	2.47	0.77
HEAT-SHOCK 27-KD PROTEIN 1	7	4.94	2.01	2.45	0.75
NF-kappa B	7	6.95	2.85	2.44	0.74
Phospholipase D	7	6.37	2.62	2.43	0.73
Antigen Receptors	7	6.46	2.68	2.41	0.71
Antisense RNA	7	6.55	2.72	2.41	0.71
KAZAL-TYPE SERINE PROTEASE INHIBITOR 1	7	6.22	2.59	2.40	0.70
Leucine zipper	7	6.38	2.66	2.40	0.70
Androgen Receptors	7	4.79	2.01	2.38	0.68
RDC1	7	6.92	2.91	2.38	0.68
Developmental role	7	6.50	2.75	2.37	0.67
CDKN1A	7	5.65	2.42	2.34	0.64
SUPERFAMILY	7	6.38	2.73	2.34	0.64
Raffinose	7	6.82	2.94	2.32	0.62
nuclear translocation	7	6.99	3.03	2.31	0.61
JUN	7	6.82	2.99	2.28	0.58
ACUTE MYELOGENOUS LEUKEMIA	7	6.09	2.67	2.28	0.58
ADCYAP1	7	4.39	1.93	2.27	0.57
Phosphatidic Acids	7	6.68	2.95	2.27	0.57

FIG. 27-9B

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Cachexia	7	6.34	2.80	2.26	0.56
Leiomyosarcoma	7	4.98	2.21	2.25	0.55
TGFA	7	5.92	2.62	2.25	0.55
Phosphorylase	7	6.17	2.78	2.22	0.52
Calcium-Binding Proteins	7	6.48	2.92	2.22	0.52
Pyruvate Kinase	7	6.54	2.96	2.21	0.51
Arsenite	7	5.38	2.45	2.20	0.50
CD14	7	6.17	2.81	2.19	0.49
Ceramide	7	6.82	3.11	2.19	0.49
CYP19	7	5.55	2.54	2.19	0.49
Chimeric Proteins	7	5.63	2.58	2.18	0.48
Liver Extracts	7	5.46	2.51	2.18	0.48
MuLV	7	5.57	2.57	2.17	0.47
Plasmacytoma	7	5.53	2.55	2.17	0.47
SURFACE ANTIGEN 6	7	5.68	2.63	2.16	0.46
DES	7	6.37	2.96	2.15	0.45
PML	7	6.82	3.18	2.15	0.45
LPL	7	6.62	3.09	2.14	0.44
Hexokinase	7	6.05	2.84	2.13	0.43
GTP-Binding Proteins	7	5.30	2.49	2.12	0.42
VTN	7	5.16	2.44	2.12	0.42
Cystitis	7	5.54	2.63	2.11	0.41

FIG. 27-9C



FIG. 27-10A
FIG. 27-10B
FIG. 27-10C

FIG. 27-10

77/184

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Okadaic Acid	7	6.54	3.11	2.10	0.40
IL5	7	6.19	2.95	2.10	0.40
PROSTATE-SPECIFIC ACID PHOSPHATASE	7	3.87	1.84	2.10	0.40
PROC	7	6.67	3.19	2.09	0.39
MAPK14	7	7.00	3.35	2.09	0.39
Peptic Ulcer	7	6.32	3.03	2.08	0.38
VCAM1	7	5.62	2.70	2.08	0.38
PANCREATIC CARCINOMA	7	5.55	2.67	2.08	0.38

FIG. 27-10A

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Protein-Tyrosine Kinase	7	5.82	2.80	2.08	0.38
PLP2	7	6.05	2.93	2.07	0.37
HSPA4	7	6.70	3.26	2.05	0.35
Endothelin-1	7	6.86	3.36	2.04	0.34
Gadolinium	7	5.98	2.93	2.04	0.34
Saponin	7	5.70	2.81	2.03	0.33
IGSF3	7	6.01	2.96	2.03	0.33
H4F2	7	5.95	2.94	2.03	0.33
Recombinant DNA	7	6.64	3.29	2.02	0.32
Holoenzyme	7	6.20	3.07	2.02	0.32
potassium channel	7	5.61	2.78	2.02	0.32
CD2	7	5.66	2.82	2.01	0.31
Trisomy	7	6.05	3.06	1.97	0.27
ATOD	7	5.95	3.01	1.97	0.27
Cyclin	7	5.97	3.03	1.97	0.27
ELN	7	5.98	3.05	1.96	0.26
Chondroitin Sulfates	7	5.81	2.96	1.96	0.26
Malondialdehyde	7	6.59	3.37	1.95	0.25
Xanthine Oxidase	7	6.74	3.46	1.95	0.25
LTF	7	5.92	3.04	1.94	0.24
Phosphotransferase	7	5.55	2.85	1.94	0.24
RCD-8	7	6.36	3.27	1.94	0.24

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Choriocarcinoma	7	5.52	2.84	1.94	0.24
Osteolysis	7	3.88	2.00	1.94	0.24
Hyperlipidemia	7	6.14	3.17	1.94	0.24
beta 2-Microglobulin	7	6.60	3.42	1.93	0.23
UBIQUITIN	7	6.56	3.41	1.93	0.23
proline-rich	7	6.40	3.32	1.93	0.23
Brefeldin A	7	5.23	2.72	1.92	0.22
Androstenedione	7	5.01	2.64	1.90	0.20
Phenylmethylsulfonyl Fluoride	7	5.18	2.74	1.89	0.19
Rheumatic Disease	7	5.44	2.88	1.89	0.19
Biological Markers	7	4.56	2.42	1.88	0.18
Corticotropin	7	5.90	3.17	1.86	0.16
INSULIN-LIKE GROWTH FACTOR II	7	4.97	2.68	1.86	0.16
APOB	7	5.49	2.98	1.84	0.14
cardiac hypertrophy	7	6.23	3.39	1.84	0.14
TAGLN	7	6.38	3.47	1.84	0.14
Bromocriptine	7	5.37	2.94	1.83	0.13
Ibuprofen	7	6.08	3.34	1.82	0.12
Hypoxanthine	7	6.20	3.41	1.82	0.12
Thyrotropin	7	5.64	3.11	1.81	0.11
MBP	7	5.95	3.30	1.80	0.10
IL10	7	6.82	3.81	1.79	0.09

FIG. 27-11A
FIG. 27-11B
FIG. 27-11C

FIG. 27-11

80/184

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Phosphotyrosine	7	5.40	3.02	1.79	0.09
Estrone	7	4.84	2.70	1.79	0.09
Hyperthyroidism	7	6.40	3.58	1.79	0.09
Benzoate	7	5.99	3.35	1.79	0.09
RTKN	7	5.49	3.08	1.78	0.08
Butyrate	7	6.79	3.82	1.78	0.08
ADA	7	5.62	3.16	1.78	0.08
Thymine	7	5.98	3.36	1.78	0.08

FIG. 27-11A

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Single-Stranded DNA	7	5.56	3.13	1.77	0.07
Diethylstilbestrol	7	4.99	2.83	1.76	0.06
Lipoxygenase	7	6.16	3.49	1.76	0.06
Sterol	7	6.22	3.53	1.76	0.06
Trypan Blue	7	6.32	3.59	1.76	0.06
Eicosanoid	7	6.16	3.51	1.76	0.06
Ribulose-Bisphosphate Carboxylase	7	5.70	3.26	1.75	0.05
Hydroxyl Radical	7	6.57	3.78	1.74	0.04
S14	7	6.91	3.99	1.73	0.03
Polyethylene	7	6.07	3.52	1.72	0.02
Sex Hormones	7	5.13	2.99	1.72	0.02
Xanthine	7	5.96	3.47	1.72	0.02
Oxytocin	7	5.66	3.31	1.71	0.01
Quinacrine	7	5.08	2.97	1.71	0.01
C-Reactive Protein	7	6.15	3.62	1.70	0.00
Lactose	7	6.37	3.76	1.69	-0.01
Protease Inhibitors	7	6.89	4.08	1.69	-0.01
Carrier Proteins	7	5.97	3.54	1.69	-0.01
Oxidoreductase	7	6.32	3.76	1.68	-0.02
5'-Nucleotidase	7	4.91	2.92	1.68	-0.02
Growth Inhibitors	7	5.41	3.24	1.67	-0.03
Phenytoln	7	6.34	3.80	1.67	-0.03

FIG. 27-11B

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
F8C	7	5.49	3.30	1.66	-0.04
Inositol Phosphates	7	5.27	3.18	1.66	-0.04
Hydroxyurea	7	5.55	3.35	1.66	-0.04
Thymidine Kinase	7	5.80	3.51	1.65	-0.05
VWF	7	5.50	3.33	1.65	-0.05
Adhesions	7	6.33	3.84	1.65	-0.05
Cobalt	7	6.33	3.86	1.64	-0.06
Infertility	7	5.96	3.66	1.63	-0.07
Nicotine	7	6.34	3.90	1.63	-0.07
Adenine Nucleotides	7	5.39	3.31	1.63	-0.07
Serine protease	7	5.92	3.68	1.61	-0.09
Succinate	7	6.80	4.27	1.59	-0.11
Glomerulonephritis	7	6.34	3.98	1.59	-0.11
Horseradish Peroxidase	7	6.37	4.01	1.59	-0.11
Phosphatidylethanolamine	7	5.96	3.76	1.59	-0.11
Nitrite	7	6.37	4.03	1.58	-0.12
Nephritis	7	5.36	3.40	1.58	-0.12
PTH LH	7	3.58	2.28	1.57	-0.13
Starch	7	5.95	3.79	1.57	-0.13
Aspartic Acid	7	6.62	4.24	1.56	-0.14
Peroxide	7	5.49	3.52	1.56	-0.14
Oxidant	7	6.82	4.37	1.56	-0.14

FIG. 27-11C

FIG. 27-12A
FIG. 27-12B
FIG. 27-12C

FIG. 27-12

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Polyphosphate	7	5.39	3.46	1.56	-0.14
Platinum	7	5.26	3.39	1.55	-0.15
Oral Contraceptives	7	4.81	3.10	1.55	-0.15
Creatine Kinase	7	6.54	4.25	1.54	-0.16
MUCOPOLYSACCHARIDOSIS TYPE VII	7	6.47	4.23	1.53	-0.17
Isothiocyanate	7	5.63	3.71	1.52	-0.18
Angiotensin	7	6.22	4.20	1.48	-0.22
Heme	7	6.19	4.19	1.48	-0.22

FIG. 27-12A

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Eosinophilia	7	5.49	3.75	1.47	-0.23
Liver Cirrhosis	7	5.62	3.84	1.46	-0.24
REN	7	5.86	4.02	1.46	-0.24
Chronic Disease	7	5.56	3.84	1.45	-0.25
Vitamin A	7	5.52	3.82	1.44	-0.26
Polysaccharide	7	6.55	4.56	1.44	-0.26
Oxide	7	6.41	4.47	1.43	-0.27
Sclerosis	7	6.77	4.76	1.42	-0.28
Charcoal	7	5.18	3.65	1.42	-0.28
Hypothyroidism	7	6.09	4.29	1.42	-0.28
Tetrodotoxin	7	4.73	3.34	1.41	-0.29
Vitamin E	7	5.91	4.18	1.41	-0.29
CADHERIN 1	7	3.63	2.58	1.41	-0.29
Erythema	7	5.91	4.20	1.41	-0.29
Dextran	7	6.40	4.55	1.41	-0.29
Vanadate	7	4.32	3.08	1.40	-0.30
Adenylate Cyclase	7	6.79	4.86	1.40	-0.30
HCS	7	6.20	4.44	1.40	-0.30
Plasmin	7	4.37	3.14	1.39	-0.31
Silicone	7	4.91	3.53	1.39	-0.31
BETA-2-ADRENERGIC RECEPTOR	7	4.95	3.57	1.39	-0.31
Amyloid	7	5.98	4.32	1.38	-0.32

FIG. 27-12B



Object name	#	Quality	Expect	Obs/Exp.	2 sigma
VIP	7	4.98	3.62	1.38	-0.32
Selenium	7	5.13	3.74	1.37	-0.33
Aspirin	7	6.41	4.73	1.36	-0.34
APG-1	7	5.65	4.18	1.35	-0.35
PLASMINOGEN ACTIVATOR INHIBITOR 1	7	3.97	2.94	1.35	-0.35
Bilirubin	7	6.17	4.58	1.35	-0.35
Superoxide Dismutase	7	6.91	5.15	1.34	-0.36
Peritonitis	7	4.99	3.75	1.33	-0.37
Proteinuria	7	5.91	4.46	1.32	-0.38
congestive heart failure	7	5.38	4.07	1.32	-0.38
Phosphoru	7	6.50	4.92	1.32	-0.38
Pancreatitis	7	5.39	4.09	1.32	-0.38
F3	7	4.80	3.65	1.31	-0.39
Hydrogen Peroxide	7	6.82	5.21	1.31	-0.39
Methanol	7	6.86	5.25	1.31	-0.39
Superoxide	7	6.99	5.36	1.31	-0.39
Acetic Acid	7	6.33	4.85	1.30	-0.40
CFDP1	7	5.55	4.28	1.30	-0.40
Dehydration	7	5.96	4.60	1.29	-0.41
Cataract	7	5.82	4.50	1.29	-0.41
Sodium Chloride	7	5.56	4.32	1.29	-0.41
AFP	7	4.43	3.46	1.28	-0.42

FIG. 27-13A
FIG. 27-13B
FIG. 27-13C

FIG. 27-13

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Ichthyosis	7	5.98	4.69	1.28	-0.42
Ammonia	7	5.63	4.43	1.27	-0.43
Sepsis	7	6.90	5.42	1.27	-0.43
Crystallin	7	6.32	5.00	1.27	-0.43
Iodine	7	5.58	4.42	1.26	-0.44
GLUTATHIONE PEROXIDASE	7	4.57	3.66	1.25	-0.45
Inversion	7	6.20	4.97	1.25	-0.45
Amylase	7	4.96	3.98	1.25	-0.45

FIG. 27-13A

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Infarction	7	5.74	4.65	1.23	-0.47
IF	7	4.58	3.75	1.22	-0.48
Insulin Resistance	7	4.12	3.42	1.20	-0.50
RETINOBLASTOMA	7	3.96	3.29	1.20	-0.50
Copper	7	6.52	5.45	1.20	-0.50
Pleural Effusion	7	4.32	3.63	1.19	-0.51
Globulin	7	4.94	4.20	1.18	-0.52
INSULIN-LIKE GROWTH FACTOR I	7	4.82	4.16	1.16	-0.54
Cortisone	7	5.96	5.18	1.15	-0.55
Mitomycin	7	4.40	3.85	1.14	-0.56
Vincristine	7	4.38	3.90	1.13	-0.57
Sulfur	7	4.80	4.28	1.12	-0.58
ANGIOTENSIN I	7	4.99	4.46	1.12	-0.58
CERVICAL CANCER	7	3.16	2.82	1.12	-0.58
Triglyceride	7	5.97	5.38	1.11	-0.59
Phospholipase	7	5.93	5.35	1.11	-0.59
SST	7	4.93	4.46	1.10	-0.60
Paralysis	7	5.15	4.68	1.10	-0.60
Carbachol	7	4.11	3.77	1.09	-0.61
Thrombocytopenia	7	5.16	4.74	1.09	-0.61
Prednisolone	7	5.13	4.74	1.08	-0.62
Oil	7	5.83	5.52	1.06	-0.64

FIG. 27-13B

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Carbon	7	6.95	6.77	1.03	-0.67
Dithiothreitol	7	4.91	4.82	1.02	-0.68
INTERLEUKIN 1-BETA	7	5.93	5.87	1.01	-0.69
Propranolol	7	4.89	4.86	1.01	-0.69
gamma-Aminobutyric Acid	7	4.46	4.57	0.98	-0.72
Histamine	7	5.65	5.81	0.97	-0.73
Nausea	7	4.91	5.09	0.96	-0.74
Adenosine Diphosphate	7	5.40	5.63	0.96	-0.74
Fibrin	7	4.39	4.60	0.96	-0.74
Magnesium	7	5.55	5.85	0.95	-0.75
Glutamate	7	5.68	6.02	0.94	-0.76
Hemoglobin	7	5.97	6.44	0.93	-0.77
Vomiting	7	5.09	5.50	0.92	-0.78
Hemorrhage	7	5.44	6.01	0.91	-0.79
Nitrogen	7	6.75	7.51	0.90	-0.80
IL8	7	3.51	3.94	0.89	-0.81
Atrium	7	4.78	5.54	0.86	-0.84
Glycogen	7	4.32	5.05	0.86	-0.84
Ester	7	5.83	7.07	0.82	-0.88
Tuberculosis	7	4.17	5.06	0.82	-0.88
Thyroid Hormones	7	4.00	4.89	0.82	-0.88
Ascites	7	3.99	5.43	0.74	-0.96

FIG. 27-13C

FIG. 27-14A
FIG. 27-14B
FIG. 27-14C

FIG. 27-14

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Cholesterol	7	5.00	7.41	0.67	-1.03
Sucrose	7	4.51	6.73	0.67	-1.03
Pneumonia	7	4.07	6.36	0.64	-1.06
IL1A	7	2.93	5.14	0.57	-1.13
FGF-3	6	5.04	1.18	4.26	2.56
STAT5B	6	5.35	1.38	3.88	2.18
HIF1A	6	5.52	1.44	3.83	2.13
Neuregulin	6	5.13	1.34	3.82	2.12

FIG. 27-14A

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
EIF4E	6	5.79	1.54	3.77	2.07
Thrombin Receptors	6	5.49	1.47	3.74	2.04
CADHERIN 3	6	4.98	1.33	3.73	2.03
Hemangioblastoma	6	5.59	1.51	3.69	1.99
ALPHA-1 THYROID HORMONE RECEPTOR	6	5.15	1.40	3.67	1.97
TIMP3	6	5.56	1.55	3.60	1.90
SOD2	6	4.78	1.34	3.57	1.87
Nodular Goiter	6	5.13	1.47	3.48	1.78
Ki-67 Antigen	6	5.99	1.74	3.45	1.75
ANXA1	6	5.47	1.60	3.42	1.72
MYB-BINDING PROTEIN 1A	6	4.71	1.41	3.34	1.64
Pleomorphic Adenoma	6	5.50	1.67	3.29	1.59
ITGB3	6	5.20	1.59	3.28	1.58
JAK1	6	5.22	1.60	3.27	1.57
OSM	6	5.55	1.70	3.26	1.56
DEAD/H BOX 5	6	5.66	1.74	3.26	1.56
NME1	6	4.62	1.42	3.26	1.56
PRLR	6	5.16	1.60	3.23	1.53
CONGENITAL ADRENAL HYPERPLASIA	6	4.61	1.46	3.15	1.45
NTRK3	6	4.70	1.51	3.12	1.42
TRANSCRIPTION FACTOR Sp1	6	5.65	1.82	3.11	1.41
NOL1	6	5.55	1.81	3.06	1.36

FIG. 27-14B

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
M6PR	6	5.10	1.69	3.02	1.32
FOSL1	6	4.64	1.54	3.01	1.31
IL15	6	5.45	1.81	3.00	1.30
E2F1	6	5.34	1.78	3.00	1.30
CSF1R	6	5.43	1.83	2.98	1.28
CDC25C	6	4.88	1.64	2.97	1.27
CCND2	6	4.67	1.57	2.97	1.27
Prolactinoma	6	5.58	1.88	2.96	1.26
CDC42	6	5.74	1.94	2.95	1.25
FGF7	6	5.63	1.91	2.95	1.25
SDC1	6	5.10	1.75	2.91	1.21
HEAD AND NECK SQUAMOUS CELL CARCINOMA	6	4.55	1.57	2.91	1.21
STAT1	6	5.81	2.00	2.90	1.20
Mifepristone	6	5.07	1.75	2.90	1.20
SLC4A1	6	5.78	2.00	2.89	1.19
ITGB1	6	5.80	2.02	2.88	1.18
CDK6	6	4.32	1.50	2.87	1.17
Neuroendocrine Tumors	6	5.13	1.79	2.87	1.17
PXN	6	5.16	1.81	2.86	1.16
CDKN1B	6	5.34	1.87	2.86	1.16
LGALS3	6	4.80	1.70	2.83	1.13
IVL	6	5.39	1.91	2.82	1.12

FIG. 27-14C

FIG. 27-15A
FIG. 27-15B
FIG. 27-15C

FIG. 27-15

92/184

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
BURKITT LYMPHOMA	6	5.71	2.02	2.82	1.12
Chemokine Receptors	6	5.99	2.12	2.82	1.12
CSH1	6	5.88	2.09	2.82	1.12
PRECOCIOUS PUBERTY	6	5.04	1.79	2.81	1.11
Inhibin	6	5.80	2.08	2.79	1.09
UVEAL MELANOMA	6	4.33	1.56	2.77	1.07
RASA1	6	5.51	1.99	2.77	1.07
CYTOPLASMIC PROTEIN-TYROSINE KINASE	6	5.83	2.11	2.76	1.06

FIG. 27-15A



Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Caspase 1	6	5.02	1.83	2.75	1.05
Fibroadenoma	6	4.54	1.66	2.74	1.04
JUNB	6	5.26	1.92	2.74	1.04
Dipeptidyl Peptidases	6	5.57	2.03	2.74	1.04
Protein Isoforms	6	5.82	2.13	2.74	1.04
Flavone	6	5.27	1.94	2.72	1.02
CCR5	6	5.15	1.90	2.71	1.01
Neurofibroma	6	5.58	2.06	2.71	1.01
Blocking Antibodies	6	5.79	2.14	2.70	1.00
NTKL	6	4.31	1.61	2.69	0.99
EWSR1	6	4.56	1.70	2.68	0.98
SCYA2	6	5.37	2.01	2.67	0.97
WT1	6	4.57	1.71	2.67	0.97
Cyproterone Acetate	6	5.15	1.93	2.67	0.97
STAT3	6	5.50	2.06	2.67	0.97
Lobular Carcinoma	6	4.13	1.56	2.65	0.95
Tyrphostin	6	5.69	2.16	2.64	0.94
CDK4	6	5.40	2.05	2.63	0.93
Euchromatin	6	4.42	1.69	2.62	0.92
Large-Cell Lymphoma	6	5.72	2.20	2.60	0.90
THPO	6	4.95	1.92	2.58	0.88
PLEK	6	4.72	1.83	2.58	0.88

FIG. 27-15B

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Isoflavone	6	4.80	1.87	2.56	0.86
MMP3	6	5.13	2.01	2.56	0.86
CD79A	6	4.33	1.69	2.56	0.86
Poly A	6	4.85	1.90	2.55	0.85
PTGS1	6	5.82	2.28	2.55	0.85
BMP2	6	4.74	1.86	2.55	0.85
Clomiphene	6	5.03	1.98	2.54	0.84
Histone Deacetylase	6	4.98	1.97	2.53	0.83
Lysophospholipid	6	5.08	2.01	2.52	0.82
ALOPECIA AREATA	6	3.98	1.58	2.52	0.82
MT1E	6	5.22	2.07	2.52	0.82
NTF3	6	4.91	1.95	2.51	0.81
Paraganglioma	6	4.57	1.82	2.51	0.81
Diethylnitrosamine	6	5.32	2.12	2.51	0.81
Hyperprolactinemia	6	5.49	2.19	2.51	0.81
Sphingolipid	6	5.86	2.35	2.49	0.79
SP3	6	4.63	1.86	2.48	0.78
Nucleoside-Diphosphate Kinase	6	4.13	1.66	2.48	0.78
2-Acetylaminofluorene	6	5.20	2.10	2.48	0.78
Hirudin	6	5.29	2.14	2.47	0.77
Factor XIII	6	4.86	1.97	2.47	0.77
PF4	6	5.72	2.32	2.47	0.77

FIG. 27-15C

FIG. 27-16A
FIG. 27-16B
FIG. 27-16C

FIG. 27-16

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
NEVI	6	5.55	2.26	2.45	0.75
Lipoxygenase Inhibitors	6	4.61	1.89	2.44	0.74
TIMP2	6	4.79	1.97	2.44	0.74
CCAAT-Enhancer-Binding Proteins	6	3.97	1.63	2.43	0.73
Ursodeoxycholic Acid	6	4.97	2.04	2.43	0.73
Diphtheria Toxin	6	5.25	2.19	2.40	0.70
Nocodazole	6	5.77	2.41	2.39	0.69
NRCAM	6	4.82	2.03	2.37	0.67

FIG. 27-16A

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Cytokine Receptors	6	5.82	2.49	2.34	0.64
Tropomyosin	6	5.09	2.18	2.33	0.63
MERTK	6	4.72	2.02	2.33	0.63
Rickets	6	5.06	2.18	2.32	0.62
ANXA5	6	5.64	2.43	2.32	0.62
Cholangiocarcinoma	6	4.50	1.94	2.32	0.62
Docosahexaenoic Acids	6	5.76	2.49	2.31	0.61
Polyvinyl Alcohol	6	5.04	2.18	2.31	0.61
Pyrrolidine	6	5.58	2.42	2.31	0.61
ADENOMATOUS POLYPOSIS OF THE COLON	6	4.38	1.90	2.30	0.60
Exotoxin	6	5.49	2.39	2.30	0.60
CDH17	6	4.41	1.93	2.29	0.59
PPBP	6	5.71	2.50	2.28	0.58
Membrane Glycoproteins	6	5.93	2.60	2.28	0.58
Pituitary Hormones	6	5.68	2.50	2.27	0.57
MYB	6	5.33	2.35	2.27	0.57
wnt	6	4.16	1.84	2.26	0.56
Teratocarcinoma	6	5.57	2.48	2.24	0.54
Myeloproliferative Disorder	6	5.18	2.31	2.24	0.54
cysteine protease	6	5.79	2.58	2.24	0.54
GRB2	6	4.58	2.04	2.24	0.54
Asbesto	6	5.41	2.43	2.23	0.53

FIG. 27-16B

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Mineralocorticoid	6	5.57	2.52	2.21	0.51
Monosomy	6	4.98	2.25	2.21	0.51
myogenesis	6	5.14	2.33	2.20	0.50
ENTPD2	6	4.55	2.07	2.20	0.50
Fibrous Histiocytoma	6	4.47	2.05	2.18	0.48
Carcinoid Tumor	6	4.79	2.20	2.18	0.48
SCLC	6	4.40	2.02	2.18	0.48
RALY	6	4.22	1.95	2.17	0.47
Hyperoxia	6	5.46	2.53	2.16	0.46
TXN	6	5.74	2.66	2.16	0.46
HEREDITARY PANCREATITIS	6	5.58	2.59	2.16	0.46
Hemangiopericytoma	6	3.50	1.62	2.16	0.46
ANPEP	6	5.17	2.40	2.15	0.45
GAMMA-2 PHOSPHOLIPASE C	6	4.88	2.27	2.15	0.45
Streptavidin	6	5.39	2.53	2.13	0.43
Hyperparathyroidism	6	5.80	2.73	2.13	0.43
Trans-Activator	6	5.39	2.54	2.13	0.43
Hyperaldosteronism	6	5.40	2.54	2.12	0.42
PROS1	6	4.87	2.29	2.12	0.42
Amenorrhea	6	5.47	2.58	2.12	0.42
Butanol	6	5.51	2.61	2.11	0.41
N-Acetylneuraminic Acid	6	5.16	2.45	2.11	0.41

FIG. 27-16C

FIG. 27-17A
FIG. 27-17B
FIG. 27-17C

FIG. 27-17

98/184

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Carotenoid	6	5.40	2.56	2.11	0.41
Thymidine Phosphorylase	6	3.13	1.49	2.10	0.40
Factor Xa	6	4.78	2.28	2.09	0.39
Butyric Acid	6	4.87	2.34	2.08	0.38
POLYCYSTIC KIDNEYS	6	5.04	2.42	2.08	0.38
Lymphoproliferative Disorder	6	5.38	2.60	2.07	0.37
Glycosphingolipid	6	5.05	2.46	2.06	0.36
Protein-Tyrosine-Phosphatase	6	4.99	2.43	2.05	0.35

FIG. 27-17A

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
DOMAINS	6	4.71	2.30	2.05	0.35
Bombesin	6	5.24	2.57	2.04	0.34
Leupeptin	6	5.81	2.84	2.04	0.34
Pulmonary Fibrosis	6	5.94	2.91	2.04	0.34
SUPPRESSOR OF TUMORIGENICITY 8	6	4.65	2.29	2.03	0.33
APOE	6	5.82	2.87	2.03	0.33
NASOPHARYNGEAL CANCER	6	4.80	2.37	2.02	0.32
Glycogen Synthase	6	4.68	2.31	2.02	0.32
Antithrombin	6	4.50	2.23	2.02	0.32
Thrombospondin	6	4.37	2.18	2.01	0.31
Subarachnoid Hemorrhage	6	5.47	2.73	2.01	0.31
INTERLEUKIN 1-ALPHA	6	5.58	2.78	2.00	0.30
Chemolactic Factors	6	5.57	2.78	2.00	0.30
RNA POLYMERASE III TRANSCRIPT 1	6	4.30	2.15	2.00	0.30
Octreotide	6	4.98	2.51	1.99	0.29
Chondroitin	6	5.16	2.61	1.98	0.28
Trace Elements	6	5.84	2.96	1.98	0.28
Thapsigargin	6	5.93	3.01	1.97	0.27
ALPHA-L INTEGRIN	6	4.56	2.32	1.97	0.27
BCR	6	5.15	2.63	1.96	0.26
AKT1	6	4.99	2.55	1.96	0.26
GH1	6	4.70	2.41	1.95	0.25

FIG. 27-17B

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Neuritis	6	4.38	2.25	1.95	0.25
Pentose	6	4.72	2.43	1.94	0.24
MEMBER Q HISTONE 2B FAMILY	6	4.39	2.27	1.94	0.24
Calcineurin	6	4.90	2.54	1.93	0.23
Naltrexone	6	4.39	2.27	1.93	0.23
MEMBRANE METALLOENDOPEPTIDASE	6	4.63	2.40	1.93	0.23
B7	6	4.74	2.46	1.92	0.22
Angina Pectoris	6	5.29	2.75	1.92	0.22
ENOLASE 2	6	5.89	3.07	1.92	0.22
Procollagen	6	5.55	2.92	1.90	0.20
BAG1	6	5.58	2.95	1.89	0.19
Pre-Eclampsia	6	5.55	2.93	1.89	0.19
DNM1	6	4.81	2.54	1.89	0.19
Trypsin Inhibitors	6	5.88	3.12	1.88	0.18
Delayed Hypersensitivity	6	5.36	2.85	1.88	0.18
Leukotriene B4	6	5.89	3.15	1.87	0.17
Viral Antigens	6	5.19	2.78	1.87	0.17
Alcian Blue	6	4.84	2.60	1.86	0.16
EDN1	6	5.83	3.13	1.86	0.16
ALPHA-M INTEGRIN	6	5.64	3.04	1.86	0.16
Mutagen	6	5.33	2.87	1.86	0.16
Putrescine	6	5.84	3.15	1.86	0.16

FIG. 27-17C



FIG. 27-18A
FIG. 27-18B
FIG. 27-18C

FIG. 27-18

101/184

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Acute-Phase Proteins	6	4.92	2.65	1.85	0.15
increases	6	5.40	2.93	1.84	0.14
PLAT	6	5.40	2.93	1.84	0.14
Corn Oil	6	5.58	3.03	1.84	0.14
Xylose	6	4.61	2.51	1.84	0.14
Amiloride	6	5.82	3.18	1.83	0.13
Monosaccharide	6	4.50	2.46	1.83	0.13
Protein Subunits	6	4.74	2.60	1.82	0.12

FIG. 27-18A

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Disaccharide	6	4.97	2.73	1.82	0.12
Insulinoma	6	4.82	2.66	1.81	0.11
Aromatic Hydrocarbons	6	4.95	2.73	1.81	0.11
Stearic Acids	6	4.67	2.59	1.80	0.10
Dietary Fats	6	4.82	2.68	1.80	0.10
Hyperinsulinemia	6	4.97	2.77	1.80	0.10
Sphingomyelin	6	5.73	3.19	1.80	0.10
Ranitidine	6	5.08	2.83	1.79	0.09
Ethanolamine	6	5.07	2.84	1.79	0.09
TNFRSF6	6	4.74	2.66	1.78	0.08
Arteriosclerosis	6	4.98	2.81	1.77	0.07
Hematoxilin	6	5.63	3.19	1.77	0.07
Graves' Disease	6	4.76	2.73	1.75	0.05
Glucosamine	6	5.50	3.15	1.74	0.04
Deferoxamine	6	4.78	2.74	1.74	0.04
CP	6	5.97	3.43	1.74	0.04
Lymphokine	6	5.55	3.19	1.74	0.04
Puromycin	6	5.32	3.07	1.73	0.03
Mitochondrial DNA	6	5.76	3.32	1.73	0.03
Isomerase	6	5.07	2.93	1.73	0.03
Protoporphyrin	6	4.56	2.64	1.73	0.03
Peptide Fragments	6	5.34	3.10	1.72	0.02

FIG. 27-18B

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Palmitate	6	5.72	3.32	1.72	0.02
Cytoskeletal Proteins	6	5.98	3.48	1.72	0.02
Kidney Disease	6	4.70	2.74	1.72	0.02
Lipid Peroxides	6	4.98	2.90	1.72	0.02
Lysophosphatidylcholine	6	4.54	2.65	1.71	0.01
MEMBER 1 SUBFAMILY B ATP-BINDING CASSETTE	6	4.40	2.60	1.70	0.00
Uridine Triphosphate	6	5.12	3.03	1.69	-0.01
Cholinesterase	6	5.57	3.30	1.69	-0.01
BONE GAMMA-CARBOXYGLUTAMIC ACID PROTEIN	6	4.79	2.85	1.68	-0.02
Ethidium	6	5.71	3.41	1.68	-0.02
Oleic Acid	6	5.82	3.47	1.68	-0.02
IGHG2	6	4.29	2.56	1.67	-0.03
Pulmonary Hypertension	6	5.50	3.30	1.67	-0.03
Venom	6	5.51	3.30	1.67	-0.03
RESPIRATORY DISTRESS SYNDROME	6	5.81	3.49	1.66	-0.04
beta-Endorphin	6	4.98	3.00	1.66	-0.04
Coenzyme A	6	5.65	3.41	1.66	-0.04
Uremia	6	5.44	3.29	1.66	-0.04
Ribonucleoprotein	6	4.99	3.03	1.65	-0.05
THM	6	4.57	2.81	1.63	-0.07
Indole	6	5.31	3.27	1.63	-0.07
Hepatitis C	6	5.30	3.29	1.61	-0.09

FIG. 27-18C

FIG. 27-19A
FIG. 27-19B
FIG. 27-19C

FIG. 27-19

104/184

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Colitis	6	5.81	3.61	1.61	-0.09
Myelodysplastic Syndromes	6	4.32	2.69	1.61	-0.09
Calcium Phosphates	6	4.95	3.10	1.60	-0.10
ACE	6	5.82	3.66	1.59	-0.11
SERPINB4	6	5.97	3.77	1.58	-0.12
Cytochrome-c Oxidase	6	4.89	3.09	1.58	-0.12
Nickel	6	5.83	3.69	1.58	-0.12
Trichloroacetic Acid	6	4.81	3.06	1.57	-0.13

FIG. 27-19A

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
beta Carotene	6	4.43	2.81	1.57	-0.13
GAS	6	5.00	3.20	1.56	-0.14
G6PD	6	5.82	3.74	1.56	-0.14
Heavy Metals	6	4.73	3.04	1.55	-0.15
Ammonium Chloride	6	4.53	2.92	1.55	-0.15
GSR	6	4.49	2.93	1.53	-0.17
Leukotriene	6	5.38	3.51	1.53	-0.17
Suramin	6	4.40	2.88	1.53	-0.17
Hemagglutinin	6	4.64	3.03	1.53	-0.17
Encephalomyelitis	6	4.56	2.98	1.53	-0.17
ASTHMA	6	4.92	3.22	1.53	-0.17
Zymosan	6	5.09	3.34	1.52	-0.18
Phosphatidylserine	6	5.98	3.93	1.52	-0.18
Allopurinol	6	4.52	2.99	1.51	-0.19
C3	6	4.12	2.73	1.51	-0.19
Freund's Adjuvant	6	4.21	2.80	1.51	-0.19
Hematuria	6	4.81	3.19	1.51	-0.19
Diuretic	6	5.39	3.58	1.51	-0.19
Opioid Receptors	6	3.81	2.55	1.49	-0.21
Hydroxyapatite	6	5.51	3.70	1.49	-0.21
PALMOPLANTAR KERATODERMA	6	5.43	3.67	1.48	-0.22
ENDOMETRIOSIS	6	3.66	2.48	1.48	-0.22

FIG. 27-19B

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Corticosterone	6	5.98	4.07	1.47	-0.23
P-Glycoprotein	6	4.76	3.24	1.47	-0.23
Encephalitis	6	4.98	3.39	1.47	-0.23
Opportunistic Infection	6	4.53	3.09	1.47	-0.23
Uridine	6	5.40	3.71	1.45	-0.25
Blindness	6	5.24	3.61	1.45	-0.25
ESOPHAGEAL CANCER	6	3.55	2.47	1.44	-0.26
Propionate	6	5.62	3.93	1.43	-0.27
OSTEOARTHRITIS	6	5.33	3.72	1.43	-0.27
NPPA	6	4.64	3.27	1.42	-0.28
Linoleic Acid	6	4.81	3.40	1.41	-0.29
Gelatin	6	5.75	4.07	1.41	-0.29
Anthracycline	6	3.98	2.82	1.41	-0.29
NDUFB3	6	5.03	3.57	1.41	-0.29
RHO6	6	3.67	2.61	1.40	-0.30
TH	6	4.65	3.32	1.40	-0.30
CCK	6	4.78	3.43	1.39	-0.31
Dipeptide	6	5.32	3.82	1.39	-0.31
INSR	6	4.49	3.23	1.39	-0.31
Hydroxylase	6	5.20	3.74	1.39	-0.31
Asparagine	6	5.73	4.13	1.39	-0.31
Demyelinating	6	4.39	3.17	1.39	-0.31

FIG. 27-19C

FIG. 27-20A
FIG. 27-20B
FIG. 27-20C

FIG. 27-20

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Sodium Azide	6	4.32	3.12	1.38	-0.32
Hydrolase	6	5.74	4.16	1.38	-0.32
Hypothermia	6	5.46	3.97	1.38	-0.32
Citric Acid	6	4.22	3.08	1.37	-0.33
Stomatitis	6	4.91	3.58	1.37	-0.33
Guanidine	6	5.07	3.71	1.37	-0.33
alpha-Tocopherol	6	4.74	3.48	1.36	-0.34
Myocardial Ischemia	6	4.37	3.25	1.35	-0.35

FIG. 27-20A

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Hepatitis B	6	5.52	4.11	1.34	-0.36
ki-67	6	3.00	2.24	1.34	-0.36
Acetonitrile	6	5.13	3.85	1.33	-0.37
Interferon-alpha	6	4.51	3.38	1.33	-0.37
NPY	6	4.16	3.12	1.33	-0.37
Influenza	6	5.54	4.17	1.33	-0.37
Barium	6	5.22	3.93	1.33	-0.37
Tetracycline	6	5.82	4.41	1.32	-0.38
Pyridine	6	5.05	3.83	1.32	-0.38
Osteoporosis	6	4.81	3.66	1.31	-0.39
Chloroquine	6	5.37	4.11	1.31	-0.39
Ammonium Sulfate	6	5.72	4.38	1.31	-0.39
Cholera Toxin	6	4.85	3.72	1.30	-0.40
Interleukin-8	6	3.99	3.07	1.30	-0.40
Gonadotropin	6	4.57	3.53	1.29	-0.41
Bleomycin	6	4.62	3.57	1.29	-0.41
DEAE-Cellulose	6	5.13	3.97	1.29	-0.41
Alkylating Agent	6	5.00	3.87	1.29	-0.41
TESTICULAR TUMORS	6	3.65	2.83	1.29	-0.41
NONINSULIN-DEPENDENT DIABETES MELLITUS	6	4.37	3.39	1.29	-0.41
Acidosis	6	5.83	4.52	1.29	-0.41
Cadmium	6	5.13	4.02	1.28	-0.42

FIG. 27-20B



Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Cyclic GMP	6	4.22	3.32	1.27	-0.43
Polyethylene Glycols	6	5.55	4.37	1.27	-0.43
Blood Glucose	6	5.57	4.39	1.27	-0.43
Aldosterone	6	4.93	3.91	1.26	-0.44
Formaldehyde	6	5.23	4.15	1.26	-0.44
Hypoglycemia	6	4.93	3.94	1.25	-0.45
Chemokine	6	3.83	3.07	1.25	-0.45
Ascorbic Acid	6	5.54	4.46	1.24	-0.46
Pyruvate	6	5.75	4.66	1.23	-0.47
MS	6	5.15	4.18	1.23	-0.47
Vasculitis	6	4.98	4.06	1.23	-0.47
Melatonin	6	3.97	3.27	1.21	-0.49
Cholestasis	6	4.14	3.43	1.21	-0.49
Erythromycin	6	4.65	3.87	1.20	-0.50
Coagulase	6	4.70	3.91	1.20	-0.50
Cellulose	6	5.96	4.96	1.20	-0.50
Epilepsy	6	5.70	4.78	1.19	-0.51
Cholera	6	3.54	3.00	1.18	-0.52
Glutamic Acid	6	5.92	5.10	1.16	-0.54
Sodium Fluoride	6	3.29	2.86	1.15	-0.55
Nitrate	6	5.37	4.70	1.14	-0.56
Manganese	6	4.48	3.93	1.14	-0.56

FIG. 27-20C

FIG. 27-21A
FIG. 27-21B
FIG. 27-21C

FIG. 27-21

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
ACHE	6	4.54	4.05	1.12	-0.58
Hypercalcemia	6	3.50	3.16	1.11	-0.59
Ulcer	6	4.85	4.42	1.10	-0.60
Phenol	6	4.90	4.49	1.09	-0.61
Acid Phosphatase	6	4.96	4.58	1.08	-0.62
Ganglioside	6	3.96	3.65	1.08	-0.62
Cytosine	6	4.68	4.33	1.08	-0.62
Hydroxyproline	6	3.57	3.34	1.07	-0.63

FIG. 27-21A

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Colchicine	6	4.82	4.56	1.06	-0.64
MMP9	6	2.82	2.69	1.05	-0.65
Vasopressin	6	4.54	4.32	1.05	-0.65
Theophylline	6	4.58	4.45	1.03	-0.67
Verapamil	6	4.82	4.72	1.02	-0.68
Diarthea	6	5.40	5.50	0.98	-0.72
PTGS2	6	2.93	3.02	0.97	-0.73
Morphine	6	4.24	4.42	0.96	-0.74
PHEOCHROMOCYTOMA	6	3.58	3.76	0.95	-0.75
Carcinogen	6	3.82	4.02	0.95	-0.75
Divalent Cations	6	3.98	4.24	0.94	-0.76
Guanine	6	4.58	4.88	0.94	-0.76
Fatigue	6	4.38	4.76	0.92	-0.78
Rupture	6	4.57	5.04	0.91	-0.79
Analgesic	6	4.43	4.89	0.91	-0.79
Norepinephrine	6	4.75	5.27	0.90	-0.80
Epinephrine	6	4.57	5.08	0.90	-0.80
Cisplatin	6	3.82	4.31	0.89	-0.81
GCG	6	3.91	4.49	0.87	-0.83
PLG	6	2.83	3.37	0.84	-0.86
Shock	6	5.99	7.21	0.83	-0.87
Granuloma	6	3.55	4.56	0.78	-0.92

FIG. 27-21B

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Cation	6	4.58	6.59	0.70	-1.00
TDGF1	5	4.76	1.25	3.80	1.40
PTN	5	4.80	1.28	3.75	1.35
CYR61	5	4.66	1.25	3.74	1.34
INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN 7	5	4.30	1.16	3.71	1.31
FOLH1	5	4.74	1.28	3.71	1.31
SCYB10	5	4.62	1.26	3.67	1.27
AKT2	5	4.32	1.22	3.54	1.14
FGF3	5	4.65	1.34	3.46	1.06
ITGA6	5	4.23	1.23	3.45	1.05
MET PROTOONCOGENE	5	4.59	1.34	3.44	1.04
CSK	5	4.19	1.24	3.38	0.98
NRAS	5	4.29	1.27	3.37	0.97
TSC2	5	4.40	1.31	3.36	0.96
EPHRIN RECEPTOR EphA2	5	4.20	1.26	3.34	0.94
IGFBP6	5	4.20	1.27	3.30	0.90
FGFR3	5	4.82	1.48	3.26	0.86
IL8RA	5	4.30	1.33	3.22	0.82
Prostatic Disease	5	4.46	1.39	3.22	0.82
SSTR1	5	4.37	1.36	3.20	0.80
PEUTZ-JEGHERS SYNDROME	5	4.40	1.38	3.19	0.79
Oncogene Proteins	5	4.04	1.28	3.16	0.76

FIG. 27-21C

FIG. 27-22A
FIG. 27-22B
FIG. 27-22C

FIG. 27-22

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Hippel-Lindau Disease	5	4.81	1.53	3.14	0.74
GSTM1	5	4.78	1.53	3.12	0.72
MEMBRANE	5	4.62	1.49	3.11	0.71
Serous Cystadenocarcinoma	5	4.36	1.41	3.09	0.69
PTGER1	5	4.56	1.48	3.07	0.67
PTGER2	5	4.56	1.49	3.07	0.67
Endometrial Carcinoma	5	3.98	1.30	3.06	0.66
Cancer Vaccines	5	3.99	1.33	3.00	0.60

FIG. 27-22A

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Villous Adenoma	5	4.40	1.47	2.99	0.59
Interleukin-18	5	4.12	1.38	2.98	0.58
IGF2R	5	4.38	1.48	2.96	0.56
TNS	5	4.13	1.40	2.94	0.54
TRANSCRIPTION FACTOR 2	5	4.04	1.38	2.93	0.53
MYELOID CELL LEUKEMIA 1	5	4.19	1.45	2.90	0.50
src-Family Kinases	5	4.77	1.66	2.88	0.48
SYK	5	4.95	1.73	2.87	0.47
MACS	5	4.54	1.58	2.87	0.47
Thyroid Nodule	5	4.74	1.66	2.87	0.47
ICAM2	5	4.33	1.51	2.86	0.46
Immunoconjugate	5	4.40	1.54	2.86	0.46
Mantle-Cell Lymphoma	5	4.30	1.51	2.85	0.45
MITOGEN-ACTIVATED KINASE KINASE 1	5	4.46	1.56	2.85	0.45
Prolactin Receptors	5	4.16	1.46	2.85	0.45
Adenomatous Polyps	5	4.90	1.72	2.84	0.44
GSK3B	5	4.13	1.45	2.84	0.44
VIL2	5	4.38	1.54	2.84	0.44
Bowen's Disease	5	4.40	1.56	2.82	0.42
UTERINE LEIOMYOMA	5	4.97	1.76	2.82	0.42
Endometrial Hyperplasia	5	4.58	1.64	2.80	0.40
FRZB	5	3.98	1.43	2.79	0.39

FIG. 27-22B

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Embryonal Rhabdomyosarcoma	5	4.12	1.48	2.79	0.39
CXCR4	5	4.91	1.77	2.78	0.38
Prostatic Hyperplasia	5	4.05	1.46	2.77	0.37
Serine kinase	5	4.32	1.58	2.72	0.32
ALPHA-1 LAMININ	5	4.33	1.60	2.72	0.32
MUC2	5	3.94	1.45	2.71	0.31
ATF1	5	4.14	1.53	2.70	0.30
MMP13	5	4.16	1.56	2.67	0.27
H19	5	3.96	1.48	2.67	0.27
Soybean Proteins	5	4.21	1.58	2.67	0.27
NPY6R	5	3.78	1.42	2.66	0.26
TYK2	5	4.06	1.54	2.63	0.23
Gastric Mucin	5	4.06	1.54	2.63	0.23
RAC1	5	4.91	1.87	2.62	0.22
Glucagonoma	5	4.05	1.55	2.62	0.22
DNA DAMAGE-INDUCIBLE TRANSCRIPT 3	5	4.37	1.67	2.61	0.21
IMP Dehydrogenase	5	4.03	1.54	2.61	0.21
Relaxin	5	4.79	1.84	2.60	0.20
Monocrotaline	5	4.32	1.66	2.60	0.20
FOXM1	5	4.16	1.60	2.60	0.20
Proliferative Vitreoretinopathy	5	4.35	1.68	2.59	0.19
VTNR	5	4.41	1.71	2.58	0.18

FIG. 27-22C

FIG. 27-23A
FIG. 27-23B
FIG. 27-23C

FIG. 27-23

116/184

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
PI31	5	4.78	1.85	2.58	0.18
B-CELL TRANSLOCATION GENE 2	5	4.97	1.94	2.56	0.16
Gastrointestinal Hormones	5	4.22	1.65	2.56	0.16
Keratinosis	5	4.76	1.87	2.55	0.15
Tissue Kallikreins	5	4.13	1.62	2.54	0.14
KRT19	5	3.71	1.46	2.54	0.14
LOX	5	4.16	1.64	2.53	0.13
IL18	5	4.41	1.75	2.53	0.13

FIG. 27-23A



Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Levonorgestrel	5	4.31	1.71	2.52	0.12
Swainsonine	5	4.15	1.65	2.51	0.11
gamma-Linolenic Acid	5	4.57	1.82	2.51	0.11
NPM1	5	4.06	1.62	2.51	0.11
Mucoepidermoid Carcinoma	5	3.88	1.55	2.50	0.10
KRT18	5	4.50	1.81	2.49	0.09
HYDM	5	4.52	1.82	2.48	0.08
Craniopharyngioma	5	4.35	1.75	2.48	0.08
STHM	5	4.48	1.81	2.47	0.07
SQSTM1	5	4.32	1.75	2.47	0.07
Curcumin	5	4.99	2.03	2.46	0.06
STAT5A	5	4.40	1.80	2.45	0.05
NTRK1	5	5.00	2.04	2.45	0.05
HMOX1	5	4.75	1.96	2.42	0.02
Pulmonary Sarcoidosis	5	4.44	1.85	2.41	0.01
IL9	5	3.90	1.62	2.41	0.01
IRF1	5	3.64	1.52	2.40	0.00
CD63	5	4.23	1.76	2.40	0.00
BMP4	5	3.96	1.65	2.40	0.00
Connexin	5	4.29	1.80	2.39	-0.01
Activin	5	4.80	2.02	2.38	-0.02
MUC5AC	5	3.23	1.36	2.38	-0.02

FIG. 27-23B

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
EEF2	5	4.20	1.77	2.37	-0.03
DNA Topoisomerases	5	4.65	1.96	2.37	-0.03
Sunburn	5	3.74	1.58	2.37	-0.03
X-LINKED PREMATURE OVARIAN FAILURE	5	3.57	1.51	2.37	-0.03
NTF5	5	3.64	1.54	2.37	-0.03
NP	5	4.74	2.01	2.36	-0.04
IL11	5	4.37	1.86	2.35	-0.05
KALLIKREIN 2	5	3.67	1.56	2.35	-0.05
EthylNitrosourea	5	4.58	1.95	2.35	-0.05
F5	5	4.28	1.82	2.35	-0.05
Chromogranin	5	4.64	1.98	2.35	-0.05
Cystadenocarcinoma	5	3.71	1.58	2.35	-0.05
RBL2	5	4.55	1.94	2.34	-0.06
Cryptorchidism	5	4.79	2.05	2.34	-0.06
Recombinant Interferon-gamma	5	4.96	2.12	2.34	-0.06
ALPHA-4 INTEGRIN	5	3.89	1.66	2.34	-0.06
Lutein	5	4.33	1.86	2.33	-0.07
SONIC HEDGEHOG	5	3.71	1.59	2.33	-0.07
NP25	5	3.80	1.63	2.33	-0.07
Serpin	5	4.65	2.00	2.32	-0.08
Sulindac	5	4.78	2.06	2.32	-0.08
CD58	5	3.98	1.72	2.31	-0.09

FIG. 27-23C

FIG. 27-24A
FIG. 27-24B
FIG. 27-24C

FIG. 27-24

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Ganglioneuroma	5	3.73	1.62	2.30	-0.10
Reticulin	5	4.52	1.97	2.30	-0.10
Deoxyglucose	5	4.54	1.97	2.30	-0.10
SPF45	5	3.64	1.59	2.30	-0.10
Adenosquamous Carcinoma	5	3.54	1.54	2.29	-0.11
Atrophic Gastritis	5	4.20	1.84	2.29	-0.11
Norgestrel	5	3.32	1.45	2.28	-0.12
VHL	5	3.82	1.68	2.28	-0.12

FIG. 27-24A

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
TGM2	5	4.57	2.01	2.28	-0.12
CSN2	5	4.63	2.03	2.28	-0.12
V-SRC AVIAN SARCOMA VIRAL ONCOGENE	5	3.57	1.57	2.27	-0.13
Vinca Alkaloids	5	4.20	1.85	2.27	-0.13
RAB1B	5	4.39	1.94	2.27	-0.13
Sarcoma 180	5	4.52	1.99	2.27	-0.13
LIPC	5	4.11	1.82	2.26	-0.14
LOW-GRADE B-CELL MALIGNANCY	5	4.61	2.04	2.26	-0.14
IDIOPATHIC PULMONARY FIBROSIS	5	4.37	1.94	2.26	-0.14
DSP	5	3.74	1.66	2.25	-0.15
Transferrin Receptors	5	4.54	2.02	2.25	-0.15
CD36	5	4.79	2.13	2.24	-0.16
CTRL	5	4.31	1.92	2.24	-0.16
GZMB	5	4.07	1.82	2.24	-0.16
Osteitis	5	4.21	1.89	2.22	-0.18
Sesquiterpene	5	4.20	1.89	2.22	-0.18
PTK9	5	4.72	2.13	2.22	-0.18
SCYA4	5	3.95	1.79	2.21	-0.19
TUBEROUS SCLEROSIS	5	4.57	2.07	2.21	-0.19
Anti-Idiotypic Antibodies	5	4.58	2.08	2.20	-0.20
CDKN2A	5	3.55	1.61	2.20	-0.20
MYOG	5	3.78	1.72	2.19	-0.21

FIG. 27-24B

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
SLC3A2	5	3.65	1.67	2.19	-0.21
G8	5	3.40	1.56	2.18	-0.22
PTAFR	5	3.39	1.56	2.18	-0.22
Raloxifene	5	3.23	1.48	2.18	-0.22
Transaldolase	5	3.99	1.83	2.18	-0.22
BCL2	5	4.82	2.23	2.17	-0.23
Benzamide	5	3.88	1.79	2.16	-0.24
Safflower Oil	5	3.89	1.80	2.16	-0.24
CXC Chemokines	5	3.96	1.84	2.15	-0.25
SCYA11	5	3.71	1.72	2.15	-0.25
Flutamide	5	4.09	1.90	2.15	-0.25
Hyperandrogenism	5	3.37	1.57	2.15	-0.25
ADPRT	5	4.06	1.89	2.14	-0.26
Gossypol	5	4.13	1.93	2.14	-0.26
Tetradecanoylphorbol Acetate	5	4.10	1.93	2.12	-0.28
Fibrillar Collagens	5	3.73	1.78	2.10	-0.30
Flurbiprofen	5	4.50	2.15	2.09	-0.31
Deoxyuridine	5	4.56	2.19	2.08	-0.32
Hyperlipoproteinemia	5	4.14	1.99	2.08	-0.32
Hirsutism	5	4.37	2.10	2.08	-0.32
Glucuronidase	5	4.62	2.22	2.08	-0.32
Anisomycin	5	4.27	2.06	2.07	-0.33

FIG. 27-24C

FIG. 27-25A
FIG. 27-25B
FIG. 27-25C

FIG. 27-25

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
HDC	5	3.96	1.91	2.07	-0.33
THR	5	4.09	1.97	2.07	-0.33
Macular Degeneration	5	4.14	2.00	2.07	-0.33
CNTF	5	4.04	1.95	2.07	-0.33
Magnesium Deficiency	5	4.16	2.01	2.06	-0.34
LYMPHOTOXIN-ALPHA	5	3.40	1.65	2.06	-0.34
B2M	5	4.10	1.99	2.06	-0.34
Deoxyadenosine	5	3.95	1.93	2.05	-0.35

FIG. 27-25A

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Norethindrone	5	3.32	1.62	2.05	-0.35
SSX1	5	3.55	1.74	2.04	-0.36
Dermatan Sulfate	5	4.34	2.13	2.04	-0.36
NDUFA2	5	4.13	2.03	2.03	-0.37
Estradiol Receptors	5	3.23	1.59	2.03	-0.37
SDC2	5	4.40	2.18	2.02	-0.38
NOS3	5	4.31	2.14	2.01	-0.39
IL1RN	5	4.21	2.10	2.00	-0.40
PHB	5	3.34	1.67	2.00	-0.40
CTSG	5	4.17	2.09	2.00	-0.40
BMP	5	4.13	2.07	2.00	-0.40
Sialoglycoprotein	5	3.70	1.87	1.98	-0.42
Bacterial Toxins	5	4.06	2.05	1.98	-0.42
GCK	5	3.98	2.01	1.98	-0.42
CD68	5	4.75	2.40	1.98	-0.42
Galactosyltransferase	5	4.40	2.23	1.97	-0.43
Geminoma	5	2.91	1.48	1.97	-0.43
GLUCOSE-6-PHOSPHATE ISOMERASE	5	3.85	1.96	1.97	-0.43
Unstable Angina	5	4.37	2.22	1.97	-0.43
Phosphofructokinase	5	4.81	2.45	1.97	-0.43
Pulmonary Surfactants	5	4.29	2.19	1.96	-0.44
F8	5	3.98	2.04	1.95	-0.45

FIG. 27-25B

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Goiter	5	4.99	2.58	1.94	-0.46
Interleukin-2 Receptors	5	4.31	2.23	1.93	-0.47
HLA-D HISTOCOMPATIBILITY TYPE	5	4.33	2.24	1.93	-0.47
Transducin	5	3.37	1.75	1.93	-0.47
Factor X	5	4.08	2.11	1.93	-0.47
HOMOLOG-LIKE DROSOPHILA SINGED	5	4.72	2.45	1.92	-0.48
Omeprazole	5	4.85	2.52	1.92	-0.48
UP	5	3.81	1.99	1.91	-0.49
3-@HYDROXY-3-METHYLGLUTARYL-CoA REDUCTASE	5	4.77	2.50	1.91	-0.49
Polyurethane	5	4.30	2.25	1.91	-0.49
Piroxicam	5	4.53	2.38	1.90	-0.50
TYR	5	4.93	2.60	1.90	-0.50
Glycosylphosphatidylinositol	5	4.37	2.31	1.89	-0.51
Dimethylnitrosamine	5	3.92	2.07	1.89	-0.51
ABDOMINAL AORTIC ANEURYSM	5	4.13	2.19	1.89	-0.51
Ethyl Methanesulfonate	5	3.92	2.08	1.89	-0.51
Silver Nitrate	5	4.20	2.23	1.88	-0.52
Interferon-beta	5	4.80	2.56	1.88	-0.52
Picoline	5	4.23	2.26	1.87	-0.53
Factor VII	5	4.13	2.20	1.87	-0.53
Lichen Planus	5	3.93	2.11	1.86	-0.54
TGM1	5	3.54	1.91	1.85	-0.55



FIG. 27-26A
FIG. 27-26B
FIG. 27-26C

FIG. 27-26

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
HLA-DR Antigens	5	3.88	2.10	1.85	-0.55
PPP1R13B	5	3.95	2.13	1.85	-0.55
PTEN	5	3.00	1.62	1.85	-0.55
Ganciclovir	5	4.50	2.44	1.85	-0.55
Losartan	5	4.33	2.35	1.85	-0.55
Oligodeoxynucleotide	5	4.60	2.50	1.84	-0.56
CLU	5	3.67	1.99	1.84	-0.56
Carcinoma	5	3.96	2.15	1.84	-0.56

FIG. 27-26A

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Arsenic	5	4.97	2.71	1.83	-0.57
TNFRSF5	5	4.51	2.47	1.83	-0.57
PHOSPHORIBOSYLTRANSFERASE 1	5	4.65	2.55	1.83	-0.57
Arteriovenous Malformations	5	4.33	2.37	1.83	-0.57
Spirolactone	5	4.37	2.40	1.82	-0.58
Avidin	5	4.79	2.64	1.82	-0.58
Wegener's Granulomatosis	5	3.80	2.10	1.81	-0.59
ALPHA-X INTEGRIN	5	3.78	2.09	1.81	-0.59
Lipid A	5	4.48	2.48	1.81	-0.59
Buthionine Sulfoximine	5	4.53	2.51	1.81	-0.59
SP2	5	3.92	2.17	1.81	-0.59
Dopamine Agonists	5	4.45	2.47	1.80	-0.60
Titanium	5	4.65	2.58	1.80	-0.60
Hypokinesia	5	3.71	2.06	1.80	-0.60
Methacrylate	5	4.65	2.59	1.79	-0.61
SYP	5	4.40	2.47	1.78	-0.62
Polyuria	5	4.54	2.55	1.78	-0.62
CHONDROSARCOMA	5	3.99	2.24	1.78	-0.62
PROTEIN EXPRESSED IN NONMETASTATIC CELLS 1	5	2.83	1.59	1.78	-0.62
Homocysteine	5	4.96	2.80	1.77	-0.63
Minocycline	5	4.13	2.34	1.77	-0.63
Angiotensin Amide	5	4.93	2.79	1.77	-0.63

FIG. 27-26B

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
LEP	5	4.58	2.60	1.76	-0.64
Thyroiditis	5	4.82	2.73	1.76	-0.64
DEAFNESS	5	4.34	2.47	1.76	-0.64
Fatty Liver	5	4.52	2.58	1.75	-0.65
Pentoxifylline	5	4.58	2.62	1.75	-0.65
Polylysine	5	4.38	2.51	1.75	-0.65
Histocompatibility Antigens	5	4.65	2.66	1.75	-0.65
Nordihydroguaiaretic Acid	5	4.40	2.52	1.74	-0.66
Keratan Sulfate	5	3.15	1.81	1.74	-0.66
CD59	5	3.32	1.91	1.74	-0.66
Glycosuria	5	3.39	1.95	1.74	-0.66
Glyceraldehyde	5	3.54	2.04	1.73	-0.67
Aprotinin	5	4.91	2.83	1.73	-0.67
Hexosamine	5	3.81	2.20	1.73	-0.67
Thalidomide	5	3.66	2.11	1.73	-0.67
Dyspepsia	5	3.97	2.29	1.73	-0.67
RCCP2	5	2.91	1.68	1.73	-0.67
Hypogonadism	5	4.21	2.44	1.73	-0.67
Contractile Proteins	5	3.81	2.21	1.73	-0.67
Intestinal Obstruction	5	4.08	2.37	1.73	-0.67
Phosphocreatine	5	4.32	2.51	1.72	-0.68
Glucocorticoid Receptors	5	4.33	2.51	1.72	-0.68

FIG. 27-26C

FIG. 27-27A
FIG. 27-27B
FIG. 27-27C

FIG. 27-27

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Acyltransferase	5	4.20	2.44	1.72	-0.68
Carbamate	5	4.80	2.80	1.71	-0.69
LDL Receptors	5	4.23	2.47	1.71	-0.69
Schistosomiasis	5	4.57	2.69	1.70	-0.70
ALZHEIMER DISEASE	5	4.23	2.49	1.70	-0.70
OSTEOGENIC SARCOMA	5	3.55	2.09	1.70	-0.70
Calcitriol	5	3.66	2.16	1.69	-0.71
Thallium	5	3.73	2.21	1.69	-0.71

FIG. 27-27A

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
BETA-2 INTEGRIN	5	4.91	2.90	1.69	-0.71
Chronic Bronchitis	5	4.58	2.71	1.69	-0.71
Ribonucleoside	5	3.49	2.07	1.68	-0.72
Evans Blue	5	4.40	2.62	1.68	-0.72
Ewing's Sarcoma	5	3.48	2.08	1.68	-0.72
Cysteamine	5	4.03	2.42	1.67	-0.73
Milk Proteins	5	4.15	2.49	1.67	-0.73
Synovitis	5	4.38	2.63	1.67	-0.73
Phosphoserine	5	4.01	2.41	1.67	-0.73
Sulfoxide	5	4.44	2.67	1.66	-0.74
S-Adenosylmethionine	5	4.19	2.52	1.66	-0.74
TYMS	5	3.75	2.26	1.66	-0.74
PRIMARY BILIARY CIRRHOSIS	5	4.66	2.81	1.66	-0.74
Steel	5	4.22	2.56	1.65	-0.75
Toluidine	5	4.55	2.76	1.65	-0.75
DIA4	5	3.84	2.33	1.65	-0.75
Rotenone	5	4.54	2.76	1.64	-0.76
HLA-A	5	3.98	2.43	1.64	-0.76
Leukotriene C4	5	4.50	2.74	1.64	-0.76
PROTEASE INHIBITOR 1	5	4.72	2.89	1.63	-0.77
Sulfatase	5	3.31	2.04	1.62	-0.78
TM4SF1	5	4.40	2.71	1.62	-0.78

FIG. 27-27B

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
hemangioma	5	3.55	2.19	1.62	-0.78
SHBG	5	3.79	2.34	1.62	-0.78
Chloride Channels	5	4.23	2.62	1.62	-0.78
Silicon	5	4.36	2.70	1.62	-0.78
Lymphocytosis	5	4.09	2.53	1.61	-0.79
Cyclooxygenase Inhibitors	5	4.83	2.99	1.61	-0.79
Convalescence	5	4.08	2.53	1.61	-0.79
Ethylenediamine	5	4.23	2.62	1.61	-0.79
Propylthiouracil	5	3.81	2.37	1.61	-0.79
CD9	5	4.82	3.01	1.60	-0.80
ion transport	5	4.20	2.63	1.60	-0.80
ZYX	5	4.20	2.63	1.60	-0.80
HEMOLYTIC-UREMIC SYNDROME	5	3.56	2.23	1.60	-0.80
Protamine	5	4.96	3.12	1.59	-0.81
Demethylation	5	4.81	3.02	1.59	-0.81
Glycolipid	5	4.78	3.00	1.59	-0.81
Calcimycin	5	4.64	2.92	1.59	-0.81
Periodontitis	5	4.23	2.66	1.59	-0.81
NADPH Oxidase	5	4.15	2.62	1.59	-0.81
Retinal Degeneration	5	3.80	2.40	1.59	-0.81
Tuberculin	5	4.08	2.58	1.58	-0.82
DILATED CARDIOMYOPATHY 1A	5	4.72	3.00	1.57	-0.83

FIG. 27-27C

FIG. 27-28A
FIG. 27-28B
FIG. 27-28C

FIG. 27-28

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Glucose-6-Phosphate	5	3.99	2.54	1.57	-0.83
Cytomegalovirus Infection	5	4.02	2.58	1.56	-0.84
Ketone Bodies	5	3.71	2.38	1.56	-0.84
Prostaglandin D2	5	3.91	2.52	1.55	-0.85
Periodic Acid	5	3.50	2.25	1.55	-0.85
Reperfusion Injury	5	4.32	2.79	1.55	-0.85
NBP	5	3.59	2.32	1.55	-0.85
Membrane Lipids	5	4.65	3.04	1.53	-0.87

FIG. 27-28A

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Endothelin	5	4.99	3.28	1.52	-0.88
NCAM1	5	4.16	2.73	1.52	-0.88
Pyridoxine	5	4.03	2.65	1.52	-0.88
Ketoconazole	5	4.79	3.16	1.51	-0.89
Portal Hypertension	5	4.13	2.73	1.51	-0.89
Perchloric Acid	5	3.81	2.53	1.51	-0.89
DHFR	5	4.34	2.88	1.51	-0.89
Alginate	5	4.01	2.66	1.51	-0.89
Opioid Peptides	5	3.99	2.65	1.51	-0.89
Succinate Dehydrogenase	5	4.39	2.92	1.50	-0.90
Hemangioma	5	3.65	2.43	1.50	-0.90
NEUROPATHY	5	4.48	2.98	1.50	-0.90
PLA2G1B	5	4.46	2.97	1.50	-0.90
CHOLESTASIS	5	4.41	2.94	1.50	-0.90
Cytochalasin B	5	4.92	3.29	1.50	-0.90
MMP1	5	3.57	2.39	1.50	-0.90
HLA Antigens	5	3.74	2.50	1.50	-0.90
Fumarate	5	3.98	2.66	1.50	-0.90
Hemostatic	5	4.57	3.06	1.49	-0.91
Thromboxane B2	5	4.96	3.34	1.49	-0.91
Melanin	5	4.81	3.24	1.48	-0.92
Gelatinase	5	3.40	2.30	1.48	-0.92

FIG. 27-28B



Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Carbonic Anhydrases	5	4.33	2.94	1.47	-0.93
Methylcellulose	5	4.09	2.79	1.46	-0.94
Cerebellar Ataxia	5	3.91	2.67	1.46	-0.94
Capsid	5	4.22	2.89	1.46	-0.94
Papain	5	4.79	3.28	1.46	-0.94
Inosine	5	4.23	2.90	1.46	-0.94
C7	5	4.05	2.79	1.45	-0.95
Nuclear RNA	5	3.53	2.44	1.45	-0.95
Ribose	5	4.30	2.97	1.45	-0.95
HP	5	4.15	2.87	1.45	-0.95
Tyramine	5	3.81	2.64	1.45	-0.95
Estrilol	5	3.16	2.19	1.44	-0.96
Antinuclear Antibodies	5	4.32	2.99	1.44	-0.96
Rhodamine	5	3.97	2.75	1.44	-0.96
Pronase	5	4.96	3.45	1.44	-0.96
Iodoacetamide	5	4.13	2.87	1.44	-0.96
Fura-2	5	4.55	3.17	1.43	-0.97
Hapten	5	4.23	2.95	1.43	-0.97
Contact Dermatitis	5	3.78	2.65	1.42	-0.98
Hemocyanin	5	3.98	2.80	1.42	-0.98
Thermolysin	5	3.14	2.22	1.42	-0.98
Glycoside	5	3.73	2.63	1.42	-0.98

FIG. 27-28C

FIG. 27-29A
FIG. 27-29B
FIG. 27-29C

FIG. 27-29

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
MYASTHENIA GRAVIS	5	3.98	2.82	1.41	-0.99
Pulmonary Embolism	5	3.99	2.83	1.41	-0.99
Dietary Proteins	5	3.81	2.72	1.40	-1.00
Acridine Orange	5	4.10	2.92	1.40	-1.00
Oligomycin	5	3.31	2.36	1.40	-1.00
Viral Proteins	5	3.92	2.80	1.40	-1.00
Thromboxane	5	4.99	3.57	1.40	-1.00
Endotoxemia	5	3.73	2.68	1.39	-1.01

FIG. 27-29A

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Pruritus	5	4.47	3.21	1.39	-1.01
Contracture	5	4.40	3.16	1.39	-1.01
Rhinitis	5	4.15	2.99	1.39	-1.01
Double-Stranded RNA	5	3.14	2.26	1.39	-1.01
Hemolytic Anemia	5	4.14	2.99	1.39	-1.01
Foreign Bodies	5	4.57	3.29	1.39	-1.01
Macrolide	5	3.80	2.74	1.39	-1.01
Oligopeptide	5	4.40	3.18	1.38	-1.02
Captopril	5	4.55	3.29	1.38	-1.02
Peptidoglycan	5	3.32	2.40	1.38	-1.02
SELP	5	3.58	2.59	1.38	-1.02
Chromium	5	4.50	3.26	1.38	-1.02
Methylene Blue	5	4.90	3.56	1.37	-1.03
Flavoprotein	5	3.49	2.54	1.37	-1.03
Carboxypeptidase	5	3.96	2.89	1.37	-1.03
Sodium Bicarbonate	5	3.91	2.87	1.36	-1.04
Burns	5	4.94	3.63	1.36	-1.04
SCT	5	3.63	2.68	1.36	-1.04
Carbon Tetrachloride	5	4.07	3.00	1.36	-1.04
CEREBROVASCULAR ACCIDENT	5	4.23	3.13	1.35	-1.05
Viral DNA	5	4.09	3.03	1.35	-1.05
Bradycardia	5	4.92	3.67	1.34	-1.06

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Endopeptidase	5	4.13	3.10	1.33	-1.07
Hexose	5	4.51	3.38	1.33	-1.07
Septic Shock	5	4.51	3.38	1.33	-1.07
CTSB	5	3.41	2.57	1.33	-1.07
Polystyrene	5	4.49	3.39	1.33	-1.07
Muscular Dystrophies	5	4.48	3.41	1.32	-1.08
Globin	5	3.78	2.87	1.31	-1.09
Aluminum	5	4.72	3.59	1.31	-1.09
Monensin	5	4.50	3.45	1.31	-1.09
Hepatomegaly	5	4.47	3.47	1.29	-1.11
Melphalan	5	3.41	2.64	1.29	-1.11
Sorbitol	5	3.97	3.09	1.28	-1.12
Pyelonephritis	5	3.56	2.77	1.28	-1.12
Alopecia	5	4.15	3.24	1.28	-1.12
Anoxia	5	4.23	3.30	1.28	-1.12
Bacteremia	5	3.98	3.12	1.28	-1.12
Cardiotoxicity	5	3.47	2.72	1.28	-1.12
Chlorine	5	3.81	3.01	1.27	-1.13
Digitonin	5	3.73	2.95	1.27	-1.13
Brain Infarction	5	4.40	3.48	1.27	-1.13
Salicylate	5	4.57	3.64	1.26	-1.14
Methyldrednisolone	5	4.83	3.85	1.26	-1.14

FIG. 27-29C

FIG. 27-30A
FIG. 27-30B
FIG. 27-30C

FIG. 27-30

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
POMC	5	3.48	2.77	1.25	-1.15
Carbon Monoxide	5	4.56	3.67	1.24	-1.16
Lithium Chloride	5	3.74	3.03	1.23	-1.17
ATPase	5	3.57	2.91	1.23	-1.17
calcium channel	5	4.65	3.82	1.22	-1.18
INSULIN-DEPENDENT DIABETES MELLITUS	5	4.54	3.73	1.22	-1.18
Tachycardia	5	4.85	4.04	1.20	-1.20
Chymotrypsin	5	4.79	4.00	1.20	-1.20

FIG. 27-30A

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Liver Failure	5	3.73	3.12	1.20	-1.20
Lipase	5	4.57	3.84	1.19	-1.21
Pyrimidine	5	4.55	3.82	1.19	-1.21
Leukopenia	5	4.09	3.44	1.19	-1.21
Cyanogen Bromide	5	4.36	3.68	1.19	-1.21
Uric Acid	5	4.47	3.80	1.18	-1.22
5,10-METHYLENETETRAHYDROFOLATE REDUCTASE	5	3.91	3.34	1.17	-1.23
Cyclic Nucleotides	5	3.31	2.84	1.17	-1.23
Cyclosporine	5	4.76	4.22	1.13	-1.27
Hydroxylamine	5	3.74	3.35	1.11	-1.29
Anticoagulant	5	4.96	4.52	1.10	-1.30
Nephrotic Syndrome	5	3.74	3.42	1.09	-1.31
Lidocaine	5	4.94	4.54	1.09	-1.31
Fructose	5	4.16	3.83	1.09	-1.31
Choline	5	4.82	4.47	1.08	-1.32
Dementia	5	4.57	4.26	1.07	-1.33
Cytochrome P-450	5	4.65	4.33	1.07	-1.33
Chloroform	5	4.35	4.06	1.07	-1.33
Mannitol	5	4.57	4.26	1.07	-1.33
Dopamine Receptors	5	3.40	3.19	1.07	-1.33
Carbon Dioxide	5	4.62	4.36	1.06	-1.34
Lupus	5	4.37	4.13	1.06	-1.34

FIG. 27-30B

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Ataxia	5	4.75	4.50	1.06	-1.34
Hydroxide	5	3.78	3.60	1.05	-1.35
C-Peptide	5	2.74	2.62	1.05	-1.35
Nitroprusside	5	3.79	3.63	1.04	-1.36
Cyanide	5	3.91	3.76	1.04	-1.36
Mesothelioma	5	2.58	2.49	1.03	-1.37
Paclitaxel	5	2.57	2.49	1.03	-1.37
Trifluoperazine	5	3.15	3.07	1.02	-1.38
Gentamicin	5	3.70	3.62	1.02	-1.38
Calcium Channels	5	3.46	3.48	1.00	-1.40
TRH	5	3.58	3.59	0.99	-1.41
Phenobarbital	5	4.40	4.54	0.97	-1.43
Malaria	5	3.72	3.85	0.97	-1.43
Naloxone	5	3.47	3.60	0.96	-1.44
Convulsions	5	4.33	4.54	0.95	-1.45
Radioisotope	5	3.33	3.62	0.92	-1.48
Ouabain	5	3.52	3.84	0.92	-1.48
AVP	5	3.55	3.88	0.91	-1.49
Mental Retardation	5	4.32	4.73	0.91	-1.49
Cimetidine	5	3.58	3.93	0.91	-1.49
TACHYKININ 1	5	3.82	4.22	0.91	-1.49
Confusion	5	4.15	4.65	0.89	-1.51

FIG. 27-30C

FIG. 27-31A
FIG. 27-31B
FIG. 27-31C

FIG. 27-31

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
PRTS	5	4.16	4.80	0.87	-1.53
Fluoride	5	3.55	4.32	0.82	-1.58
Prednisone	5	3.40	4.37	0.78	-1.62
Lithium	5	3.23	4.40	0.73	-1.67
Telomerase	5	1.58	2.15	0.73	-1.67
Etoposide	5	2.57	3.61	0.71	-1.69
MMP2	5	1.83	2.68	0.68	-1.72
PLAU	5	1.99	3.40	0.58	-1.82

FIG. 27-31A



Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Fractures	5	2.76	4.94	0.56	-1.84
ETV1	4	3.87	1.13	3.41	0.61
TIMP4	4	3.97	1.18	3.38	0.58
SDF1	4	3.96	1.19	3.32	0.52
CELLULAR SENESENCE-RELATED 1	4	3.72	1.16	3.21	0.41
MAD2L1	4	3.77	1.21	3.13	0.33
LAMR1	4	3.99	1.28	3.12	0.32
TELOMERE REVERSE TRANSCRIPTASE	4	3.88	1.25	3.11	0.31
S100A4	4	3.83	1.23	3.11	0.31
IGF1R	4	3.92	1.26	3.10	0.30
THBS2	4	3.62	1.17	3.09	0.29
BACULOVIRAL IAP REPEAT-CONTAINING PROTEIN 5	4	3.98	1.30	3.07	0.27
FIGF	4	3.55	1.16	3.07	0.27
XLKD1	4	3.33	1.09	3.06	0.26
FBLN1	4	3.51	1.16	3.02	0.22
PEA15	4	3.47	1.16	3.00	0.20
FOXO1A	4	3.74	1.26	2.98	0.18
MAP2K4	4	3.47	1.17	2.96	0.16
BMP6	4	3.80	1.28	2.96	0.16
EDG2	4	3.57	1.21	2.94	0.14
Angiogenesis Factor	4	3.94	1.34	2.94	0.14
MMP14	4	3.75	1.28	2.94	0.14

FIG. 27-31B

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
MDK	4	3.99	1.36	2.93	0.13
TERT	4	3.82	1.31	2.92	0.12
SCYA21	4	3.49	1.20	2.91	0.11
CTNNG	4	3.83	1.32	2.89	0.09
RAP1A	4	3.85	1.33	2.89	0.09
Phyllodes Tumor	4	3.40	1.18	2.89	0.09
BRCD2	4	3.41	1.18	2.88	0.08
PROTEASE INHIBITOR 5	4	3.58	1.24	2.88	0.08
DAD1	4	3.45	1.20	2.88	0.08
CTGF	4	3.97	1.41	2.82	0.02
GRO1	4	3.79	1.35	2.80	0.00
Adenosarcoma	4	3.41	1.21	2.80	0.00
Mucinous Cystadenoma	4	3.91	1.40	2.80	0.00
AREG	4	3.99	1.43	2.79	-0.01
BREAST CANCER ANTIESTROGEN RESISTANCE 1	4	3.76	1.35	2.79	-0.01
DECAPENTAPLEGIC 2	4	3.96	1.42	2.78	-0.02
TEP1	4	3.55	1.28	2.77	-0.03
PLACENTAL GROWTH FACTOR	4	3.38	1.22	2.76	-0.04
KRT20	4	3.65	1.33	2.75	-0.05
THBS1	4	3.65	1.33	2.75	-0.05
RET PROTOONCOGENE	4	3.39	1.23	2.74	-0.06
DECAPENTAPLEGIC 3	4	3.79	1.39	2.73	-0.07

FIG. 27-31C

FIG. 27-32A
FIG. 27-32B
FIG. 27-32C

FIG. 27-32

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
SOLUBLE BETA-GALACTOSIDE BINDING LECTIN 1	4	3.79	1.39	2.73	-0.07
MKI67	4	3.58	1.31	2.73	-0.07
APR-2	4	3.90	1.44	2.71	-0.09
TP73	4	4.00	1.48	2.71	-0.09
Estrogen Antagonists	4	3.37	1.25	2.70	-0.10
wnt-1	4	3.75	1.39	2.70	-0.10
AXL	4	3.45	1.28	2.69	-0.11
FGF8	4	3.82	1.43	2.68	-0.12

FIG. 27-32A

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
MMP8	4	3.72	1.39	2.68	-0.12
FKSG2	4	3.57	1.33	2.68	-0.12
Neurocytoma	4	3.30	1.23	2.67	-0.13
MSN	4	3.79	1.42	2.67	-0.13
FAMILIAL CANCER	4	3.76	1.41	2.67	-0.13
JUP	4	3.98	1.49	2.66	-0.14
ITGB4	4	3.50	1.32	2.66	-0.14
MYCL1	4	3.16	1.19	2.65	-0.15
FHIT	4	3.58	1.35	2.65	-0.15
FGF4	4	3.99	1.51	2.65	-0.15
IGSF2	4	3.50	1.32	2.65	-0.15
MULTIPLE LIPOMAS MACROCEPHALY	4	3.08	1.16	2.64	-0.16
PAWR	4	3.52	1.33	2.64	-0.16
INHIBITOR OF DNA BINDING 1	4	3.37	1.28	2.64	-0.16
COWDEN DISEASE	4	3.40	1.29	2.63	-0.17
HIC1	4	2.98	1.14	2.62	-0.18
SSTR2	4	3.50	1.34	2.62	-0.18
PECAM1	4	3.57	1.36	2.62	-0.18
WNT3	4	2.97	1.14	2.61	-0.19
NRG1	4	3.38	1.30	2.61	-0.19
EFS2	4	3.45	1.33	2.61	-0.19
BRCA1 Protein	4	3.16	1.21	2.60	-0.20

FIG. 27-32B

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
S100A6	4	3.66	1.40	2.60	-0.20
Lignan	4	3.77	1.45	2.60	-0.20
Papillomavirus Infection	4	3.91	1.51	2.60	-0.20
TYPE 2 PLASMINOGEN ACTIVATOR INHIBITOR	4	3.23	1.25	2.59	-0.21
CEACAM1	4	3.77	1.45	2.59	-0.21
Serous Cystadenoma	4	3.22	1.24	2.59	-0.21
HOXA1	4	2.98	1.15	2.59	-0.21
RAF1	4	3.78	1.47	2.58	-0.22
Fucosyltransferase	4	3.80	1.47	2.58	-0.22
Neurofibrosarcoma	4	3.40	1.32	2.58	-0.22
SLC6A10	4	3.35	1.30	2.57	-0.23
Calcitonin Receptors	4	3.40	1.32	2.57	-0.23
WNT5A	4	2.98	1.17	2.54	-0.26
TBX2	4	2.96	1.17	2.53	-0.27
SCYC1	4	3.37	1.34	2.53	-0.27
MET	4	2.97	1.18	2.52	-0.28
KRT5	4	3.34	1.32	2.52	-0.28
WNT10B	4	2.81	1.12	2.51	-0.29
CCR7	4	3.16	1.26	2.51	-0.29
Colonic Polyps	4	3.94	1.57	2.51	-0.29
Estramustine	4	3.75	1.50	2.49	-0.31
Hypothalamic Hormones	4	3.40	1.37	2.49	-0.31

FIG. 27-32C

FIG. 27-33A
FIG. 27-33B
FIG. 27-33C

FIG. 27-33

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
CCNG1	4	3.07	1.24	2.48	-0.32
Anthrax	4	3.87	1.56	2.48	-0.32
Disintegrin	4	3.79	1.53	2.48	-0.32
REGULATOR OF CHROMATIN MATRIX-ASSOCIATED	4	3.80	1.53	2.48	-0.32
BWS	4	3.74	1.52	2.47	-0.33
MLANA	4	3.24	1.31	2.47	-0.33
TITF1	4	3.41	1.39	2.46	-0.34
Keratoacanthoma	4	3.81	1.55	2.46	-0.34

FIG. 27-33A

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
WILMS TUMOR AND PSEUDOHERMAPHRODITISM	4	3.05	1.24	2.45	-0.35
MYCN	4	3.58	1.46	2.45	-0.35
ADENOMYOSIS	4	3.62	1.48	2.45	-0.35
ST7	4	3.40	1.39	2.44	-0.36
MYOD1	4	3.46	1.42	2.43	-0.37
Ganglioneuroblastoma	4	3.62	1.49	2.43	-0.37
Bioflavonoid	4	3.51	1.45	2.43	-0.37
RRM1	4	2.82	1.16	2.43	-0.37
GATA3	4	2.81	1.16	2.42	-0.38
Hemangiosarcoma	4	3.40	1.41	2.41	-0.39
STATHMIN 1	4	3.24	1.34	2.41	-0.39
MMP7	4	3.40	1.41	2.41	-0.39
CATALYTIC SUBUNIT DNA-ACTIVATED PROTEIN KINASE	4	3.75	1.56	2.40	-0.40
Azoxymethane	4	3.94	1.64	2.40	-0.40
Mucinous Cystadenocarcinoma	4	3.33	1.40	2.39	-0.41
CCND3	4	3.57	1.50	2.38	-0.42
COL1A1	4	3.37	1.41	2.38	-0.42
X-LINKED IMMUNODEFICIENCY	4	3.74	1.57	2.38	-0.42
ONCOCYTOMA	4	3.48	1.46	2.38	-0.42
FGFR4	4	2.71	1.14	2.38	-0.42
MC1R	4	2.98	1.25	2.38	-0.42
Bispecific Antibodies	4	3.37	1.42	2.37	-0.43

FIG. 27-33B

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
MGMT	4	3.52	1.48	2.37	-0.43
KLK11	4	3.21	1.35	2.37	-0.43
Stromelysin 1	4	3.93	1.66	2.37	-0.43
THRB	4	2.99	1.26	2.37	-0.43
CNR2	4	3.59	1.51	2.37	-0.43
Neurofibromatosis 2	4	2.99	1.26	2.36	-0.44
Methylazoxymethanol Acetate	4	3.13	1.33	2.36	-0.44
FACTOR	4	3.00	1.27	2.36	-0.44
RARA	4	3.56	1.51	2.35	-0.45
Angiofibroma	4	3.51	1.49	2.35	-0.45
FGF5	4	2.98	1.27	2.35	-0.45
ILK	4	3.38	1.44	2.35	-0.45
PRB2	4	2.74	1.16	2.35	-0.45
ADP-Ribosylation Factors	4	3.48	1.49	2.34	-0.46
CALCR	4	3.41	1.46	2.34	-0.46
HDAC1	4	3.71	1.59	2.34	-0.46
MCCUNE-ALBRIGHT SYNDROME	4	3.37	1.45	2.33	-0.47
THROMBOSPONDIN II	4	2.74	1.17	2.33	-0.47
FST	4	3.80	1.63	2.33	-0.47
ANGPT2	4	2.92	1.25	2.33	-0.47
Catechol Estrogens	4	3.55	1.53	2.32	-0.48
ADULT FOLATE RECEPTOR 1	4	3.23	1.39	2.32	-0.48



FIG. 27-34A
FIG. 27-34B
FIG. 27-34C

FIG. 27-34

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
ANGPT1	4	2.99	1.30	2.30	-0.50
ETS1	4	3.09	1.35	2.29	-0.51
Calmodulin-Binding Proteins	4	3.21	1.40	2.29	-0.51
Neoplastic Processes	4	3.68	1.61	2.29	-0.51
Theobromine	4	3.79	1.66	2.29	-0.51
F11	4	3.59	1.57	2.28	-0.52
Myeloid Metaplasia	4	3.58	1.57	2.28	-0.52
Gliosarcoma	4	3.65	1.60	2.28	-0.52
MULTIPLE LIPOMATOSIS	4	3.06	1.35	2.28	-0.52

FIG. 27-34A

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
MELANOMA NCK PROTEIN	4	3.09	1.37	2.26	-0.54
RDX	4	3.16	1.40	2.25	-0.55
KLK1	4	2.56	1.14	2.25	-0.55
MAPK9	4	3.47	1.54	2.25	-0.55
ALPHA-1 TYPE XVIII COLLAGEN	4	2.97	1.32	2.25	-0.55
Anovulation	4	3.55	1.58	2.24	-0.56
Interleukin-13	4	3.50	1.56	2.24	-0.56
NOP56	4	3.54	1.59	2.24	-0.56
OCLN	4	3.23	1.45	2.23	-0.57
CASR	4	3.20	1.44	2.23	-0.57
Activin Receptors	4	3.12	1.41	2.22	-0.58
ADM	4	3.83	1.73	2.22	-0.58
Symporter	4	3.68	1.66	2.21	-0.59
YY1	4	3.56	1.61	2.21	-0.59
CYSTEINE- AND GLYCINE-RICH PROTEIN 1	4	3.47	1.57	2.21	-0.59
POU1F1	4	3.01	1.36	2.21	-0.59
THYROID-STIMULATING HORMONE RECEPTOR	4	3.57	1.62	2.21	-0.59
SCP2	4	2.95	1.34	2.20	-0.60
Myoma	4	3.80	1.73	2.20	-0.60
70-KD THYROID AUTOANTIGEN	4	2.96	1.35	2.20	-0.60
SUPERFAMILY	4	3.16	1.44	2.20	-0.60

FIG. 27-34B

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
INHBA	4	3.90	1.77	2.20	-0.60
TALIN	4	3.71	1.69	2.20	-0.60
Cushing Syndrome	4	3.23	1.48	2.19	-0.61
Bradykinin Receptors	4	3.72	1.70	2.19	-0.61
Interleukin-15	4	2.96	1.36	2.17	-0.63
Synthetic Estrogens	4	2.98	1.38	2.17	-0.63
Buserelin	4	3.40	1.57	2.17	-0.63
S-ADENOSYLMETHIONINE DECARBOXYLASE	4	3.37	1.56	2.17	-0.63
SLC4A3	4	3.65	1.69	2.16	-0.64
COL1A1	4	3.37	1.56	2.16	-0.64
BETA-2 GAP JUNCTION PROTEIN	4	3.20	1.48	2.16	-0.64
Leukoplakia	4	3.56	1.65	2.16	-0.64
INDUCIBLE GENE GADD45	4	3.37	1.57	2.15	-0.65
Catechin	4	3.78	1.76	2.15	-0.65
Acoustic Neuroma	4	3.37	1.57	2.15	-0.65
Corneal Neovascularization	4	3.15	1.47	2.15	-0.65
STAT6	4	3.16	1.47	2.14	-0.66
FOLLICULAR THYROID CARCINOMA	4	2.94	1.37	2.14	-0.66
IL6R	4	3.32	1.56	2.14	-0.66
1-Methyl-3-isobutylxanthine	4	3.41	1.59	2.14	-0.66
Peplomycin	4	3.16	1.48	2.14	-0.66
Somatomedin	4	3.65	1.71	2.14	-0.66

FIG. 27-35A
FIG. 27-35B
FIG. 27-35C

FIG. 27-35

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Angiogenesis Inhibitors	4	2.99	1.40	2.13	-0.67
P29	4	3.24	1.52	2.13	-0.67
KAPOSI SARCOMA	4	3.57	1.67	2.13	-0.67
BETA PROTEIN-TYROSINE KINASE 2	4	3.20	1.50	2.13	-0.67
Taq Polymerase	4	3.21	1.51	2.13	-0.67
NCOA1	4	2.98	1.40	2.13	-0.67
Dieldrin	4	3.79	1.78	2.12	-0.68
Factor VIIa	4	3.81	1.79	2.12	-0.68

FIG. 27-35A

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
ANXA2	4	3.37	1.59	2.12	-0.68
AMYLOID BETA A4 PRECURSOR PROTEIN	4	3.05	1.44	2.12	-0.68
TAP1	4	3.05	1.44	2.12	-0.68
TPO	4	3.82	1.80	2.12	-0.68
TEK	4	3.00	1.42	2.12	-0.68
Ganglioglioma	4	2.99	1.41	2.12	-0.68
ZAP70	4	3.31	1.57	2.11	-0.69
Sodium Iodide	4	3.47	1.65	2.11	-0.69
Heparinoid	4	2.81	1.33	2.11	-0.69
COLONY-STIMULATING FACTOR 1 RECEPTOR	4	2.71	1.29	2.10	-0.70
Histone acetylation	4	3.58	1.70	2.10	-0.70
SMALL CELL CANCER OF THE LUNG	4	2.74	1.31	2.10	-0.70
TP63	4	2.91	1.39	2.10	-0.70
Etretinate	4	3.67	1.76	2.09	-0.71
alpha-Linolenic Acid	4	3.51	1.68	2.09	-0.71
Gingival Hyperplasia	4	3.20	1.54	2.09	-0.71
GTPase-Activating Proteins	4	2.95	1.42	2.08	-0.72
SSTR5	4	2.56	1.23	2.08	-0.72
KRT13	4	3.32	1.59	2.08	-0.72
Aldrin	4	3.20	1.54	2.08	-0.72
Subacute Thyroiditis	4	2.95	1.42	2.08	-0.72
Matrilysin	4	2.97	1.43	2.07	-0.73

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Distamycin	4	3.33	1.61	2.07	-0.73
P2Y5	4	3.24	1.56	2.07	-0.73
CDKN1C	4	3.16	1.52	2.07	-0.73
RETICULUM CELL SARCOMA	4	3.23	1.56	2.07	-0.73
Low-Grade Lymphoma	4	2.96	1.43	2.07	-0.73
Osteopetrosis	4	3.97	1.92	2.06	-0.74
APRT	4	3.64	1.77	2.06	-0.74
GYS1	4	2.74	1.33	2.06	-0.74
BRAIN CYTOPLASMIC 1	4	3.23	1.57	2.06	-0.74
Thymosin	4	3.97	1.93	2.05	-0.75
MYOSIN LIGHT CHAIN KINASE	4	3.23	1.58	2.05	-0.75
MT2A	4	3.56	1.74	2.04	-0.76
Neuraminic Acids	4	3.61	1.77	2.04	-0.76
DNA METHYLTRANSFERASE 1	4	3.51	1.73	2.03	-0.77
alpha-L-Fucosidase	4	3.16	1.56	2.03	-0.77
FASN	4	3.65	1.80	2.03	-0.77
DBI	4	3.06	1.51	2.03	-0.77
CTSL	4	3.82	1.89	2.03	-0.77
SRF	4	3.20	1.58	2.02	-0.78
Catechol O-Methyltransferase	4	3.37	1.67	2.02	-0.78
MVP	4	3.52	1.74	2.02	-0.78
Osteoma	4	3.09	1.53	2.02	-0.78

FIG. 27-35C

FIG. 27-36A
FIG. 27-36B
FIG. 27-36C

FIG. 27-36

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
SCG2	4	2.95	1.46	2.02	-0.78
Selenomethionine	4	3.40	1.68	2.02	-0.78
Ovarian Cysts	4	3.51	1.74	2.01	-0.79
APOD	4	2.74	1.36	2.01	-0.79
Croton Oil	4	3.37	1.68	2.01	-0.79
MEMBER 1 SUBFAMILY C ATP-BINDING CASSETTE	4	3.79	1.89	2.00	-0.80
Lymphoblastic Lymphoma	4	3.33	1.66	2.00	-0.80
Pneumoconiosis	4	3.31	1.66	1.99	-0.81
CD47	4	2.81	1.41	1.99	-0.81
JUND	4	3.46	1.74	1.99	-0.81

FIG. 27-36A

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Gastrinoma	4	2.97	1.49	1.99	-0.81
COMT	4	3.87	1.95	1.99	-0.81
GIP	4	3.75	1.89	1.98	-0.82
Cystatin	4	3.23	1.63	1.98	-0.82
ANGIOGENIN	4	3.00	1.51	1.98	-0.82
BETA-1 GAP JUNCTION PROTEIN	4	3.16	1.60	1.98	-0.82
Dimethylhydrazine	4	3.16	1.60	1.98	-0.82
Seborrheic Keratosis	4	2.56	1.30	1.97	-0.83
PROTEIN 1	4	3.23	1.64	1.97	-0.83
Feline Leukemia	4	3.23	1.64	1.97	-0.83
PERNICIOUS ANEMIA	4	3.46	1.76	1.97	-0.83
FACTOR D	4	3.22	1.64	1.97	-0.83
Drosophila Proteins	4	3.33	1.70	1.96	-0.84
DECAPENTAPLEGIC 4	4	2.99	1.53	1.96	-0.84
Immunotoxin	4	3.64	1.87	1.95	-0.85
LH Receptors	4	2.98	1.53	1.95	-0.85
Fenretinide	4	2.47	1.27	1.95	-0.85
ACP2	4	2.96	1.52	1.95	-0.85
CONTACTIN-ASSOCIATED PROTEIN 1	4	2.96	1.52	1.95	-0.85
Prostaglandin-Endoperoxide Synthase	4	2.67	1.37	1.94	-0.86
Simvastatin	4	3.81	1.96	1.94	-0.86

FIG. 27-36B



Object name	#	Quality	Expect	Obs/Exp.	2 sigma
ALY	4	3.10	1.60	1.94	-0.86
CYTOTOXIC T LYMPHOCYTE-ASSOCIATED 4	4	3.20	1.65	1.94	-0.86
ATF2	4	3.37	1.74	1.94	-0.86
Microtubule-Associated Proteins	4	3.43	1.77	1.94	-0.86
IAPP	4	3.55	1.84	1.94	-0.86
STN	4	3.36	1.74	1.93	-0.87
Secondary Hyperparathyroidism	4	3.90	2.02	1.93	-0.87
HRPT2	4	3.32	1.72	1.93	-0.87
Placental Extracts	4	2.92	1.52	1.92	-0.88
Pelvic Pain	4	3.47	1.81	1.92	-0.88
Selectin	4	3.51	1.84	1.91	-0.89
IMMEDIATE-EARLY RESPONSE 3	4	2.56	1.34	1.91	-0.89
Arsenical	4	2.98	1.56	1.91	-0.89
GPD1	4	2.81	1.48	1.90	-0.90
P125	4	2.57	1.35	1.90	-0.90
Selenious Acid	4	3.92	2.06	1.90	-0.90
Lymphotoxin	4	3.78	1.99	1.90	-0.90
Interferon Receptors	4	2.32	1.22	1.90	-0.90
CREBBP	4	2.57	1.35	1.90	-0.90
Procarbazine	4	3.55	1.87	1.90	-0.90
KELOIDS	4	2.99	1.57	1.90	-0.90

FIG. 27-37A
FIG. 27-37B
FIG. 27-37C

FIG. 27-37

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Ureteral Obstruction	4	3.79	2.00	1.90	-0.90
GHR	4	3.15	1.67	1.89	-0.91
CASP3	4	3.37	1.78	1.89	-0.91
Proteome	4	3.10	1.64	1.89	-0.91
Acetyl-CoA Carboxylase	4	3.37	1.79	1.89	-0.91
Nasal Polyps	4	3.55	1.88	1.89	-0.91
MethylNitrosourea	4	3.93	2.08	1.88	-0.92
GDNF	4	3.23	1.72	1.88	-0.92

FIG. 27-37A

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Molecular Chaperones	4	3.52	1.87	1.88	-0.92
INSM1	4	2.74	1.46	1.88	-0.92
Factor XIIIa	4	3.41	1.81	1.88	-0.92
Stilbene	4	3.79	2.02	1.88	-0.92
CTF1	4	2.74	1.46	1.88	-0.92
Properdin	4	3.15	1.68	1.88	-0.92
FCGR1A	4	2.98	1.59	1.88	-0.92
Gigantism	4	2.81	1.50	1.87	-0.93
Deoxycholic Acid	4	3.65	1.95	1.87	-0.93
ALPHA II DNA TOPOISOMERASE	4	3.47	1.86	1.87	-0.93
1-Butanol	4	3.21	1.72	1.87	-0.93
GSN	4	3.51	1.88	1.87	-0.93
CSN1	4	2.95	1.59	1.86	-0.94
Methylcholanthrene	4	3.33	1.79	1.86	-0.94
GLS	4	3.72	2.00	1.86	-0.94
UGB	4	2.98	1.60	1.86	-0.94
TYPE II MATURITY-ONSET DIABETES OF THE YOUNG	4	3.38	1.82	1.85	-0.95
Troponin	4	3.41	1.84	1.85	-0.95
Osteomalacia	4	3.77	2.04	1.85	-0.95
CD80	4	3.75	2.03	1.85	-0.95
Mevalonic Acid	4	2.96	1.60	1.85	-0.95
Intestinal Disease	4	3.30	1.79	1.84	-0.96

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Papillary Adenocarcinoma	4	2.96	1.61	1.84	-0.96
DCN	4	3.50	1.90	1.84	-0.96
Mannosidase	4	3.05	1.66	1.84	-0.96
S8	4	2.99	1.63	1.84	-0.96
Pyruvic Acid	4	3.38	1.85	1.83	-0.97
Troponin I	4	3.21	1.76	1.83	-0.97
MYXEDEMA	4	2.99	1.64	1.82	-0.98
Superantigen	4	3.63	1.99	1.82	-0.98
CA2	4	3.31	1.82	1.82	-0.98
Autoimmune Thyroiditis	4	3.49	1.92	1.82	-0.98
Benzophenone	4	2.96	1.63	1.82	-0.98
Streptozocin	4	3.23	1.78	1.82	-0.98
Linolenic Acids	4	3.76	2.07	1.81	-0.99
NCL	4	3.05	1.69	1.81	-0.99
Dysmenorrhea	4	2.91	1.61	1.81	-0.99
FIH	4	3.90	2.16	1.81	-0.99
Pyrimidine Nucleotides	4	3.23	1.79	1.80	-1.00
Peptide Receptors	4	3.23	1.80	1.80	-1.00
Oxonic Acid	4	3.57	1.98	1.80	-1.00
TRAF3	4	2.56	1.43	1.79	-1.01
Hypomethylation	4	3.58	2.00	1.79	-1.01
RE2	4	3.13	1.75	1.79	-1.01

FIG. 27-37C

FIG. 27-38A
FIG. 27-38B
FIG. 27-38C

FIG. 27-38

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
TOBACCO ADDICTION	4	3.64	2.03	1.79	-1.01
PPY	4	3.96	2.21	1.79	-1.01
THBD	4	3.99	2.23	1.79	-1.01
Endothelin-3	4	2.92	1.64	1.78	-1.02
Dietary Calcium	4	3.32	1.87	1.77	-1.03
chromosomal translocation	4	3.99	2.25	1.77	-1.03
Asialoglycoprotein	4	3.50	1.97	1.77	-1.03
GRO2	4	3.13	1.77	1.77	-1.03

FIG. 27-38A

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Actomyosin	4	3.57	2.02	1.77	-1.03
Pravastatin	4	3.21	1.82	1.77	-1.03
Ramipril	4	2.81	1.59	1.77	-1.03
Bullous Pemphigoid	4	3.49	1.98	1.76	-1.04
Hypophosphatemia	4	3.50	1.98	1.76	-1.04
CALR	4	3.34	1.89	1.76	-1.04
Famotidine	4	3.93	2.23	1.76	-1.04
Soybean Oil	4	3.40	1.93	1.76	-1.04
MAST CELL DISEASE	4	3.47	1.98	1.76	-1.04
ADRENAL HYPERPLASIA	4	2.56	1.46	1.75	-1.05
SLC2A2	4	2.74	1.57	1.75	-1.05
GRP	4	3.96	2.27	1.74	-1.06
S-Nitroso-N-Acetylpenicillamine	4	3.54	2.03	1.74	-1.06
Danazol	4	3.57	2.05	1.74	-1.06
Topotecan	4	2.81	1.61	1.74	-1.06
MYOGENIC DIFFERENTIATION ANTIGEN 1	4	3.40	1.95	1.74	-1.06
Exophthalmos	4	3.23	1.87	1.72	-1.08
Nitrogen Dioxide	4	3.24	1.88	1.72	-1.08
TARTRATE-RESISTANT TYPE 5 ACID PHOSPHATASE	4	3.33	1.94	1.72	-1.08
Polymethyl Methacrylate	4	3.52	2.05	1.72	-1.08
Histamine Receptors	4	3.23	1.89	1.71	-1.09
MYCOSIS FUNGOIDES	4	3.57	2.08	1.71	-1.09

FIG. 27-38B

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Pancreatic Hormones	4	2.67	1.56	1.71	-1.09
NME2	4	2.16	1.26	1.71	-1.09
Pseudopregnancy	4	2.99	1.75	1.71	-1.09
FIBROSARCOMA ONCOGENE FAMILY	4	3.16	1.85	1.70	-1.10
HEREDITARY SPHEROCYTOSIS	4	2.74	1.61	1.70	-1.10
Xeroderma Pigmentosum	4	3.50	2.06	1.70	-1.10
Ankyrin	4	3.52	2.08	1.69	-1.11
ALPHA-1 MICROGLOBULIN/BIKUNIN PRECURSOR	4	2.81	1.66	1.69	-1.11
Resorcinol	4	2.95	1.75	1.69	-1.11
ALPP	4	3.51	2.07	1.69	-1.11
Polycythemia	4	3.51	2.08	1.68	-1.12
CD38	4	3.33	1.98	1.68	-1.12
B9	4	2.98	1.78	1.68	-1.12
CD7	4	3.06	1.82	1.68	-1.12
Megestrol Acetate	4	2.65	1.58	1.68	-1.12
Berberine	4	3.40	2.03	1.68	-1.12
Brain Disease	4	2.98	1.79	1.67	-1.13
S-Nitrosoglutathione	4	2.81	1.70	1.66	-1.14
Pro-Opiomelanocortin	4	2.98	1.80	1.66	-1.14
IRS2	4	2.40	1.45	1.66	-1.14
DNA Adducts	4	3.79	2.29	1.65	-1.15
Histoplasmosis	4	3.31	2.01	1.65	-1.15

FIG. 27-38C

FIG. 27-39A
FIG. 27-39B
FIG. 27-39C

FIG. 27-39

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
ENPP3	4	3.54	2.15	1.64	-1.16
CYP1B1	4	3.34	2.03	1.64	-1.16
Trypsinogen	4	2.98	1.82	1.64	-1.16
Somatostatin Receptors	4	3.00	1.83	1.64	-1.16
G17	4	3.74	2.29	1.63	-1.17
Silicone Oils	4	2.71	1.66	1.63	-1.17
APC	4	2.58	1.59	1.63	-1.17
CDK5	4	2.32	1.43	1.62	-1.18

FIG. 27-39A



Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Ficoll	4	3.82	2.35	1.62	-1.18
Bezafibrate	4	2.73	1.68	1.62	-1.18
Phorbol 12,13-Dibutyrate	4	3.98	2.46	1.62	-1.18
Ribonucleotide Reductases	4	3.65	2.26	1.62	-1.18
Sucralfate	4	2.99	1.85	1.62	-1.18
Histone H1	4	3.74	2.32	1.61	-1.19
HIV Protease	4	2.71	1.69	1.61	-1.19
Pentagastrin	4	3.57	2.23	1.61	-1.19
Coagulant	4	3.42	2.13	1.61	-1.19
Fibroma	4	3.40	2.12	1.60	-1.20
PROTEUS SYNDROME	4	2.91	1.82	1.60	-1.20
SPN	4	3.06	1.91	1.60	-1.20
Antipain	4	2.92	1.82	1.60	-1.20
Cathepsin	4	3.79	2.37	1.60	-1.20
Nitrosamine	4	3.62	2.27	1.59	-1.21
NHC	4	2.32	1.46	1.59	-1.21
PP	4	2.99	1.88	1.59	-1.21
RETINAL DETACHMENT	4	3.90	2.45	1.59	-1.21
Spectrin	4	3.74	2.36	1.59	-1.21
Plague	4	3.09	1.95	1.58	-1.22
ACUTE MYELOCYTIC LEUKEMIA	4	2.74	1.73	1.58	-1.22
SAA1	4	3.08	1.95	1.58	-1.22

FIG. 27-39B

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
PAPILLARY THYROID CARCINOMA	4	2.58	1.63	1.58	-1.22
Carboxymethylcellulose	4	3.30	2.09	1.58	-1.22
Cardiomegaly	4	3.62	2.29	1.58	-1.22
MALIGNANT MESOTHELIOMA	4	3.00	1.90	1.57	-1.23
Halogen	4	3.44	2.19	1.57	-1.23
HPSE	4	2.16	1.38	1.57	-1.23
Pleurisy	4	3.41	2.18	1.56	-1.24
Clotrimazole	4	3.33	2.13	1.56	-1.24
Gastrointestinal Hemorrhage	4	3.23	2.07	1.56	-1.24
Benzoquinone	4	2.91	1.86	1.56	-1.24
GRAVES DISEASE	4	3.90	2.50	1.56	-1.24
Phosphorylcholine	4	3.37	2.16	1.56	-1.24
AHR	4	2.57	1.65	1.56	-1.24
Viologen	4	2.71	1.74	1.56	-1.24
Tin	4	3.82	2.45	1.56	-1.24
GSTP1	4	2.83	1.82	1.56	-1.24
Triamcinolone Acetonide	4	3.21	2.07	1.56	-1.24
ALPHA-1 TYPE II COLLAGEN	4	3.58	2.31	1.55	-1.25
Anorexia Nervosa	4	3.51	2.27	1.55	-1.25
GAP43	4	3.15	2.04	1.55	-1.25
Impotence	4	3.83	2.48	1.54	-1.26
CRH	4	3.74	2.42	1.54	-1.26

FIG. 27-39C

FIG. 27-40A
FIG. 27-40B
FIG. 27-40C

FIG. 27-40

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
BETA-3 INTEGRIN	4	2.57	1.67	1.54	-1.26
CS	4	3.45	2.23	1.54	-1.26
FUT3	4	3.34	2.16	1.54	-1.26
Surface Immunoglobulins	4	3.50	2.27	1.54	-1.26
TAT	4	3.13	2.03	1.54	-1.26
Liver Glycogen	4	3.15	2.05	1.54	-1.26
Infectious Mononucleosis	4	3.32	2.17	1.53	-1.27
Paraprotein	4	3.01	1.97	1.53	-1.27

FIG. 27-40A

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
VEGFC	4	1.97	1.29	1.52	-1.28
Phosphofructokinase-1	4	2.81	1.85	1.52	-1.28
Cytotoxin	4	3.75	2.48	1.51	-1.29
EPHX1	4	3.40	2.24	1.51	-1.29
PSEUDONEONATAL ADRENOLEUKODYSTROPHY	4	2.67	1.76	1.51	-1.29
FCGR3A	4	3.64	2.41	1.51	-1.29
Arachidonic Acids	4	2.57	1.70	1.51	-1.29
Potassium Permanganate	4	2.71	1.80	1.51	-1.29
Interleukin-5	4	2.91	1.93	1.51	-1.29
Succinic Acid	4	3.13	2.08	1.50	-1.30
CD33	4	3.23	2.15	1.50	-1.30
Thiamine Deficiency	4	2.67	1.78	1.50	-1.30
FAMILIAL HYPERCHOLESTEROLEMIA	4	2.91	1.94	1.50	-1.30
Neuroendocrine Carcinoma	4	2.37	1.58	1.50	-1.30
PFDN5	4	3.09	2.06	1.50	-1.30
Sulfone	4	3.56	2.39	1.49	-1.31
Disease Susceptibility	4	3.23	2.16	1.49	-1.31
Glucose Intolerance	4	3.75	2.52	1.49	-1.31
IMMUNE SUPPRESSION	4	3.58	2.41	1.49	-1.31
Sclerosing Cholangitis	4	2.98	2.01	1.49	-1.31
ATAXIA-TELANGIECTASIA	4	2.57	1.73	1.48	-1.32
Glucan	4	3.33	2.25	1.48	-1.32

FIG. 27-40B

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Dimyristoylphosphatidylcholine	4	3.15	2.13	1.48	-1.32
Dermatomyositis	4	3.51	2.37	1.48	-1.32
Thioacetamide	4	2.81	1.90	1.48	-1.32
p100	4	2.99	2.02	1.48	-1.32
PCOS1	4	2.50	1.69	1.48	-1.32
Glutathione Transferase	4	3.08	2.09	1.48	-1.32
Pyrene	4	3.39	2.30	1.47	-1.33
Stearate	4	3.45	2.34	1.47	-1.33
RNU1G4	4	3.24	2.20	1.47	-1.33
Sodium Selenite	4	3.05	2.09	1.46	-1.34
DIANPH	4	3.75	2.57	1.46	-1.34
Snake Venoms	4	3.82	2.62	1.45	-1.35
Ethinyl Estradiol	4	3.23	2.23	1.45	-1.35
Thrombocytosis	4	3.39	2.34	1.45	-1.35
Neurofilament Proteins	4	3.26	2.26	1.44	-1.36
Benzoic Acid	4	3.89	2.70	1.44	-1.36
EPHRIN RECEPTOR EphA3	4	3.79	2.64	1.44	-1.36
DPP4	4	2.81	1.96	1.44	-1.36
Methimazole	4	3.48	2.42	1.44	-1.36
Antiporter	4	3.23	2.25	1.43	-1.37
SECTM1	4	3.97	2.77	1.43	-1.37
Hypokalemia	4	3.78	2.64	1.43	-1.37

FIG. 27-41A
FIG. 27-41B
FIG. 27-41C

FIG. 27-41

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Mycotoxin	4	3.13	2.18	1.43	-1.37
ELASTASE 2	4	3.76	2.63	1.43	-1.37
Ventricular Dysfunction	4	3.51	2.46	1.43	-1.37
Appendicitis	4	3.90	2.73	1.43	-1.37
PTHR1	4	2.16	1.51	1.43	-1.37
Quartz	4	3.23	2.27	1.42	-1.38
Myxoma	4	2.82	1.99	1.42	-1.38
BZRP	4	3.15	2.22	1.42	-1.38

FIG. 27-41A

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Hypertriglyceridemia	4	3.65	2.57	1.42	-1.38
Blast Crisis	4	2.92	2.06	1.42	-1.38
Pepstatin	4	3.16	2.23	1.42	-1.38
Cytokinin	4	2.32	1.64	1.41	-1.39
Rabies	4	2.95	2.09	1.41	-1.39
Histiocytosis	4	3.15	2.23	1.41	-1.39
HFE	4	2.96	2.09	1.41	-1.39
alpha-Glucosidase	4	3.24	2.29	1.41	-1.39
Protein Precursors	4	3.06	2.17	1.41	-1.39
Hernia	4	3.39	2.41	1.41	-1.39
Ubiquinone	4	3.23	2.30	1.40	-1.40
Benzidine	4	3.20	2.28	1.40	-1.40
EIF2C2	4	3.38	2.41	1.40	-1.40
SICKLE CELL ANEMIA	4	3.31	2.36	1.40	-1.40
TRANSCRIPTION FACTOR 1	4	2.57	1.84	1.40	-1.40
Vindesine	4	2.40	1.72	1.40	-1.40
T-LYMPHOCYTE SURFACE CD2 ANTIGEN	4	2.71	1.94	1.40	-1.40
MTCYB	4	3.16	2.27	1.39	-1.41
Albuminuria	4	3.12	2.25	1.39	-1.41
Myristic Acid	4	2.73	1.96	1.39	-1.41
Pancreatic Insufficiency	4	3.08	2.22	1.39	-1.41
Codeine	4	3.23	2.33	1.39	-1.41

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Thromboembolism	4	3.82	2.75	1.39	-1.41
Polynucleotide	4	2.95	2.13	1.39	-1.41
Cytidine	4	3.78	2.72	1.39	-1.41
Cholic Acid	4	3.22	2.32	1.39	-1.41
KNG	4	2.99	2.16	1.39	-1.41
Daunorubicin	4	3.65	2.64	1.39	-1.41
Metoclopramide	4	3.76	2.71	1.39	-1.41
Mineral Oil	4	2.92	2.11	1.38	-1.42
Erythema Nodosum	4	2.67	1.94	1.38	-1.42
Hydroquinone	4	3.37	2.46	1.37	-1.43
Tetanus Toxoid	4	3.23	2.37	1.37	-1.43
Uracil	4	3.81	2.79	1.37	-1.43
Chromosome Aberrations	4	3.82	2.80	1.37	-1.43
Insecticide	4	3.55	2.60	1.37	-1.43
Duodenal Ulcer	4	3.97	2.91	1.36	-1.44
Facies	4	3.15	2.31	1.36	-1.44
Ethane	4	2.81	2.06	1.36	-1.44
Thrombocytopenic Purpura	4	2.82	2.07	1.36	-1.44
Benzimidazole	4	3.05	2.24	1.36	-1.44
Catechol	4	3.83	2.81	1.36	-1.44
Aminogluthethimide	4	2.51	1.84	1.36	-1.44
Ribonucleotide	4	2.74	2.02	1.36	-1.44



FIG. 27-42A
FIG. 27-42B
FIG. 27-42C

FIG. 27-42

173/184

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Ruthenium Red	4	3.48	2.56	1.36	-1.44
Doxycycline	4	3.93	2.89	1.36	-1.44
Homovanillic Acid	4	3.80	2.81	1.35	-1.45
Venous Thrombosis	4	3.98	2.95	1.35	-1.45
Carbodiimide	4	3.33	2.46	1.35	-1.45
Dimethylformamide	4	3.07	2.28	1.35	-1.45
Hypertrophic Cardiomyopathy	4	3.09	2.29	1.35	-1.45
Blister	4	3.22	2.39	1.35	-1.45

FIG. 27-42A

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Glucose-6-Phosphatase	4	3.40	2.53	1.35	-1.45
Nucleoprotein	4	3.53	2.63	1.34	-1.46
IGBP1	4	3.13	2.33	1.34	-1.46
Glucoside	4	3.13	2.33	1.34	-1.46
AMYOTROPHIC LATERAL SCLEROSIS 1	4	3.77	2.80	1.34	-1.46
Galactosamine	4	3.30	2.46	1.34	-1.46
Gluten	4	2.82	2.10	1.34	-1.46
Urinary Incontinence	4	3.16	2.36	1.34	-1.46
Subtilisin	4	3.46	2.59	1.34	-1.46
CD19	4	3.12	2.33	1.34	-1.46
Alkalosis	4	3.23	2.42	1.33	-1.47
Miconazole	4	3.13	2.35	1.33	-1.47
Nicardipine	4	3.41	2.56	1.33	-1.47
Protein Deficiency	4	3.51	2.63	1.33	-1.47
Lactic Acidosis	4	3.33	2.50	1.33	-1.47
Purine Nucleotides	4	2.99	2.25	1.33	-1.47
Nitroglycerin	4	3.54	2.67	1.32	-1.48
Bronchogenic Carcinoma	4	2.82	2.13	1.32	-1.48
Cholate	4	3.09	2.34	1.32	-1.48
Enalapril	4	3.15	2.40	1.32	-1.48
Cannabinoid	4	2.80	2.13	1.32	-1.48
Fc Receptors	4	3.88	2.95	1.32	-1.48

FIG. 27-42B

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Vertigo	4	3.51	2.66	1.32	-1.48
Iodoacetic Acid	4	2.81	2.14	1.31	-1.49
Inositol 1,4,5-Trisphosphate	4	3.47	2.65	1.31	-1.49
Cholecystitis	4	3.37	2.58	1.31	-1.49
Thrombophlebitis	4	3.15	2.41	1.31	-1.49
Tolbutamide	4	3.40	2.60	1.31	-1.49
Dipyridamole	4	3.99	3.06	1.31	-1.49
IRAK1	4	2.32	1.78	1.30	-1.50
Hydralazine	4	3.37	2.59	1.30	-1.50
ALPHA PROTEIN S	4	2.73	2.10	1.30	-1.50
Pyridoxal	4	3.40	2.62	1.30	-1.50
Palmitic Acid	4	3.72	2.86	1.30	-1.50
CD57	4	2.99	2.31	1.30	-1.50
Nimodipine	4	3.15	2.43	1.30	-1.50
Cardiac Glycosides	4	2.74	2.12	1.29	-1.51
Muscle Proteins	4	3.32	2.58	1.29	-1.51
Metyrapone	4	3.39	2.63	1.29	-1.51
GLUTATHIONURIA	4	3.55	2.76	1.29	-1.51
Periodontal Disease	4	3.50	2.73	1.28	-1.52
Aflatoxin B1	4	3.23	2.52	1.28	-1.52
Cyclophilin	4	2.56	2.00	1.28	-1.52
Dextran Sulfate	4	3.40	2.65	1.28	-1.52

FIG. 27-43A
FIG. 27-43B
FIG. 27-43C

FIG. 27-43

176/184

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Dwarfism	4	3.74	2.92	1.28	-1.52
Dihydropyridine	4	3.72	2.90	1.28	-1.52
Polyvinyl Chloride	4	2.81	2.19	1.28	-1.52
ESSENTIAL HYPERTENSION	4	3.92	3.07	1.28	-1.52
Bronchiolitis	4	2.67	2.09	1.28	-1.52
Betamethasone	4	3.21	2.52	1.27	-1.53
Atenolol	4	3.34	2.63	1.27	-1.53
Coumarin	4	3.51	2.77	1.27	-1.53

FIG. 27-43A

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Gliosid	4	3.92	3.12	1.26	-1.54
Pancuronium	4	2.71	2.16	1.26	-1.54
Pregnenolone	4	3.16	2.52	1.26	-1.54
Malate Dehydrogenase	4	3.15	2.52	1.25	-1.55
Diphtheria	4	2.67	2.13	1.25	-1.55
Carrageenan	4	3.13	2.50	1.25	-1.55
Cesium	4	3.16	2.52	1.25	-1.55
Polymyxin B	4	3.48	2.78	1.25	-1.55
Leprosy	4	3.45	2.76	1.25	-1.55
Fluonine	4	3.15	2.53	1.25	-1.55
Camptothecin	4	2.82	2.27	1.24	-1.56
Autolysis	4	3.16	2.55	1.24	-1.56
Capsaicin	4	3.65	2.96	1.23	-1.57
DOWN SYNDROME	4	3.78	3.06	1.23	-1.57
Naproxen	4	3.13	2.54	1.23	-1.57
NTS	4	3.16	2.57	1.23	-1.57
Antacid	4	2.32	1.89	1.23	-1.57
Dehydroepiandrosterone Sulfate	4	2.57	2.09	1.23	-1.57
Acetazolamide	4	3.40	2.78	1.22	-1.58
Prolapse	4	3.37	2.76	1.22	-1.58
Methyltransferase	4	3.58	2.94	1.22	-1.58
Thromboxane A2	4	4.00	3.29	1.22	-1.58

FIG. 27-43B

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Syphilis	4	3.37	2.77	1.22	-1.58
CHOLELITHIASIS	4	3.41	2.81	1.21	-1.59
BRCA2	4	1.82	1.51	1.21	-1.59
Tetrachlorodibenzodioxin	4	2.96	2.45	1.21	-1.59
Lymphopenia	4	3.16	2.62	1.21	-1.59
Chest Pain	4	3.94	3.28	1.20	-1.60
Porphyrin	4	3.40	2.84	1.20	-1.60
Sitosterol	4	3.74	3.12	1.20	-1.60
Diclofenac	4	3.48	2.90	1.20	-1.60
Fluoxetine	4	2.99	2.50	1.20	-1.60
Oxygenase	4	3.48	2.92	1.19	-1.61
Propionic Acids	4	3.24	2.72	1.19	-1.61
Lipofuscin	4	2.81	2.36	1.19	-1.61
Tartrate	4	3.40	2.86	1.19	-1.61
Azide	4	3.76	3.17	1.19	-1.61
Sodium Salicylate	4	2.81	2.37	1.19	-1.61
Glaucoma	4	3.98	3.35	1.19	-1.61
Aminophylline	4	2.99	2.52	1.19	-1.61
Sulfonamide	4	3.81	3.23	1.18	-1.62
Carboplatin	4	2.83	2.40	1.18	-1.62
Kanamycin	4	3.37	2.86	1.18	-1.62
Maltose	4	3.37	2.87	1.17	-1.63

FIG. 27-43C

FIG. 27-44A
FIG. 27-44B
FIG. 27-44C

FIG. 27-44

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Chagas Disease	4	3.33	2.84	1.17	-1.63
Drug Toxicity	4	3.16	2.70	1.17	-1.63
Diphosphonate	4	2.51	2.14	1.17	-1.63
Omithine	4	3.88	3.32	1.17	-1.63
Hyperbilirubinemia	4	3.09	2.65	1.17	-1.63
Gluconate	4	3.24	2.78	1.16	-1.64
Dinitrophenol	4	2.74	2.36	1.16	-1.64
Otitis Media	4	3.40	2.93	1.16	-1.64

FIG. 27-44A

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
alpha 1-Antitrypsin	4	3.41	2.94	1.16	-1.64
Immune Sera	4	3.32	2.88	1.15	-1.65
Reserpine	4	3.79	3.29	1.15	-1.65
Sinusitis	4	3.07	2.68	1.15	-1.65
Nicotinic Acids	4	2.98	2.61	1.14	-1.66
Miloxantrone	4	2.58	2.26	1.14	-1.66
SHORT STATURE	4	3.62	3.18	1.14	-1.66
Leukocytosis	4	3.84	3.38	1.13	-1.67
TOP1	4	2.92	2.58	1.13	-1.67
Ligase	4	3.58	3.19	1.12	-1.68
Gynecomastia	4	2.16	1.93	1.12	-1.68
Digoxin	4	3.37	3.02	1.12	-1.68
Cadaver	4	3.13	2.82	1.11	-1.69
Guanosine Triphosphate	4	2.48	2.25	1.10	-1.70
Folic Acid	4	3.48	3.17	1.10	-1.70
Aluminum Hydroxide	4	2.56	2.34	1.10	-1.70
Borohydride	4	3.07	2.81	1.10	-1.70
Methane	4	2.91	2.66	1.09	-1.71
Splenomegaly	4	3.89	3.56	1.09	-1.71
SLC2A4	4	2.13	1.96	1.09	-1.71
Spontaneous Abortion	4	3.09	2.84	1.09	-1.71
Cerebral Infarction	4	3.16	2.94	1.08	-1.72

FIG. 27-44B



Object name	#	Quality	Expect	Obs/Exp.	2 sigma
CP1	4	2.82	2.64	1.07	-1.73
Thiocyanate	4	3.06	2.86	1.07	-1.73
Diabetes Insipidus	4	2.58	2.42	1.07	-1.73
PARKINSON DISEASE	4	3.13	2.94	1.07	-1.73
MB	4	3.38	3.18	1.06	-1.74
Candidiasis	4	2.97	2.80	1.06	-1.74
Acrylamide	4	3.58	3.39	1.06	-1.74
Cholesterol Esters	4	2.67	2.54	1.05	-1.75
Muscle Weakness	4	3.55	3.38	1.05	-1.75
Taurine	4	3.57	3.40	1.05	-1.75
Memantine	4	2.74	2.62	1.05	-1.75
Ethylene	4	3.58	3.43	1.04	-1.76
Diltiazem	4	3.48	3.33	1.04	-1.76
Airway Obstruction	4	2.98	2.86	1.04	-1.76
Halothane	4	3.75	3.60	1.04	-1.76
Antiemetic	4	1.98	1.92	1.03	-1.77
Gamma-Globulin	4	3.84	3.73	1.03	-1.77
Benzene	4	3.72	3.63	1.03	-1.77
Pulmonary Edema	4	3.37	3.29	1.03	-1.77
Inulin	4	2.96	2.89	1.02	-1.78
Craniofacial	4	3.16	3.09	1.02	-1.78
Tritium	4	3.40	3.36	1.01	-1.79

FIG. 27-45A
FIG. 27-45B
FIG. 27-45C

FIG. 27-45

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Tremor	4	3.54	3.49	1.01	-1.79
Dizziness	4	3.40	3.37	1.01	-1.79
Dermatitis	4	3.82	3.78	1.01	-1.79
Postoperative Complications	4	3.40	3.37	1.01	-1.79
Myocarditis	4	2.96	2.97	0.99	-1.81
Oxalate	4	2.99	3.01	0.99	-1.81
Aneurysm	4	3.55	3.58	0.99	-1.81

FIG. 27-45A

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Amyloidosis	4	3.23	3.27	0.99	-1.81
Fistula	4	3.82	3.92	0.97	-1.83
Polynuropathies	4	3.13	3.23	0.97	-1.83
Hypermethylation	4	2.00	2.07	0.97	-1.83
Guanylate Cyclase	4	2.82	2.93	0.96	-1.84
Benzodiazepine	4	3.65	3.84	0.95	-1.85
Overdose	4	3.40	3.58	0.95	-1.85
Levamisole	4	2.58	2.74	0.94	-1.86
CORTICOTROPIN-RELEASING HORMONE	4	2.55	2.71	0.94	-1.86
Arrhythmia	4	4.00	4.27	0.94	-1.86
Anesthetic	4	3.99	4.32	0.92	-1.88
Cystine	4	2.96	3.21	0.92	-1.88
Isofamidine	4	2.16	2.41	0.90	-1.90
Abdominal Pain	4	3.96	4.42	0.90	-1.90
Calcium Chloride	4	2.32	2.64	0.88	-1.92
Sudden Death	4	2.98	3.43	0.87	-1.93
Mercury	4	3.40	3.98	0.85	-1.95
Hematoma	4	2.66	3.11	0.85	-1.95

FIG. 27-45B

Object name	#	Quality	Expect	Obs/Exp.	2 sigma
Anorexia	4	3.57	4.19	0.85	-1.95
Hemolysis	4	3.58	4.25	0.84	-1.96
Haloperidol	4	2.89	3.49	0.83	-1.97
Enterotoxin	4	2.51	3.03	0.83	-1.97
Bicarbonate	4	3.56	4.47	0.80	-2.00
Hypotension	4	4.00	5.11	0.78	-2.02
Enkephalin	4	2.23	2.86	0.78	-2.02
Penicillin	4	3.12	4.04	0.77	-2.03
Potassium Channels	4	2.13	2.85	0.75	-2.05
Abscess	4	2.94	3.97	0.74	-2.06
Adrenergic Receptors	4	1.74	2.53	0.69	-2.11
Monoamine Oxidase	4	2.38	3.56	0.67	-2.13
Caffeine	4	3.00	4.49	0.67	-2.13
Jaundice	4	2.80	4.20	0.67	-2.13
Glutamate Receptors	4	2.13	3.23	0.66	-2.14
Dyspnea	4	2.51	4.02	0.62	-2.18
Phenylephrine	4	2.13	3.71	0.57	-2.23
Headache	4	2.79	5.07	0.55	-2.25

FIG. 27-45C